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   Natural Science:
“When the ebbing tide retreats
Along the rocky shoreline
It leaves a trail of tidal pools
In a short-lived galaxy
Each microcosmic planet
A complete society
A simple kind of mirror
To reflect upon our own
All the busy little creatures
Chasing out their destinies
Living in their pools
They soon forget about the sea . . .”
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  Introduction 
 
  S. aureus is an important pathogen in human disease and the 
cause of a range of infections from mild, such as skin infections 
and food poisoning, to life-threatening, such as pneumonia, 
sepsis, osteomyelitis, and infective endocarditis. P1 P Over the last 
20 years the incidence of both community-acquired and 
hospital-acquired S. aureus infections has increased, accounting 
for 13 percent of nosocomial infections in U.S. hospitals between 
1979 and 1995.P2-4P Despite antibiotic therapy these infections still 
have severe consequences, stressing the importance of 
prevention. P5,6 P 
S. aureus produces many toxins and is capable of developing 
resistance to all available antibiotics. In 1961 methicillin 
resistance was first noted P7P and since the 1970s, methicillin-
resistant S aureus (MRSA) has become the main cause of 
nosocomial infections in many countries all over the world. P8-10P 
Glycopeptides such as vancomycin are the last resort antibiotics 
in these countries. However, in 1997 a partially vancomycin-
resistant S aureus (VRSA) strain was isolated.P11-13P  
S. aureus nasal carriage is the major risk factor for the 
development of S. aureus infections in various clinical settings, 
including post-operative wound infections, P5,14P in patients 
undergoing continuous ambulatory peritoneal dialysis and 
hemodialysis, P15,16 P and in patients infected with the human 
immunodeficiency virus. P17 P A large majority of these infections 
are of endogenous origin, in that individuals are infected by 
their own S. aureus isolate,P15,16,18P as was recently confirmed by 
von Eiff et al.P19 P Eradication of S. aureus nasal carriage by 
application of topical mupirocine results in a reduction in 
endogenous infections in various risk populations. P16,20-22P In 
contrast, the absolute risk of developing a  S. aureus infection as 
a nasal carrier is low (less than 5% for nosocomial bacteraemia). 
The problem of S. aureus is still considered an important one, 
and further research is required to elucidate the host-pathogen 
interplay and to develop effective strategies in the prevention of 
S. aureus infections.P19,23-27 P This article aims to review what is 
currently known of the host and bacterial factors determining S. 
aureus nasal carriage and to set the stage for this thesis. 
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  S. aureus Nasal Carriage 
 
  Humans, as other mammals, are a natural reservoir of S. aureus 
and the primary ecological niches of S. aureus strains in humans 
are the anterior nares, although staphylococci can be isolated 
from many sites, including throat, axilla and perineum. P28-31P 
However, the elimination of S. aureus from the nose results in the 
subsequent disappearance from other areas of the body. P28,32-34P 
While carriage of S. aureus in the nose plays a key role in the 
epidemiology and pathogenesis of infection, and is a major risk 
factor for the developmentP Pof both community-acquired and 
nosocomial infections, the biology of nasal colonization remains 
incompletely understood. P5,15,19,23,35,36P 
 
Cross-sectional P Psurveys of healthy adult populations have 
reported S. aureus nasal carriage rates between 20 and 55%.P31,37-
42
P From longitudinal studies it became clear that S. aureus nasal 
carriage patterns differ between individuals, andP Pthat 10 to 35% 
of individuals carry S. aureus persistently, 20 P Pto 75% carry S. 
aureus intermittently, and 5 to 50% never carry S. aureus in their 
nose.P37,38,43-47P Persistent carriage is more common in young 
children than in adults, and many people change their pattern of 
carriage between the age of 10 and 20 years. P43P The reasons for 
these differences in colonization patterns remain unknown so 
far. 
 
The number of S. aureus bacteria inP Pthe anterior nares is 
significantly higher in persistent carriers than in intermittent P 
Pcarriers,P48 P resulting in an increased P Prisk of S. aureus infections.P49-
51
P Moreover, persistent carriers are often colonized by a 
selected single strain of S. aureus over long time periods, while 
intermittent carriers carry many different strains over 
time.P37,38,47,52,53P Persistent carriage seems to have a protective 
effect on the acquisition of other strains.P54 P These data suggestP 
Pthat the basic determinants of persistent and intermittent 
carriage P Pare different.  
Comparison of results between studies is made difficult by the 
lack of conformity in both the methods of ascertainment and 
varying criteria for the definition P Pof persistent or intermittent 
carriage used, as well as the absence of information on antibiotic
exposure, an important confounding variable. In clinical studies, 
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often due to logistic reasons, only one nasal swab culture is 
performed to ascertain S. aureus nasal carriage. The result of this 
is that the group with one negative culture will in fact consist of a 
mix of true non-carriers plus intermittent carriers, while the 
group with one positive culture will in fact consist of a mix of true
persistent carriers plus intermittent carriers. When studying 
determinants of S. aureus nasal carriage or when performing an 
intervention trial in this way, the differences between the 
positive- and negative-culture groups will be blurred by the 
presence of intermittent carriers in both groups. The correct P 
Pseparation of the population into persons who are true persistentP 
Pcarriers versus intermittent and non-carriers is a prerequisite to 
adequately perform studies into the molecular P Pand genetic basis 
of S. aureus nasal carriage, as well as intervention studies. 
 
 
 
 
  Determinants of S. aureus Nasal Carriage 
 
Bacterial factors  Much research has focused on specific staphylococcal factors 
like cell wall components (lipoteichoic acid P55,56 P), surface 
proteins (protein AP52 P, microbial surface components recognizing 
adhesive matrix molecules (MSCRAMM)P57-59P) and staphylococcal
interactions with other host proteins and carbohydrate moieties 
such as mucin P60,61 P, or other mucus components. P62,63P Other 
substances found in the respiratory tract, including secretory 
immunoglobulin A, P64 P glycolipids,P65 P gangliosidesP66,67P and 
surfactant protein A,P68 P may also constitute receptor sites for 
staphylococcal adherence. Hydrophobic interactions and 
surface charge provide forces that are probably also involved in 
mediating staphylococcal binding to epithelia.P56,60,69 P 
On the basis of all these results, however, no common genetic or 
phenotypic characteristics segregating persistent from 
intermittent colonizing strains have been identified, so far. 
Recently Day et al. reported the P Pexistence of ecologically 
abundant hypervirulent clones. TheyP Psuggested that factors 
promoting the ecological fitness, i.e. the capacity to colonize 
persons, also increase its virulence and that S. aureus is not 
solely an opportunistic pathogen.P24 P Their study was, however, 
retracted later because in repeated experiments this association 
could not be corroborated. Future studies will hopefully dissect 
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the interrelation between colonization capacity and virulence 
and shed new light on the mechanisms of disease pathogenesis. 
The just finished ‘S. aureus genome project’ would be the logical 
starting point.P26P  
 
Bacterial interference may be another explanation of the non-
carrier state: when an ecological niche is already occupied by 
other bacteria, e.g. coagulase-negative staphylococci, 
Corynebacterium species or artificially with S. aureus 502A, wild 
type S. aureus does not seem to have the means to replace this 
resident bacterial population.P38,70-72P The exact mechanism for 
this effect has not been elucidated so far. P73,74P Cross-inhibition of 
the expression of various virulence factors by the recently 
identified accessory gene regulator (agr) and staphylococcal 
accessory regulator (sar), may be one mechanism by which one 
strain excludes others from colonizing sites including the 
anterior nares,P75-80P although a large S. aureus population 
genetics analysis failed to confirm this suggestion. P81 P Bacterial 
interference by active colonization using S. aureus 502A has 
been successful in nurseries during out-breaks of S. aureus 
infections in the 1960s and for treatment of patients with 
recurrent furunculosis. P82-84P Bacterial interference using 
Corynebacterium species has recently been reported to be 
successful in eradicating MRSA nasal carriage.P85 P 
 
 
Host factors  The observation that different S. aureus nasal carriage patterns 
(non, intermittent and persistent) can be discerned, suggests a 
host influence. This view is supported by the fact that persistent 
carriage rates vary between different ethnic groups, P40,42,86P are 
higher in males than in females P87P and depend on age (higher in 
early childhood, lower at old age) P43,54,88-90P and hormonal status.P91P 
In addition, S. aureus seems to have a greater affinity for nasal 
epithelial cells obtained from carriers than from noncarriers P92P 
and adheres better to nasal epithelial cells from patients with 
eczema than to cells from patients without eczema. P93P  
Genetic studies have not provided us with a definitive answer, 
yet. Two twin studies have been performed, the first showing 
concordant results in monozygotic twins, P94P while the other could 
not confirm these results. P95 P An earlier study that evaluated the 
relationship between HLA Class II haplotype and nasal carriage 
demonstrated HLA-DR3 to be associated with carriage, but a 
large proportion of the patient group suffered from an 
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autoimmune disease, which was not adjusted for in the 
analysis.P96 P 
Environmental factors can also influence the S. aureus nasal 
carrier state. Hospitalization for example, has been shown to be 
an important risk factor for S. aureus nasal carriage. P41,44,97-99 P 
 
Many underlying diseases or conditions have been associated 
with a higher S. aureus nasal carriage and subsequent infection 
rate: insulin-dependent diabetes mellitus, P100,101P hemodialysis 
and continuous ambulatory peritoneal dialysis, P15,16,102,103 P 
intravenous drug abuse,P104,105 P repeated injections for 
allergies,P106P S. aureus skin infections and other skin 
diseases,P107,108 P river-rafting,P109P liver cirrhosis, P110,111 P liver 
transplantation,P112P human immunodeficiency virus (HIV) 
infection or AIDS,P17,18 P qualitative or quantitative defects in 
leukocyte function,P113 P Wegener’s granulomatosis,P114 P nasal 
abnormalities,P115P and rhinosinusitis. P116P  
One common factor in these seems to be the repeated violation 
of the skin or mucosa as anatomical barriers. However, local or 
systemic immune deficiencies probably also play an important 
role. Cole et al. reported that nasal secretions obtained from S. 
aureus nasal carriers lacked antimicrobial activity against S. 
aureus in vitro, while nasal fluid from non-carriers was 
bactericidal.P117 P Defensins (antimicrobial peptides) as part of the 
innate immune system, and/or the local immune IgA response 
could well be involved. P117-119P  
 
 
 
 
  Scope of this Thesis  
  Much is known about S. aureus, S. aureus infections and the host 
and bacterial factors involved in S. aureus nasal carriage. 
However, many questions remain unanswered. To fully exploit S. 
aureus nasal carriage as the key to preventing S. aureus 
infections, we will first have to unlock the fundamental 
mechanisms underlying it. It was the general aim of the work 
presented in this thesis to contribute to the further elucidation 
and understanding of the determinants and consequences of S. 
aureus nasal carriage in humans. The aim of the research 
presented in this thesis was addressed in three separate lines of 
work: 
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Section 1  Defining S. aureus nasal carriage 
  Currently no internationally accepted definitions of the different 
S. aureus nasal carrier states exist. To compare findings from 
different studies and to be able to extrapolate results from 
studies to ‘real life’ situations, consensus on how to define the S. 
aureus carrier states is essential. 
≡ In chapter 2 we set out to derive and validate a ‘culture 
rule’ for accurate determination of the individual carrier 
state, to be used in large scale epidemiologic studies to 
follow.  
 
 
Section 2  Determinants of S. aureus nasal carriage 
  In trying to explain carriage, research has focused primarily on 
bacterial factors. Often in vitro data could not be corroborated in
vivo, not to mention real life. Furthermore, most studies on host 
factors associated with carriage have been performed in the 
hospital setting. We, therefore, decided to study the UhostU as the 
main source of determinants of S. aureus nasal carriage in the 
Ucommunity setting U. To achieve this a total of five studies were 
undertaken:  
≡ The first study (chapter 3) describes the development of 
a ‘human model’ as a tool to study if the human host was 
indeed an important determinant of S. aureus nasal 
carriage. After artificially inoculating long-term 
persistent carrier and long-term non-carrier volunteers 
with a mixture of S. aureus strains, these persons were 
followed-up to investigate whether nasal survival of S. 
aureus was different between these two groups. 
≡ Using the ‘culture rule’ presented in chapter 2, in a large
population-based study in the city of Rotterdam, we 
intended to find (new) host factors associated with 
persistent S. aureus nasal carriage in the community 
(chapter 4). 
≡ The third study (chapter 5) aimed to investigate the 
hypothesis that environmental factors (defined as living 
within the same household) and/or familial factors 
(defined as being first degree relatives) are important 
determinants of S. aureus nasal carriage. 
≡ Finally, based on the results from the first three studies 
and biased to the opinion that the human host is indeed 
a major determinant of S. aureus nasal carriage, we 
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performed two genetic association studies. First 
(chapter 6) we investigated the association of 
polymorphisms in the vitamin D receptor gene and 
secondly (chapter 7) the association of polymorphisms 
in the glucocorticoid receptor gene with persistent S. 
aureus nasal carriage.   
 
 
Section 3  Risks of S. aureus nasal carriage 
  Many studies have delineated the risks associated with S. aureus 
nasal carriage. Most of these studies have been performed in the
hospital setting and limited data are available on the health 
effects of S. aureus nasal carriage in the community setting. 
Moreover, studies in populations at risk, such as patients on 
continuous peritoneal dialysis (CPD), have been hampered by 
lack of accurate definition of the different S. aureus nasal carrier 
states, thereby impeding the efficient targeting of prophylactic 
measures. Accurate determination of the true S. aureus carrier 
state would, theoretically, enable us to improve the prevention 
of S. aureus infections in CPD patients. In this section three 
studies were performed: 
≡ In the first study (chapter 8) we investigated the overall 
health effects of persistent S. aureus nasal carriage in the 
community. 
≡ In the second (chapter 9) and third (chapter 10) study 
we set out to determine whether subgroups of S. aureus 
nasal carriers could be distinguished among CDP 
patients in a university hospital setting (chapter 9) and 
in a tertiary care hospital (chapter 10), respectively, and 
whether these subgroups had different risks for S. 
aureus infections.  
 
 
Section 4  Dynamics of & Interference with S. aureus nasal carriage 
  In the era of emerging antibiotic resistance in S. aureus 
(including nosocomial as well as the recent emergence of 
community-acquired methicillin-resistant S. aureus (MRSA) 
strains, but also resistance to many commonly used antibiotics, 
including the ‘last resort’ of glycopeptides), prudent use of 
antibiotics in the prevention and therapy is highly needed. Also, 
alternative strategies to combat S. aureus are necessary. 
Bacterial interference has been hypothesized to be a major 
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determinant of the S. aureus carrier state.P70,72-74P The concept of 
bacterial interference has been successfully taken into clinical 
testing, employing artificial nasal inoculation with S. aureus 502A 
(SA-502A) or Corynebacterium species.P82-85,108,120P However, the 
practice of  artificial nasal inoculation with SA-502A was 
abandoned after alleged complications, P121-123P and the advent of 
newer anti-staphylococcal antibiotics.  
≡ The last section consists of a study (chapter 11) into the 
colonization dynamics of wild type S. aureus and S. 
aureus 502A after bacterial interference with the latter 
strain. We set out to investigate whether interference 
with S. aureus 502A in well defined persistent carriers 
was feasible, safe and effective in eliminating the wild 
type strain. 
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  Abstract 
 
Context  To study determinants and risks of Staphylococcus aureus nasal 
carriage adequate differentiation between the different S. aureus 
carrier states is obligatory. 
Objective  We set out to develop a ‘culture rule’ capable of differentiating 
between persistent and intermittent or non-carriers using a 
minimum of nasal swab cultures. 
Design  Prospective diagnostic study. 
Setting  51 healthy volunteers (derivation-cohort) & 106 participants of 
an ongoing study in 3882 elderly persons (validation cohort). 
Participants  In 51 healthy volunteers (derivation-cohort) 12 quantitative nasal 
cultures were performed to establish their S. aureus nasal carrier 
states. Persons with 11 or 12 cultures positive with S. aureus 
were classified as persistent carriers, those with all cultures 
negative as non-carriers. All other persons were classified as 
intermittent carriers. Using logistic regression and receiver 
operating characteristic (ROC) curves a ‘culture rule’ was 
derived. This ‘culture rule’ was subsequently validated in 106 
participants of an ongoing study in 3882 elderly persons, again 
using 12 quantitative nasal cultures. 
Outcome 
Measures 
 Areas under the ROC curves (AUC). 
Results  In both cohorts, the positive predictive value of two consecutive 
positive cultures for persistent carriage was 79%. The model 
best differentiating between persistent and intermittent or non-
carriers used the number of positive cultures combined with the 
amount of S. aureus in these cultures. Using the outcome of two 
cultures, the areas under the ROC curves (AUC) were 0.981 
(95% CI 0.949-1.0) for the derivation- and 0.936 (95% CI 0.881-
0.990) for the validation-cohort.  
Conclusions  Combining qualitative and quantitative results of two nasal swab 
cultures accurately predicted the persistent S. aureus carrier 
state with a reliability of 93.6%. This ‘culture rule’ can thus be 
used in studies on determinants and risks of S. aureus nasal 
carriage. 
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  Introduction 
 
  Staphylococcus aureus nasalP Pcarriage is a major risk factor for 
both community-acquired and nosocomial infections, P1-7P and the 
anterior nares are the primary reservoir of S. aureus in humans.P8-
10
P Three S. aureus nasal carriage patterns can be discerned: 
persistent-, intermittent- and non-carriage.P11-22 P However, no 
consensus has been reached on how to exactly identify these 
different states, but most studies use 10-12 weekly nasal swab 
cultures.P23P 
The number of colony forming units (CFU) of S. aureus isolated 
from P Pthe anterior nares are higher in persistent than in 
intermittent carriers, P24,25P resulting in more extensive dispersal of 
staphylococci in the environment P25P and in an increasedP Prisk of S. 
aureus infections.P26-28P Bacterial variability (i.e. theP Pnumber of S. 
aureus genotypes isolatedP Pin repeated cultures from one 
individual) is lower for persistent than for intermittent 
carriers,P15,22,29 P indicatingP Pthat the underlying mechanisms 
determining persistent and intermittent carriage P Pdiffers. 
Adequate differentiation between persistent and intermittent 
carriage is thus relevant for epidemiological studies.  
At present a large survey on S. aureus nasalP Pcarriage in a 
population aged 60 and over is being conducted at our 
institution. The main objectives are to study determinants and 
risks of S. aureus nasalP Pcarriage. This is part of the Rotterdam 
Study, a population-based prospective study on chronic 
diseases in the elderly. The Rotterdam Study started in 1990 in 
7983 persons, and has just finished its third phase, in which more
than 4000 persons have been included. In this large survey an 
efficient and reliable way to assess S. aureus nasalP Pcarriage was 
obligatory. It would be impossible to perform 10-12 weekly 
nasal swab cultures in all participants. Thus, we developed a 
‘culture rule’ to discriminate reliably between persistent-
carriage and non-or-intermittent carriage, with a minimum of 
nasal swab cultures.  
Our main questions were 1) how many quantitative nasal swab 
cultures are needed to accurately predict persistent carriage in 
a cohort of healthy adult volunteers, and 2) does the derived 
‘culture rule’ correctly predict persistent carriage in the elderly 
cohort of the ongoing Rotterdam study. 
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  Material & Methods 
 
  Patient cohorts and microbiological investigations 
Derivation cohort 
 
 In 1988 a cohort of healthy volunteers (staff members of the 
departments of Medical Microbiology & Infectious Diseases and 
Virology of the Erasmus MC) was formed to investigate bacterial 
and human factors associated with S. aureus nasal carriage.P23 P 
Between September 1995 and March 1996 51 volunteers were 
invited and agreed to participate in this study. Nasal swab 
cultures were performed weekly for 12 weeks. All nasal swab 
cultures were taken by one study physician (MFQK-V), 
according to protocol (see below). 
 
Validation cohort 
 
 Based on the results of the derivation cohort, two quantitative 
nasal swab cultures with one-week interval were performed in 
3882 participants of the Rotterdam Study. While this study was 
ongoing, 106 participants entering the study between October 
1997 and April 1998 were invited and agreed to be included in 
the validation cohort. Persons with 2 positive or 2 negative nasal 
swab cultures were oversampled to estimate the predictive 
value of these cultures for persistent-carriage and non-or-
intermittent carriage. One trained research assistant visited the 
participants at home and performed 10 additional nasal swab 
cultures at one-week intervals, according to protocol. 
 
  The study was approved by the Medical Ethics Review 
Committee of the Erasmus MC, University Medical Center 
Rotterdam. Informed consent was obtained of all participants.  
 
  Definitions 
  S. aureus nasalP Pcarriage state was assessed using the results of 
nasal swab culture number 3 to 12, as follows: 
persistent carrier   9 or 10 out of 10 cultures positive with S. aureus 
non-carrier   no positive cultures 
intermittent carrier  all intermediate numbers of positive cultures 
 
  Microbiological procedures 
  Nasal swab cultures were performed according to a standard 
operating procedure as described earlier. P23 P Nasal swabs 
specimens were obtained using sterile cotton-wool swabs 
(Transwab, Medical Wire & Equipment Co. Ltd., Corsham, 
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United Kingdom). Both the left and right anterior nares were 
swabbed by rubbing the swab four times around the inside of 
each nostril while applying an even pressure and rotating the 
swab without interruption. The swabs were immediately placed 
in Stuart’s transport medium and kept at 4 P0 PC until inoculation 
(within 24 hours). 
Swabs were then cultured quantitatively on phenol-red mannitol 
salt agar (PHMA) and in phenol red mannitol salt broth (PHMB). 
The flasks with transport media containing the nasal swab were 
vortexed for 15 seconds. The swab was then pressed firmly 
against the wall of the flask using a sterile pincet and cultured in 
8 ml of PHMB.  Subsequently, 500µL of the remaining bacterial 
suspension was inoculated evenly unto a large PHMA culture 
plate (∅ 14 cm). Another PHMA culture plate (∅ 8.5 cm) was 
divided into three sectors, which were inoculated with 10µL of 
the original bacterial suspension, 10µL of a 1:10 diluted bacterial 
suspension, and 1µL of the 1:10 diluted bacterial suspension, 
respectively. The PHMB was incubated at 37 P0 PC for 7 days; the 
PHMA culture plates were incubated at 37 P0 PC for 48 hours and at 
room temperature for 5 days. Both were interpreted after 7 days 
of incubation. If after 7 days no S. aureus had grown on the 
PHMA, but the PHMB demonstrated a yellow color, a PHMA 
culture plate (∅ 8.5 cm) was inoculated with 10µL PHMB and 
incubated as before. Culture results were recorded as 0 (no S. 
aureus), 1 (S. aureus only from PHMB), 2 (2-9 CFU), 3 (10-99 
CFU), 4 (100-999 CFU), or 5 (≥ 1000 CFU) (CFU= colony forming 
units). 
Identification of S. aureus was based upon colony morphology on
the PHMA. Suspected colonies were cultured overnight on 
Columbia blood agar plates (Becton-Dickinson B.V., Etten-Leur, 
The Netherlands). A catalase test and a latex agglutination test 
(Staphaurex Plus PRP, Murex, Dartford, UK) were then performed. 
All S. aureus isolates were stored at -70 P0 PC in glycerol containing 
liquid media. 
 
  Statistical analysis 
  Percentages and continuous data were compared by Fisher’s 
exact test and Mann-Whitney’s test, respectively. Logistic 
regression was performed and receiver operating characteristic 
(ROC) curves were constructed for different tests and 
combinations of tests (number of positive cultures, P10PLog-
transformed CFUs (P10PLog[CFU+1]) and the geometric mean 
CFUs of two or more cultures to study their ability to 
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discriminate between persistent carriage and non-carriage or 
intermittent carriage.P30P Culture results of the derivation cohort 
were added as independent covariates to a logistic regression 
model with our “gold standard” diagnosis of persistent carriage 
or not (derived from 10 consecutive cultures) as binary outcome 
variate. The right side of the regression equation was: [ß0 + 
ß1*number of positive cultures + ß2*geometric mean of CFUs]. 
Fitting the model gave us ß0 to ß2. Then, we calculated the odds 
of persistent carriage for all persons of the validation cohort by 
adding their respective culture outcomes in the formula: odds = 
[e(ß0 + ß1*number of positive cultures + ß2*geometric mean of 
CFUs)]. Subsequently, the probability of persistent carriage was 
obtained by: odds / (1+odds). We choose the midpoint between 
0 and 1 as cut-point. Areas under the ROC curves (AUC) and the 
corresponding standard errors (SE) were estimated using a non-
parametric method (two sample Wilcoxon test). P31,32 P Differences 
between AUCs of the different test combinations were compared
using the method of Hanley & McNeil. P33 P 
 
 
 
  Results 
 
   Fifty-one persons were included in the derivation cohort: 19 
(37%) males and 32 (63%) females, mean age 29 years (range 20
- 52). Twenty (39%) participants were classified as non-, 16 
(31%) as intermittent and 15 (29%) as persistent carriers (Table 
1A). Positive predictive values for persistent carriage, derived 
from regression models that included the results of cultures 1 
and 2, ranged from 0.79 in a model containing the qualitative 
outcome only, to 0.88 in a model including both qualitative and 
quantitative results (Figure 1A). Using the results of only one 
culture (either 1 or 2) produced a positive predictive value of 
only 0.69. 
The validation cohort consisted of a subset of 106 participants of 
the Rotterdam Study cohort: 44 (42%) males, 62 (58%) females, 
mean age 73 years (range 62 - 89). For the present study, 
persons with one positive and one negative culture were less 
informative. Two positive cultures could either indicate 
persistent or intermittent carriage. Possibly, the number of CFUs 
S. aureus cultured could differentiate between persistent and 
intermittent carriage. Persons with two negative cultures could 
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Table 1  Classification of the S. aureus nasal carrier state based on results 
from the first two cultures as compared with cultures 3 to 12 for the 
derivation cohort (A) and the validation cohort (B) respectively. 
For the validation cohort persons with both culture 1 and 2 positive 
or negative were oversampled (see methods). Therefore the 
distribution of the different carrier states does not represent the 
population prevalence. 
 
Table 1A : Derivation Cohort 
Results of cultures 1 and 2 
 
 
Both  
Negative 
1 Positive,  
1 Negative 
Both  
Positive 
Total 
non 19 1  20 
intermittent 7 5 4 16 
S.aureus carrier 
state based  
on cultures 3-
12 
persistent   15 15 
Total 26 6 19 51 
 
Table 1B: Validation Cohort 
Results of cultures 1 and 2 
 
 
Both  
Negative 
1 Positive,  
1 Negative 
Both  
Positive 
Total 
non 53 4  57 
intermittent 7 2 8 17 
S.aureus carrier 
state based  
on cultures 3-
12 
persistent 1  31 32 
Total 61 6 39 106 
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  help to assess the predictive value for true non-carriage. 
Therefore, after initial random inclusion of participants, we 
decided to oversample persons with two positive or two 
negative screening cultures. Fifty-seven (54%) participants were
classified as non-, 17 (16%) as intermittent and 32 (30%) as 
persistent carriers (Table 1B). In one participant both screening 
cultures were negative, while cultures 3 to 12 were all positive. 
The most probable explanation for this would be either sample 
handling mistakes or a laboratory error. Since exclusion of this 
person did not significantly alter the data and mistakes happen 
in real life, it was decided not to exclude this person. The 
positive predictive value derived from regression models that 
included the results of cultures 1 and 2 was 0.79 in a model 
containing the qualitative outcome only as well as in a model 
including also the quantitative results (Figure 1B). Using the 
results of only one culture (either 1 or 2) produced a positive 
predictive value of 0.74. 
The numbers of CFUs of S. aureus were significantly higher in 
the validation than in the derivation cohort (Figure 2). The 
median geometric mean in intermittent and persistent carriers 
were 1.4 (range 0.3–3.3) and 3.6 (1.9-3.9) in the validation versus
1.0 (0.3–2.0) and 1.8 (0.9–3.2) in the derivation cohort (p=0.001 
and p<0.001), respectively. Persistent carriers had significantly 
higher CFUs of S. aureus in their positive nasal swab cultures 
than intermittent carriers (Figure 2): 1.8 (0.9–3.2) versus 0.98 
(0.30–2.0;p=0.001) in the derivation cohort and 3.6 (1.9–3.9) 
versus 1.4 (0.30–3.3;p<0.001) in the validation cohort (Figure 2). 
In the derivation cohort logistic regression showed that the 
model best differentiating between persistent and non-or-
intermittent carriage used qualitative culture results in 
combination with quantitative data (Figure 1A). The model using 
the results of 2 cultures performed significantly better than a 
model using the results of only one culture. Adding the results of 
a third or fourth culture did not significantly improve the model. 
Results from the ROC analysis showed that all tests used had 
good performance (all areas under the ROC curves were above 
0.9), with the combined model being slightly, but not 
significantly better than the qualitative result of two nasal swab 
cultures (Figure 1A).  
In the validation cohort, two qualitative culture results (positive 
or negative) discriminated similarly between persistent and 
non-or-intermittent carriage as the combined qualitative and  
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quantitative results (Figure 1B). All logistic regression models 
were significantly improved by adding data on a third culture. 
However, in the ROC analysis the differences between the 
models were small. Adding data on a third (but not a fourth 
culture) only significantly improved the model using both 
qualitative and quantitative culture results (Figure 1B).  
The areas under the ROC curves (AUC) using the combination of 
qualitative culture results and the geometric mean CFUs of 2 
cultures were 0.981 [95% CI: 0.949-1] for the derivation cohort 
and 0.936 [95% CI: 0.881-0.990] for the validation cohort, 
respectively (Figure 1). The logistic regression equation, using 
the combination of qualitative culture results and the geometric 
mean of CFUs from 2 cultures, could be written as: 
 
Probability of persistent S. aureus nasal carriage =  
 
e P(ß0 + ß1*number of positive cultures + ß2*geometric mean of CFUs) _______________________________________________ 
1+ e P(ß0 + ß1*number of positive cultures + ß2*geometric mean of CFUs) 
 
In the derivation cohort the respective values of ß0, ß1 and ß2 
were -20.171, 9.341 and 1.661. In the validation cohort these 
values were -4.572, 2.563 and 0.274, respectively.  
Using a cutoff of 0.50, above which probability persons were 
classified as persistent carriers, it followed from the logistic 
regression equation from the derivation cohort that a person was 
a persistent carrier only if both cultures were positive with a 
geometric mean of at least 0.9 (≈ 8 CFUs per culture). This 
‘culture rule’, when applied to the validation cohort, had a 
positive predictive value of 0.78, a negative predictive value of 
0.96 and an AUC of the corresponding ROC curve of 0.936 
(0.881-.990). 
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Figure 1A  Receiver Operating Characteristic (ROC) curve illustrating the 
predictive value of different tests for the persistent Staphylococcus 
aureus nasal carrier state in the derivation cohort. 
* AUC-ROC of 2 versus 1 culture p<0.05 
 
Predictive Values ROC analysis 
Test 
nr. of 
cultures PV+ PV- AUC 95% CI 
1 0.69 0.95 0.903* 0.810-0.968 
2 0.79 1.0 0.944 0.881-1 
Qualitative culture 
results (nr. of cultures 
positive) 
3 0.88 1.0 0.972 0.927-1 
2 0.85 0.89 0.973 0.936-1 Quantitative culture 
results (Geometric 
mean of CFUs) 3 0.92 0.92 0.983 0.954-1 
2 0.88 1.0 0.981 0.949-1 
 
Combined 
3 0.88 1.0 0.985 0.957-1 
 
1 - Specificity
1.00 0.80 0.60 0.40 0.20 0.00 
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Figure 1B  Receiver Operating Characteristic (ROC) curve illustrating the 
predictive value of different tests for the persistent Staphylococcus 
aureus nasal carrier state in the validation cohort. 
* AUC-ROC of 3 versus 2 cultures in the combined test p<0.05 
 
 
Predictive Values ROC analysis 
Test 
nr. of 
cultures PV+ PV- AUC 95% CI 
1 0.74 0.95 0.901 0.840-0.960 
2 0.79 0.99 0.929 0.873-0.985 
Qualitative culture 
results (nr. of cultures 
positive) 
3 0.88 0.96 0.967 0.934-1 
2 0.83 0.91 0.936 0.881-0.990 Quantitative culture 
results (Geometric 
mean of CFUs) 3 0.84 0.93 0.976 0.953-0.999 
2 0.79 0.99 0.936 0.881-0.990 
 
Combined 
3 0.85 0.96 0.986* 0.971-1 
1 - Specificity 
1.00 0.80 0.60 0.40 0.20 0.00 
Se
ns
iti
vit
y 
1.00 
0.80 
0.60 
0.40 
0.20 
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Combined,  
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 Qualitative only,
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Figure 2  Geometric means (P10PLog) CFUs of S. aureus in positive cultures in 
intermittent versus persistent carriers from both cohorts. Boxes 
represent median, quartile and extreme values. 
 
* persistent vs. intermittent carriers in derivation cohort p=0.001 
† persistent vs. intermittent carriers in validation cohort p<0.001 
¶ intermittent carriers: derivation vs. validation cohort p=0.001 
§ persistent carriers: derivation vs. validation cohort p<0.001 
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  Discussion 
 
  We examined the diagnostic value of two weekly quantitative 
nasal swab cultures to predict the S. aureus nasal carriage state 
and developed a culture rule to enable adequate differentiation 
between persistent carriage and intermittent carriage among 
those individuals with two positive screening cultures. 
Using logistic regression and ROC analysis a ‘culture rule’ was 
derived under ‘ideal’ laboratory circumstances in a cohort of 
healthy adult volunteers. Strictly speaking, the derivation cohort 
actually was more of an exploratory dataset to help select the 
variables in the model, but not the actual predictions. The 
‘culture rule’ was subsequently validated under ‘real life’ 
conditions in a subset of elderly participants of the Rotterdam 
Study.  
In the derivation cohort, the best test combined qualitative 
culture results (number of positive cultures) with quantitative 
data (geometric mean CFUs of S. aureus in nasal swab cultures). 
In the validation cohort, however, the simple qualitative culture 
result when using data on two cultures performed as good as the 
more complicated ‘culture rule’. The ‘culture rule’ performed 
slightly less good in the validation cohort (ROC-AUC 0.981 in the 
derivation and 0.936 in the validation cohort, respectively). In 
the ideal laboratory situation, one trained physician performed 
all nasal swab cultures in a cohort of healthy individuals. In the 
real life situation of large-scale epidemiologic surveys, 
misclassification of the carrier state could have occurred for a 
variety of logistic reasons: differing nasal culturing techniques of 
study physicians, sample handling mistakes, laboratory errors, 
etc. In theory, many of these ‘errors’ are preventable, but can 
never be totally eradicated. The fact that in the validation cohort 
the first two cultures were taken at the Rotterdam Study research 
center by various study physicians, while cultures 3-12 in the 
validation cohort were performed by one trained person, 
certainly affected culture results: using cultures 3 and 4 of the 
validation cohort, instead of culture 1 and 2, the ROC-AUC was 
increased from 0.936 to 0.996.  
Misclassification of the carrier state could also have occurred 
because of factors associated with individual participants of the 
Rotterdam study. Culture results will potentially have been 
influenced by the use of medication (recent courses of 
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antibiotics), institutionalization (recent hospital admissions) and 
underlying diseases, as well as other unknown determinants.  
 
We confirm earlier data, showing that the number of CFUs of S. 
aureus in P Pthe anterior nares was higher in persistent than in 
intermittentP Pcarriers.P24,25 P We also found a striking difference in 
the amount of S. aureus in the nose of persistent carriers 
between young healthy volunteers and healthy elderly 
participants. No prior data are available regarding age and the 
number of CFUs in the noses of persistent carriers. From the 
Rotterdam study (3851 persons) the high numbers of CFUs 
(median geometric mean 2.8) in elderly persistent carriers are 
confirmed (data not shown), but the underlying mechanisms of 
this finding remain to be elucidated. The differences in number 
of CFUs in persistent carriers in both cohorts will have affected 
the performance of the derived ‘culture rule’ in the validation 
cohort. When applying this ‘culture rule’ to other patient 
populations, it will need to be validated in the specific 
population first, when possible.  
 
Combining qualitative results with quantitative data is, in our 
opinion, conceptionally the best choice. Incorporating 
quantitative data makes it possible to refine associations 
between potential determinants and S. aureus nasal carriage, 
since not only carriers are compared with non-carriers, but also 
carriers with low CFUs can be compared with carriers with high 
CFUs in their anterior nares. Incorporating quantitative data will 
also make it possible to refine associations between carriage 
state and morbidity and mortality. However, in large-scale 
epidemiologic studies, simplicity will often prevail, because of 
logistic reasons and resources. It is therefore reassuring that in 
the validation cohort the simple qualitative culture results 
performed as good as the more complicated ‘culture rule’. 
Thus, two nasal swab cultures taken at a one-week interval can 
provide sufficient information to indeed adequately predict the 
S. aureus nasal carriage state. Using only one nasal swab culture 
to predict the carriage state, as is often done, cannot be 
recommended on the basis of our data since it will lead to 
misclassification of the carriage state. On the other hand, the 
addition of a 3 Prd P or 4 Pth P quantitative nasal swab culture only 
minimally improved test performance. Importantly, no persons 
with the first 2 cultures positive were found to be non-carriers. 
The finding of two negative screening cultures in one person 
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with subsequent positive cultures is difficult to explain but may 
be attributable to sample handling mistakes or laboratory error. 
These results were included in the evaluation, though. One 
negative ‘screening’ culture virtually excludes persistent 
carriage. Predicting the non-carrier state from 2 nasal swab 
cultures is more difficult since at least 7 nasal swab cultures 
would be needed to distinguish intermittent from non-carriers. 
 
At present data on determinants of persistent S. aureus nasal 
carriage in the elderly in the Rotterdam study are being 
analyzed using this ‘culture rule’. This is the first study to 
validate the potential of a limited number of nasal swab cultures 
in predicting the S. aureus carrier state. Since the incidence of S. 
aureus infections has increased substantially and because of the 
dramatic worldwide increase in antibiotic resistance 
(methicillin- and recently even vancomycin resistance) in S. 
aureus, prevention is now more important than ever. Apart from 
its role in the Rotterdam study, we hope that the presented 
‘culture rule’ will prove to be a helpful tool in identifying 
determinants of S. aureus nasal carriage and infections, as well 
as in identifying high-risk patient populations and the 
implementation of new methods in the prevention of S. aureus 
infections. 
 
 
 
 
II - 16  DEFINITIONS/ Chapter 2/ Predicting the Staphylococcus aureus Nasal Carrier State: Derivation & Validation of a ‘Culture Rule’.
 
2004 © J.L. Nouwen \ December 8th 2004 \ Thesis: Determinants, Risks & Dynamics of Staphylococcus aureus Nasal Carriage 
 
  References 
 
  1. Chow, J.W. & Yu, V.L. Staphylococcus aureus nasal carriage in 
hemodialysis patients. Its role in infection and approaches to prophylaxis. 
Arch Intern Med 149, 1258-62 (1989). 
2. Corbella, X. et al. Staphylococcus aureus nasal carriage as a 
marker for subsequent staphylococcal infections in intensive care unit 
patients. Eur J Clin Microbiol Infect Dis 16, 351-357 (1997). 
3. Kluytmans, J.A. et al. Nasal carriage of Staphylococcus aureus as a 
major risk factor for wound infections after cardiac surgery [see comments]. 
J Infect Dis 171, 216-9 (1995). 
4. Luzar, M.A. et al. Staphylococcus aureus nasal carriage and 
infection in patients on continuous ambulatory peritoneal dialysis. N Engl J 
Med 322, 505-9 (1990). 
5. von Eiff, C., Becker, K., Machka, K., Stammer, H. & Peters, G. Nasal 
Carriage as a Source of Staphylococcus aureus Bacteremia. N Engl J Med 344,
11-16 (2001). 
6. Archer, G.L. & Climo, M.W. Staphylococcus aureus Bacteremia -- 
Consider the Source. N Engl J Med 344, 55-56 (2001). 
7. Martin, G.S., Mannino, D.M., Eaton, S. & Moss, M. The 
epidemiology of sepsis in the United States from 1979 through 2000. N Engl J 
Med 348, 1546-54 (2003). 
8. Casewell, M.W. & Hill, R.L. Elimination of nasal carriage of 
Staphylococcus aureus with mupirocin ('pseudomonic acid')--a controlled 
trial. J Antimicrob Chemother 17, 365-72 (1986). 
9. Moss, B., Squire, J.R. & Topley, E. Nose and skin carriage of 
Staphylococcus aureus in patients receiving penicillin. Lancet 1, 320-325 
(1948). 
10. Williams, R.E.O. Skin and nose carriage of bacteriophage types of 
Staphylococcus aureus. J Path Bact 58, 259-268 (1946). 
11. Kluytmans, J., van Belkum, A. & Verbrugh, H. Nasal carriage of 
Staphylococcus aureus: epidemiology, underlying mechanisms, and 
associated risks. Clin Microbiol Rev 10, 505-20 (1997). 
12. Williams, R.E.O. Healthy carriage of Staphylococcus aureus: it's 
prevalence and importance. Bacteriol Rev 26, 56-71 (1963). 
13. Armstrong-Esther, C.A. Carriage patterns of Staphylococcus 
aureus in a healthy non-hospital population of adults and children. Ann Hum 
Biol 3, 221-7 (1976). 
14. Goslings, W.R.O. & Buchli, K. Nasal carriage rate of antibiotic-
resistant staphylococci. Arch Int Med 102, 691-715 (1958). 
15. Gould, J.C. & McKillop, E.J. The carriage of Staphylococcus 
pyogenes var. aureus in the human nose. J Hyg.(Lond) 52, 304-310 (1954). 
16. Hoffler, U., Bulanda, M., Heczko, P.B. & Pulverer, G. A comparison 
of staphylococcal nasal carrier rates in Germany and Poland. Med Microbiol 
Immunol 164, 285-290 (1978). 
17. Hu, L., Umeda, A., Kondo, S. & Amako, K. Typing of Staphylococcus 
aureus colonising human nasal carriers by pulsed-field gel electrophoresis. J 
Med Microbiol 42, 127-32 (1995). 
18. Lamikanra, A. & Olusanya, O.I. A long-term study of the nasal 
carriage of Staphylococcus aureus in healthy Nigerian students. Trans R Soc 
Trop Med Hyg 82, 500-2 (1988). 
19. Maxwell, J.G., Ford, C.R., Peterson, D.E. & Mitchell, C.R. Long-term 
study of nasal staphylococci among hospital personnel. American Journal of 
Surgery 118, 849-854 (1969). 
20. Miles, A.A., Williams, R.E.O. & Clayton-Cooper, B. The carriage of 
Staphylococcus (pyogenes) aureus in man and its relation to wound infection. 
DEFINITIONS/ Chapter 2/ Predicting the Staphylococcus aureus Nasal Carrier State: Derivation & Validation of a ‘Culture Rule’.  II - 17
 
2004 © J.L. Nouwen \ December 8th 2004 \ Thesis: Determinants, Risks & Dynamics of Staphylococcus aureus Nasal Carriage 
J Path Bact 56, 513-524 (1944). 
21. Miller, D.L., McDonald, J.C., Jevons, M.P. & Williams, R.E.O. 
Staphylococcal disease and nasal carriage in the Royal Air Force. J Hyg 
Camb 60, 451-465 (1962). 
22. Riewerts Eriksen, N.H., Espersen, F., Thamdrup Rosdahl, V. & 
Jensen, K. Carriage of Staphylococcus aureus among 104 healthy persons 
during a 19 month period. Epidemiol Infect 115, 51-60 (1995). 
23. VandenBergh, M.F. et al. Follow-up of Staphylococcus aureus nasal 
carriage after 8 years: redefining the persistent carrier state. J Clin Microbiol 
37, 3133-40 (1999). 
24. White, A. Quantitative studies of nasal carriers of staphylococci 
among hospitalized patients. J Clin Invest 40, 23-30 (1961). 
25. White, A., Hemmerly, T., Martin, M.P. & Knight, V. Studies on the 
origin of drug-resistant staphylococci in a mental hospital. Am J Med 27, 26-
39 (1959). 
26. Bruun, J.N. Post-operative wound infection: predisposing factors 
and the effect of a reduction in dissemination of staphylococci. Acta Med 
Scand 514, 1-89 (1970). 
27. Calia, F.M., Wolinsky, E., Mortimer, E.A., Jr., Abrams, J.S. & 
Rammelkamp, C.H., Jr. Importance of the carrier state as a source of 
Staphylococcus aureus in wound sepsis. J Hyg.(Lond) 67, 49-57 (1969). 
28. White, A. Increased infection rates in heavy nasal carriers of 
coagulase- positive staphylococci. Antimicrob Agents Chemother 30, 667-670 
(1963). 
29. Van Belkum, A. et al. Coagulase and protein A polymorphisms do 
not contribute to persistence of nasal colonisation by Staphylococcus aureus. 
J Med Microbiol 46, 222-32 (1997). 
30. Metz, C.E. Basic principles of ROC analysis. Semin Nucl Med 8, 283-
98 (1978). 
31. Hanley, J.A. & McNeil, B.J. The meaning and use of the area under a 
receiver operating characteristic (ROC) curve. Radiology 143, 29-36 (1982). 
32. Bamber, D. The area above the ordinal dominance graph and the 
area below the receiver operating graph. J Math Psych 12, 387-415 (1975). 
33. Hanley, J.A. & McNeil, B.J. A method of comparing the areas under 
receiver operating characteristic curves derived from the same cases. 
Radiology 148, 839-43 (1983). 
 
 

2004 © J.L. Nouwen \ December 8th 2004 \ Thesis: Determinants, Risks & Dynamics of Staphylococcus aureus Nasal Carriage 
 
 
  
 
 
The Human Factor in
Staphylococcus aureus Nasal Carriage
 
 
 
  a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a
Authors  Jan L. Nouwen, M.D. M.Sc., Hélène A.M. Boelens, B.Sc., Alex van Belkum, Ph.D. Ph.D.
& Henri A. Verbrugh, M.D. Ph.D.
 
Affiliations Erasmus Medical Center, Rotterdam, The Netherlands.
Department of Medical Microbiology & Infectious Diseases
Published as The Human Factor in Staphylococcus aureus Nasal Carriage.
Infection & Immunity 72, in press (2004).
III - 2 DETERMINANTS/ Chapter 3/ The Human Factor in Staphylococcus aureus Nasal Carriage.
 
2004 © J.L. Nouwen \ December 8th 2004 \ Thesis: Determinants, Risks & Dynamics of Staphylococcus aureus Nasal Carriage 
 
  Abstract 
 
  
  
Persistent Staphylococcus aureus nasal carriers and non-carriers 
were inoculated with a mixture of different S. aureus strains. The 
majority of non-carriers and nearly all persistent carriers 
returned to their original carrier state after artificial inoculation. 
Furthermore, the majority of persistent carriers selected again 
for their historic resident strain. Using a human nasal inoculation 
model, we here demonstrate that the human factor is an 
important determinant of S. aureus nasal carriage. 
 
 
 
 
  Introduction 
 
  Staphylococcus aureus nasal carriage is a major risk factor for 
Staphylococcus aureus infections.P1,2 P Recently, cell wall 
lipoteichoic acid was described as the core factor for S. aureus 
nasal colonization. P3 P However, in earlier studies no single 
staphylococcal factor essential for nasal colonization could be 
identified. P4-7 P Furthermore, host factors, P1,8,9 P as well as 
environmental factors are recognized determinants of the S. 
aureus nasal carrier state.P10,11 P  
Three human nasal Staphylococcus aureus carriage patterns can 
be distinguished: persistent-, intermittent- and non-carriage. P12 P S. 
aureus density inP Pthe anterior nares is higher in persistent 
carriers,P13 P which may partly explain their increasedP Prisk of S. 
aureus infections.P14 P Variation among colonizing strains is higher 
for intermittent carriers, P15 P suggestingP Pthat the basic determinants
of persistent and intermittent carriage are P Pdifferent. The biology 
of S. aureus nasal carriage remains incompletely understood, 
although the importance of various host factors has been 
demonstrated.P8,16-18P In seeking further clarification, we 
performed a study in which persistent carriers and non-carriers 
were inoculated intranasally with a mixture of S. aureus strains.  
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  Material & Methods 
 
  In 1988 a cohort of healthy volunteers (staff members of the 
departments of Medical Microbiology & Infectious Diseases and 
Virology of the Erasmus MC) was formed to investigate bacterial 
and human factors associated with S. aureus nasal carriage.P15 P The
composition of this volunteer cohort was flexible, in that 
outgoing personnel were considered lost to follow-up and 
replaced by incoming personnel. All volunteers were screened 
initially with 12 quantitative nasal swab cultures with one-week 
intervals. After this initial establishment of S. aureus nasal 
carriage status, volunteers were re-screened regularly with 4 
quantitative nasal swab cultures with one-week intervals. For the 
present study only volunteers in follow-up for at least 2 years 
and with at least 16 nasal swab cultures done, were included. 
Long term persistent carriers were defined as all preceding 
cultures positive and long term non-carriers as all preceding 
cultures negative. Participants were excluded if they suffered 
from diabetes mellitus, skin diseases, chronic obstructive 
pulmonary disease, and cardiac valve abnormalities or were 
taking immunosuppressive agents. Eleven persistent carriers 
and 8 non-carriers agreed to participate in the present study. All 
participants gave written informed consent and the study was 
approved by the Medical Ethics Review Committee (METC 
Erasmus MC, nr. 156.137/1996/186). 
For the non-carriers, a mixture of 4 different S. aureus strains was
prepared consisting of S. aureus 502A (a strain used in 
intervention studies in the 1960s and 1970sP19P), S. aureus DU 5819 
(a protein A deficient Dublin strain, courtesy of Dr. T. Foster), S. 
aureus 274 (a strain from a persistent carrier) and S. aureus 1036 
(a strain from an intermittent carrier). Strains were selected from 
different carriage classes to analyze whether they have different 
colonization capacities. P15 P The strains did not produce super-
antigens and did not show different in vitro growth 
characteristics (data not shown). For the persistent carriers the 
same mixture of 4 S. aureus strains was used, while adding their 
own resident strain. 
Nasal swabs were obtained using cotton-wool swabs (Transwab, 
Corsham, United Kingdom). P15 P The left and right anterior nares 
were swabbed four times around. The swabs were immediately 
placed in Stuart’s transport medium (Transwab) and kept at 4P0 PC 
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until quantitative culture on phenol-red mannitol salt agar 
(PHMA) and in phenol red mannitol salt broth (PHMB). The 
PHMB was incubated at 37P0 PC (7 days); the PHMA culture plates 
were incubated at 37P0 PC (48 hrs) and at room temperature (5 
days). Identification of S. aureus was based upon colony 
morphology and a catalase- and latex-agglutination test 
(Staphaurex Plus PRP, Murex, Dartford, UK). The geometric mean of 
colony forming units (CFUs) in the 26 post-inoculation cultures 
was calculated as (10Log[CFUB1 B+1] + 10Log[CFUB2 B+1] + … + 
10Log[CFUB26 B+1])/26. Per culture, 16 S. aureus colonies 
(maximum amount allowing for efficient molecular 
characterization), including all S. aureus morphotypes, were 
stored at -70 P0 PC. To obtain bacterial DNA, S. aureus isolates were 
grown overnight at 37 P0 PC on Brucella blood agar and processed 
according to Boom et al.P20P DNA  was stored at -20 P 0 PC. Restriction 
fragment length polymorphisms (RFLP) of the coagulase and 
protein A genes were determined for strain identification 
purposes in the four S. aureus strains and all resident S. aureus 
strains from persistent carriers before inoculation. P21 P 
Furthermore, all S. aureus strains isolated two and thirteen 
weeks after inoculation and/or from the last positive culture 
were genotyped using this method. Pulsed-field gel 
electrophoresis (PFGE) was performed to confirm the results.P22P 
All persistent carriers were treated with mupirocin nasal 
ointment (Bactroban®, GlaxoSmith Kline, Zeist, The 
Netherlands) 2 times daily for 5 days. The non-carriers did not 
receive mupirocin treatment. Ten weeks later, with nasal swab 
cultures negative, all participants were inoculated. Inoculation 
was performed using cotton-wool swabs drenched in PHMB 
containing 10 P9 PCFUs/mL of each strain. Per nostril, one swab was 
firmly applied against the inner side of the anterior nares and 
turned around 4 times. In this way, strains were inoculated in a 
total amount of 10P9 P CFUs. At inoculation, blood was drawn for the 
determination of the erythrocyte sedimentation rate (ESR), C-
reactive protein (CRP), leukocyte count and differentiation and 
anti-staphylococcal antibodies (ASTA). These tests were 
repeated when required. Nasal cultures were performed weekly 
during the study period. All participants with positive cultures at 
the end of the study were offered mupirocin nasal ointment 
(Bactroban®).  
The primary endpoint was survival of S. aureus in the nose after 
artificial colonization. Survival ended when at least two 
consecutive nasal swab cultures were negative. Kaplan-Meier 
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curves and the log-rank test were used to compare S. aureus 
survival curves. Participant’s still carrying S. aureus in their nose 
at the end of the study were considered as censored in the 
analysis. The secondary endpoint was the geometric mean of 
CFUs over 26 weeks. Percentages and continuous data were 
compared by Fisher’s exact test and Mann-Whitney’s test, 
respectively. 
 
 
 
 
  Results 
 
  After artificial inoculation with a mixture of S. aureus strains, 
median nasal survival of S. aureus was 186 days in persistent 
carriers versus 35.5 days in non-carriers (P = 0.0427; Figure 1). 
Also, the 26 weeks Log geometric mean of CFUs was higher in 
persistent carriers (median 2.9 [range 0.6-3.7] versus 0.7 [0-
3.6]), nearly reaching statistical significance (P = 0.069).  
Six out of eight non-carriers became non-carriers again: 4 within 
2 weeks after inoculation (non-carriers 224, 317, 244 and 207), 
and 2 after 19 (non-carrier 302) and 23 weeks (non-carrier 311; 
inoculation strain S. aureus 502A), respectively (Figure 2). Non-
carrier 302 remained persistently positive with inoculation S. 
aureus strain 274 until week 11, intermittently between weeks 
12-18 and reverted to the non-carrier state again at week 19  
(Figure 2). Two non-carriers still had positive nasal cultures at 
the end of the study. Non-carrier 233 had positive cultures up to 
week 8, negative cultures between week 9-20 and then cultured 
positive again until the end of the study. This person first 
selected for S. aureus DU 5819, while ultimately a foreign S. 
aureus strain not included in the inoculation mixture was 
retained. Non-carrier 249 remained persistently positive after 
inoculation until the end study with inoculation S. aureus strain 
274, and thus had become a persistent S. aureus nasal carrier 
(Figure 2). Two of the non-carrier volunteers developed minor 
self-limiting skin lesions: non-carrier 311 colonized with S. 
aureus 502A and non-carrier 249 colonized with S. aureus strain 
274. No antibiotic treatment was necessary and all laboratory 
parameters remained completely normal. No side-effects were 
not noted in the persistent carrier group (P=0.1637). 
In the persistent carrier group, 7 persons became persistent  
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Figure 1  S. aureus survival after artificial nasal inoculation in long-term 
persistent and non S. aureus nasal carriers. 
 
Kaplan-Meier curves of S. aureus nasal survival in persistent 
carriers depicted by the black line and in non-carriers depicted by 
the dotted grey line. Survival ended when at least two consecutive 
nasal swab cultures were negative. After artificial inoculation with 
a mixture of S. aureus strains, median nasal survival of S. aureus 
was 186 days in persistent carriers versus 35.5 days in non-carriers 
(P = 0.0427; log-rank test). 
 
200 180 160 140 120 100 80 60 40 20 0
S.
 au
re
us
  n
as
al 
su
rv
iva
l 
1.0 
0.8 
0.6 
0.4 
0.2 
0.0 
Pre-inoculation
carrier state 
persistent carriers
non-carriers
P = 0.0427 
Days since inoculation
DETERMINANTS/ Chapter 3/ The Human Factor in Staphylococcus aureus Nasal Carriage. III - 7
 
2004 © J.L. Nouwen \ December 8th 2004 \ Thesis: Determinants, Risks & Dynamics of Staphylococcus aureus Nasal Carriage 
 
  carriers again after artificial nasal inoculation: 4 carrying their 
own resident strain (persistent carriers 322, 211, 216 and 248) 
and 3 (persistent carriers 318, 303 and 228) carrying unique 
foreign strains not included in the mixture. These new strains 
were all genetically different and did not represent a laboratory 
contamination. Three persistent carriers became intermittent 
carriers with their own resident strain (persistent carriers 326, 
316 and 321) and one person (persistent carrier 240) reverted to 
the non carrier state (Figure 2).  
 
 
 
 
  Discussion 
 
  The present results identify the importance of host factors in 
determining the S. aureus nasal carrier state in healthy adults. 
Half of non-carriers became non-carriers again within 2 weeks 
after inoculation. Only one non-carrier became a persistent 
carrier, coinciding with minor self-limiting skin lesions. These 
data suggest that most non-carriers are inherently resistant to 
colonization, but when S. aureus carriage is imposed, minor skin 
lesions can develop. Bacterial interference may be an 
explanation of the non-carrier state: when an ecological niche is 
already occupied by other bacteria S. aureus does not seem to 
have the means to establish a local population. P23P Recent data 
indicate that when the non-carriers were treated with mupirocin 
prior to inoculation elimination was as efficient: only 1 out of 16 
volunteers was found to be still colonized after 16 weeks (data 
not shown). This suggests that non-carriers are not protected by 
a mupirocin-susceptible resident population of bacteria. 
Among the 11 persistent carriers, 7 became a persistent carrier 
again: 4 with their own resident strain and 3 with genetically 
unique foreign strains not included in the mixture. Three 
persons became intermittent carriers, all with their own resident 
strain. Only one person reverted to the non carrier state. Given 
the opportunity, persistent carriers will select an optimally fitting
S. aureus strain, either from the inoculation mixture or from their 
environment. P15P When the intermittent carriers are included 7 out 
of 11 volunteers did select their original resident strain again.  
So far, no single common genetic or phenotypic characteristics  
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Figure  2  Post-artificial nasal inoculation culture results from 11 long-term 
persistent and 8 
non S. aureus nasal carriers during 26 weeks of follow-up.  
 
ID stands for the identification number of the individual 
participants. At time points 2 and 13 post-inoculation and of the 
last positive culture, all S. aureus strains cultured were genotyped. 
The various genotypically distinct S. aureus strains cultured are 
identified by colors and codes.  
The historic resident strains of the persistent carriers are colored 
black and coded with an O as of ‘own’.  
The 4 S. aureus strains used in the inoculation mixture are colored 
light grey and coded i1 (inoculation S. aureus strain 502A), i2 
(inoculation S. aureus strain 274 [=persistent carrier strain]), i3 
(inoculation S. aureus strain 1036 [=intermittent carrier strain]) and 
i4 (inoculation S. aureus strain DU 5819 [=protein A deficient 
strain]). Five unique foreign S. aureus strains, which were neither 
resident strains from persistent carriers, nor inoculation strains 
from the inoculation mixture, were cultured in 5 participants. 
These foreign S. aureus strains are colored dark grey and coded 
f1, f2, f3, f4 and f5. Multiple genotypically distinct S. aureus strains 
can thus be cultured at each point in time during follow-up. 
No coloring designates that cultures were negative at that point in 
time. 
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  segregating successful from less- or non-successful colonizing S. 
aureus strains have been identified.P4,6-9 P However, lipoteichoic 
acid has been implicated as an essential bacterial factor for S. 
aureus nasal colonization in a rat model recently. P3 P  
Here we conclude that in addition host characteristics 
significantly co-determine the S. aureus carrier state and that 
optimal fit between host and bacteria seems to be important. 
Further research should focus on identifying the specific host 
and bacterial factors involved. New strategies for the prevention 
of S. aureus nasal carriage and endogenous S. aureus infection 
could then be developed. 
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  Abstract 
 
Context  
  
Staphylococcus aureus nasal carriage is a known risk factor for S. 
aureus infections. Most studies on determinants of S. aureus 
nasal carriage have been performed among hospitalized 
persons and not in the general community. 
Objective  To identify determinants of S. aureus nasal carriage in a large 
community-based population.  
Design  Cross-sectional population-based study; April 1 P
st
P 1997 and 
December 31 PstP 1999. 
Setting  The Rotterdam Study. 
Participants  
  
Of 4,797 participants in the second follow-up of the Rotterdam 
Study, 3,882 persons were able to visit the study center and 
included in the study. Two quantitative nasal swab cultures with 
one-week intervals were performed. According to an earlier 
derived ‘culture rule’ two carriage patterns were distinguished: 
non-or-intermittent and persistent S. aureus nasal carriage. In 31 
persons an incomplete set cultures was obtained, leaving 3,851 
persons (median age 71 years [range 61 to 101]) with complete 
bacteriological results, 2,224 women and 1,627 men.  
Outcome 
Measures 
 Determinants of persistent S. aureus nasal carriage. 
Results  
  
Male sex (odds ratio [OR], 1.49; 95% confidence interval [CI], 
1.24-1.80), diabetes mellitus (OR, 1.43; 95% CI, 1.11-1.83) and a 
history of eczema (OR, 1.92; 95% CI, 1.49-2.46) were associated 
with persistent S. aureus nasal carriage. The proportion of 
persistent carriers increased with fasting glucose level: one 
mmol/L increase in glucose level was associated with a 1.09 
higher risk (95% CI, 1.04-1.15). Higher age (OR, 0.89 per 10 
years; 95% CI, 0.78-0.99) and current smoking (OR, 0.64; 95% 
CI, 0.49-0.84) were negatively associated with persistent 
carriage. 
Conclusions  
  
We confirm that age, sex and skin diseases are determinants of 
S. aureus nasal carriage. Smoking status and fasting blood 
glucose are newly recognized determinants of persistent S. 
aureus nasal carriage. Toxic or inflammatory effects of cigarette 
smoke and glycation of cellular structures or mucosal glucose 
level may promote S. aureus nasal colonization. 
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  Introduction 
 
  S. aureus is an important agent of human disease and the cause 
of a variety of infections ranging from mild to life-threatening. P1P 
Over the last 20 years the incidence of both community-acquired
and hospital-acquired S. aureus infections has increased,P2P while 
antibiotic treatment is increasingly hampered by the spread of S. 
aureus strains resistant to multiple antibiotics including 
methicillin and, more recently, vancomycin. P3P  
The nose (i.e. the anterior nares) has been shown to be the 
primary ecological reservoir of S. aureus in humans.P4 P S. aureus 
nasal carriage is a major risk factor for the development of S. 
aureus infections in various clinical settingsP5,6 P The majority of 
staphylococcal infections is of endogenous origin. P7P  
Three S. aureus nasal carriage patterns can be distinguished: 
persistent, intermittent and non-carriage. P5P The biology of nasal 
colonization remains incompletely understood. Several studies 
have demonstrated the importance of host factors, P5,6,8 P but 
environmental factors also contribute to S. aureus nasal 
carriage.P9-11 P  
Most studies on the determinants of S. aureus nasal carriage 
have been performed among hospitalized persons or specific 
patient groups. Large scale population-based studies are 
scarce P12P and most studies have been performed in restricted 
populations. P10,11,13 P  Our main objective was to find determinants 
of S. aureus nasal carriage in a large population of persons aged 
55 years or over.  
 
 
 
 
  Material & Methods 
 
  Population and measurements 
  This study was conducted as part of the Rotterdam Study, a 
prospective, population-based cohort study on the occurrence 
and determinants of disease and disability in elderly persons.P14P 
In 1990, all inhabitants of Ommoord, a suburb of Rotterdam in 
the Netherlands, who were 55 years of age or older and had 
III - 20 DETERMINANTS/ Chapter 4/ Smoking Pattern & Fasting Glucose Levels DetermineStaphylococcus aureus Nasal Carriage.
 
2004 © J.L. Nouwen \ December 8th 2004 \ Thesis: Determinants, Risks & Dynamics of Staphylococcus aureus Nasal Carriage 
lived in the district for at least one year were invited to 
participate in the study. Of the 10,275 eligible persons, 7983 
(78%) participated. At baseline, between 1990 and 1993, trained 
interviewers administered an extensive questionnaire covering 
socioeconomic background and medical history, among other 
topics, during a home interview. During subsequent visits to the 
study center, additional interviewing, laboratory assessments, 
and clinical examinations were performed. Information on vital 
status is obtained at regular time intervals from the municipal 
authorities in Rotterdam. The second follow-up of the Rotterdam 
Study was performed between April 1 PstP 1997 and December 31 PstP 
1999 among 4,797 remaining participants. Of these, 3,882 
persons were able to visit the study center and included in the 
current study. In 31 persons an incomplete set of nasal cultures 
was obtained, leaving 3,851 persons with complete 
bacteriological results, 2,224 women and 1,627 men. The study 
was approved by the Medical Ethics Committee of the Erasmus 
MC, University Medical Center Rotterdam. Informed consent 
was obtained of all participants.  
On visiting the study center, participating persons were 
interviewed using standardized questionnaires.P15-18P The main 
chronic medical disorders assessed were cardiovascular, 
neurologic, ophthalmologic and endocrine diseases. Persons 
were asked if they lived independently or institutionalized 
(home for the elderly or nursing home) and if they were living 
alone or together with a partner. Smoking habits were assessed 
by interview. We asked for cigarette, cigar and pipe smoking. 
Participants were asked if they were currently smoking, if they 
had smoked in the past or never smoked. Current and past 
smokers were asked when they had started smoking, when they 
had stopped smoking and how many cigarettes, cigars and/or 
pipes they had been or were smoking a day. Furthermore, they 
were asked if their spouse (when present) (had) smoked. 
Participants and their spouses were categorized in mutually 
exclusive categories of current, past and never smokers. A 
distinction was made between ‘all smoking’ (including pipe, 
cigar and cigarette smoking) and cigarette smoking only. 
Medication was assessed by interview and completed with data 
supplied by local pharmacies. Fasting glucose level was 
measured in all participants. Persons were categorized as 
having diabetes mellitus when either diabetes mellitus had been 
diagnosed earlier and they were using a diet or antidiabetic 
medication (tablets orally or insulin subcutaneously), or when 
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their fasting glucose level was 7.0 mmol/L (126 mg/dl) or 
greater. Persons were categorized as not having diabetes 
mellitus when their fasting glucose level was below 6.1 mmol/L 
and they were not using antidiabetic medication. Persons were 
categorized as having borderline impaired glucose metabolism 
when their fasting glucose level was equal to or higher than 6.1 
mmol/L (110mg/dl) but lower than 7.0 mmol/L (126 mg/dl). P19 P 
 
  Microbiological procedures 
  Nasal swabs were cultured as described earlier. P20 P In brief, nasal 
samples were obtained using sterile cotton-wool swabs 
(Transwab, Medical Wire & Equipment Co. Ltd., Corsham, 
United Kingdom). Both the left and right anterior nares were 
swabbed and swabs were immediately placed in Stuart’s 
transport medium and kept at 4 P0 PC until further processing 
(within 24 hours). Swabs were cultured quantitatively on phenol-
red mannitol salt agar (PHMA) and phenol red mannitol salt 
broth (PHMB).  
Identification of S. aureus was based upon colony morphology on
the PHMA. Suspected colonies were cultured overnight on 
Columbia blood agar plates (Becton-Dickinson B.V., Etten-Leur, 
The Netherlands). A catalase and latex agglutination test 
(Staphaurex Plus PRP, Murex, Dartford, UK) both had to be positive. 
All S. aureus isolates were stored at -70 P0 PC in glycerol containing 
liquid media. 
 
  Defining the S. aureus nasal carrier state 
  S. aureus nasal carriage was defined according to an earlier 
validated culture rule. P21 P In brief, this culture rule uses qualitative 
(number of positive nasal swab cultures) and quantitative results 
(number of colony forming units (CFUs) in those nasal swab 
cultures). Persons were classified as persistent carriers when 
both nasal swab cultures were positive with S. aureus. Persons 
were classified as intermittent carriers when only one of the two 
nasal swab cultures was positive with S. aureus. Persons were 
classified as non-carriers when both nasal swab cultures were 
negative. We combined the non-or-intermittent carrier groups to
contrast with the persistent carrier group. 
 
  Statistical analysis 
  Potential determinants of persistent S. aureus nasal carriage 
were tested univariately first. We used the Chi-square test (or 
Fisher’s exact test in case of 2x2 tables) to compare proportions. 
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For comparison of continuous data Student’s T-test, Mann-
Whitney’s test (in case of non-normal distributions), or Kruskal-
Wallis’ test (for k independent samples) were used where 
appropriate. Thereafter, variables associated with persistent 
carriage with a P value of less than 0.20 in the univariate 
analysis, were further tested using logistic regression analysis. 
Sex and age were entered in all regression models to correct for 
potential confounding. Some variables had missing data, which 
never exceeded 2.5% of participants. To include these 
individuals in the analysis, we created a missing value indicator 
when applicable. Results are reported as odds ratios with 95 
percent confidence intervals. Two-sided P values of less than 
0.05 were considered to indicate statistical significance. 
 
 
 
 
  Results 
 
  The majority of persons enrolled in the study was living 
independently, together with a partner.  More than 80% did not 
currently smoke, while 34% had never smoked. The prevalence 
of diabetes mellitus was 11.8% (446/3,768). Only 2.5% was using
sex hormones (mainly estrogen suppletion in 67 women) and 
only one person was on intermittent hemodialysis for end stage 
renal failure. Nearly half (1,627/3,785) had experienced one or 
more skin diseases prior to this study (Table 1). 
The proportion of persistent carriers was higher in men than in 
women: 0.21 versus 0.16 (odds ratio [OR], 1.49; 95% confidence 
interval [CI], 1.24-1.80; Table 2). The Log geometric mean of the 
number of colony forming units (CFU) in the two nasal swab 
cultures was also significantly higher in men than in women (0.69
versus 0.49; difference 0.20; 95% CI, 0.12-0.27). However, male 
and female persistent carriers had similar Log geometric mean 
CFUs (2.86 versus 2.73; difference 0.13; 95% CI, -0.04-0.30). 
The proportion of persistent carriers decreased slightly with age 
from 0.19 in the youngest age group (61 to 65 years) to 0.15 in 
age group 85 to 90 years (P for trend = 0.10). Logistic regression 
analysis demonstrated each 10 year increase in age to be 
associated with a 11% lower risk of persistent S. aureus nasal 
carriage (OR, 0.89 per 10 years; 95% CI, 0.78-0.99; Figure 1). 
Persons living in a nursing home (median age 89, range 74 to  
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Table 1  Main Characteristics of the study population.  
   
Characteristic 
Men 
(N=1,627) 
Women 
(N=2,224) 
Age - yr   
 Median 71 72 
 Range 61-97 61-101 
Living with partner - no. (%)   
 Yes 1,391 (85.5) 1,233 (55.4) 
 No 229 (14.1) 978 (44.0) 
 Missing 7 (0.4) 13 (0.6) 
Institutionalized - no. (%)   
 Yes 130 (8.0) 308 (13.8) 
 No 1,490 (91.6) 1,903 (85.6) 
 Missing  7 (0.4) 13 (0.6) 
Diabetes mellitus - no. (%)   
 Diabetes mellitus 208 (12.8) 238 (10.7) 
 Impaired fasting glucose  251 (15.4) 331 (14.9) 
 Normal fasting glucose 1,140 (70.1) 1,600 (71.9) 
 Missing 28 (1.7) 55 (2.5) 
Smoking - no. (%)   
 Current 350 (12.5) 320 (14.4) 
 Past 1,082 (66.5) 783 (35.2) 
 Never 186 (11.4) 1,106 (49.7) 
 Missing 9 (0.6) 15 (0.7) 
Skin diseases   
 Skin infections past 3 months - no. (%)   
 Yes 133 (8.2) 138 (6.2) 
 No  1,484 (91.2) 2,069 (93.0) 
 Missing 10 (0.6) 17 (0.8) 
 Boils ever - no. (%)   
 Yes 744 (45.7) 526 (23.7) 
 No 868 (53.4) 1,677 (75.4) 
 Missing 15 (0.9) 21 (0.9) 
 Eczema past 12 months - no. (%)   
 Yes 156 (9.6) 208 (9.4) 
 No 1,449 (89.1) 1,989 (89.4) 
 Missing 22 (1.3) 27 (1.2) 
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Table 2  Associations of sex, living conditions, diabetes mellitus, smoking 
pattern and skin diseases with persistent S. aureus nasal carriage. 
   
 S. aureus Nasal Carrier state Determinant 
 Persistent Non or 
Intermittent 
Total 
Crude  
Odds 
Ratio 
(95% CI) 
Adjusted  
Odds 
Ratio§ 
(95% CI) 
Sex  
- no. (%) 
Men 
Women 
333 (20.5) 
345 (15.5) 
1,294 (79.5) 
1,879 (84.5) 
1,627 
2,224 
1.40  
(1.19-1.66) 
1.49  
(1.24-1.80) 
        
Living with a partner 
– no. (%) 
Yes 
No 
481 (18.3) 
193 (16.0) 
2,143 (81.7) 
1,014 (84.0) 
2,624 
1,207 
1.18  
(0.98-1.41) 
1.04  
(0.60-1.81) 
        
Institutionalized  
- no. (%) 
Yes 
No 
64 (14.6) 
610 (18.0) 
374 (85.4) 
2,783 (82.0) 
438 
3,393 
0.78  
(0.59-1.03) 
0.86  
(0.64-1.16) 
        
Yes 
Impaired 
99 (22.2) 
110 (18.9) 
347 (77.8) 
472 (81.1) 
446 
582 
1.38*  
(1.09-1.76) 
1.43  
(1.11-1.83) 
Diabetes mellitus  
- no. (%) 
 No 459 (16.8) 2,281 (83.2) 2,740    
Current 
Past 
96 (14.3) 
348 (18.7) 
574 (85.7) 
1,517 (81.3) 
670 
1,865 
0.75 P¶  
(0.59-0.94) 
0.64 P  
(0.49-0.84) 
Active smoking  
- no. (%) 
Never 230 (17.8) 1,062 (82.2) 1,292    
Yes 
No 
74 (19.2) 
414 (18.1) 
311 (80.8) 
1,876 (81.9) 
385 
2,290 
1.08  
(0.82-1.42) 
1.15  
(0.86-1.53) 
Passive smoking  
- no. (%) 
(smoking spouse)        
Yes 
No 
62 (22.9) 
611 (17.2) 
209 (77.1) 
2,942 (82.8) 
271 
3,553 
1.43  
(1.06-1.92) 
1.30  
(0.96-1.75) 
Skin infections in the 
past 3 months  
- no. (%)        
Yes 
No 
254 (20.0) 
419 (16.5) 
1,016 (80.0) 
2,126 (83.5) 
1,270 
2,545 
1.27  
(1.07-1.51) 
1.17  
(0.98-1.40) 
Boils ever  
- no. (%) 
       
Eczema in the past 12 
months  - no. (%) 
Yes 
No 
100 (27.5) 
567 (16.5) 
264 (72.5) 
2,871 (83.5) 
364 
3,438 
1.92  
(1.50-2.46) 
1.92  
(1.49-2.46) 
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Figure 1  Proportion of persistent S. aureus nasal carriage according to age 
and sex. 
   
Error bars represent means with 95 percent confidence intervals.  
Lines depict linear regression line (black) with 95 percent mean 
prediction interval (grey) according to:   
Probability of persistent S. aureus nasal carriage =  
0.24 – 0.001 [95% CI, -0.002-0.000] * age. 
Numbers at the bottom of the graph represent numbers of 
partcipants in each category. 
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Figure 2A  Proportion of persistent S. aureus nasal carriage according to 
diabetes mellitus category. 
 
  Error bars represent means with 95 percent confidence intervals. 
Numbers at the bottom of the graph represent numbers of 
participants in each category. 
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Figure 2B  Proportion of persistent S. aureus nasal carriage according to 
fasting glucose level in mmol/L. 
 
  Lines depict linear regression line (black) with 95 percent mean 
prediction interval (grey) according to:   
Probability of persistent S. aureus nasal carriage =  
0.09 + 0.012 [95% CI, 0.06-0.18] * fasting glucose level (mmol/L). 
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  101) and living in a home for the elderly (median age 78, range 
62 to 97) were older than persons living independently (median 
age 71, range 61 to 93; P <0.001). Living in an institution was not 
associated with persistent S. aureus nasal carriage (OR, 0.86; 
95% CI, 0.64-1.16) after adjustment for, among others, age and 
sex  (Table 2).  
The proportion of men living with a partner was significantly 
higher as compared to women (0.86 versus 0.56; OR, 4.82; 95% 
CI, 4.10-5.68; Table 1). The presence of a household partner 
was, however, not an independent determinant of persistent 
carriage (OR, 1.04; 95% CI, 0.60-1.81; Table 2). 
 
Glucose  More persistent carriers were found among persons suffering 
from diabetes mellitus: 99/446 (0.22) in the diabetic group, 
110/582 (0.19) in the impaired fasting glucose group and 
459/2740 (0.17) in the non-diabetic group (P for trend = 0.004; 
Table 2 and Figure 2A). The diabetic group had a 1.43 higher 
risk (95% CI, 1.11-1.83) of being a persistent carrier than the 
non-diabetic group (Table 2). The proportion of persistent 
carriers increased with the fasting glucose level, even in the 
normal range: one mmol/L increase in glucose level was 
associated with a 1.09 (95% CI, 1.04-1.15) higher risk of being a 
persistent carrier (Table 2 and Figure 2B). 
 
Smoking  Current smoking was associated with a 36% lower risk of 
persistent S. aureus nasal carriage when compared to the never 
smoking group (OR, 0.64; 95% CI, 0.49-0.84). The effect was 
similar when only cigarette smoking was considered (OR, 0.63; 
95% CI, 0.48-0.84). Past smoking (OR, 0.85; 95% CI, 0.70-1.05) 
and passive smoking (i.e. smoking by a spouse) (OR, 1.15; 95% 
CI, 0.86-1.53) were not associated with persistent carriage; 
Table 2). 
The negative association with smoking was present in both 
sexes, but more pronounced in men. In men the proportion of 
persistent carriers dropped from 0.24 (44/186) in the never, to 
0.22 (235/1082) in the past and to 0.15 (53/350) in the current 
smoking group (P for trend = 0.007). In women these figures 
were 0.17 (186/1106), 0.14 (113/783) and 0.13 (43/320), 
respectively (P for trend = 0.08; Figure 3A). No difference was 
observed in the number of cigarettes smoked: both currently 
smoking men and women smoked a mean of 15 cigarettes a day 
(difference 0.57; 95% CI, -1.72-2.85). 
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Within the group of persistent carriers, smoking also reduced  
  the mean number of CFUs in the two nasal swab cultures (Figure 
3B). The Log geometric mean in never or past smoking 
persistent carriers was 2.87 versus 2.29 in current smoking 
persistent carriers (difference 0.58; 95% CI, 0.34-0.863). In the 
latter group, the daily number of cigarettes smoked tended to 
be negatively associated with the number of CFUs cultured (one 
cigarette higher daily intake correlated with 0.007 (≈ 1 CFU) 
lower Log geometric mean (95% CI, -0.021-0.006). In past 
smokers, time since quitting was not associated with being a 
persistent carrier (OR, 0.99 per year; 95% CI, 0.98-1.01). 
 
Skin diseases  Skin diseases were positively associated with persistent 
carriage, but only a history of eczema (OR, 1.92; 95% CI, 1.49-
2.46) was shown to be an independent determinant in the 
logistic regression analysis (Table 2).  
 
 
 
  Discussion 
 
  The main findings in this population-based study are the positive 
association of fasting blood glucose levels with persistent S. 
aureus nasal carriage, and the negative association or 
‘protective’ effect of current smoking on the rate and density of 
S. aureus nasal carriage. 
Three different patterns of S. aureus nasal carriage exist in 
humans. This suggests that human factors rather than bacterial 
traits play a major role in determining the carrier state. Indeed, 
rates of persistent carriage vary with age, sex and ethnic 
group.P5,10,11 P However, the host environment can also influence 
the carrier state. Hospitalization, for example, has been shown to 
be an important risk factor for S. aureus nasal carriage,P5 P while in 
the community household partners demonstrate highly 
concordant nasal carriage patterns.P10P 
Genetic background, P22-24 P local immune statusP8 P and underlying 
diseasesP25-28P have all been associated with persistent carriage 
and S. aureus infections. A supposed common factor would be 
repeated or persistent breaches in the integrity of the skin or 
mucosal surfaces, thought to provide opportunities for 
staphylococcal adherence and subsequent colonization and 
infection. 
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Figure 3A  Proportion of persistent S. aureus nasal carriage according to 
smoking pattern and sex.  
 
  Error bars represent means with 95 percent confidence intervals. 
Numbers at the bottom of the graph represent numbers of 
participants in each category. 
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Figure 3B  Log geometric mean of number of CFUs in two nasal swab cultures 
in persistent S. aureus nasal carriers according to smoking pattern 
and sex. 
 
  Error bars represent means with 95 percent confidence intervals. 
Numbers at the bottom of the graph represent numbers of 
participants in each category. 
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  The present study confirms that age, sex and a history of skin 
disease are independent determinants of S. aureus nasal 
carriage. As for diabetes mellitus and blood glucose levels, in 
earlier studies only insulin dependent diabetics were found to 
have a higher prevalence of persistent carriage. P27,29 P We now 
found that, apart from the diabetic state and its treatment, fasting 
blood glucose levels, even within the normal range, are 
associated with persistent carriage. The pathophysiological 
basis of this association remains to be discovered. Blood or 
mucosal glucose levels may influence the expression or 
modulation of bacterial adherence and colonization, perhaps by 
fostering non-enzymatic glycation of cellular structures in the 
nasal epithelia P30,31P or by promoting staphylococcal growth or 
biofilm formation.P32,33P On the other hand, hyperglycaemia is 
associated with reduced phagocytic activation of neutrophils 
and macrophages, as well as impaired killing of intracellular 
micro-organisms (including S. aureus).P34P 
The second finding is the negative association of smoking and 
persistent carriage. In a population-based cohort of children and 
adolescents we recently also found evidence that cigarette 
smoking lowers the prevalence of S. aureus nasopharyngeal 
carriage.P11P Past smokers have the same prevalence of persistent 
carriage as those who have never smoked. Therefore, the 
“protection against carriage” conferred by smoking seems 
rapidly inducible and transient in nature. The fact that within the 
cohort of persistent carriers, current smoking was associated 
with a significantly lower density of S. aureus CFUs in the nares 
also points toward a direct effect of (cigarette) smoke on 
carriage. In contrast to the study of Bogaert et al., no effect of 
passive smoking was demonstrated in our study. P11 P 
The number of studies on the effect of cigarette and/or tobacco 
smoke on growth and adherence of S. aureus are limited and 
often contradictory. In one study smoking increased nasal 
colonization with MRSA, while reducing colonization with 
methicillin sensitive S. aureus (MSSA).P35P Ex vivo studies using 
buccal cells or lower respiratory tract derived cells exposed to 
cigarette smoke demonstrated increased adherence of S. 
aureus.P36,37P In contrast, one other in vitro study reported that 
cigarette smoke inhibited the growth of S. aureus and other 
Gram-positive cocci to a greater degree than that of Gram-
negative rods. This inhibition was directly related to the 
concentration of smoke constituents in the experimental 
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dilutions used, suggesting a direct toxic effect. P38 P 
Cigarette smoking is known to induce airway inflammation. P39,40P 
Cole et al. reported that nasal secretions obtained from S. aureus 
carriers contained higher levels of inflammatory proteins 
including Defensins, but lacked antimicrobial activity in vitro, 
while nasal fluid from non-carriers was bactericidal.P8 P However, 
they did not control for the smoking status of the subjects 
studied, nor did they properly define the type of nasal carriage.  
From these and our data, we hypothesize that S. aureus 
colonization of the anterior nares is less likely to occur in 
smoking persons because of a toxic effect of smoke on S. aureus 
combined with smoke induced airway mucosa infiltration of 
inflammatory cells. 
 
In conclusion, based on a large population based study we 
confirm that age, sex, diabetes mellitus and skin diseases are 
independent determinants of S. aureus nasal carriage. In 
addition, our data suggest that active smoking may preclude 
persistent S. aureus nasal carriage, whereas a positive 
association exists between fasting glucose levels and the risk of 
persistent S. aureus nasal carriage. Considering the clinical 
impact of S. aureus these newly recognized determinants should 
prompt novel efforts to further elucidate the biology of S. aureus 
nasal colonization.  
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  Abstract 
 
Context  Staphylococcus aureus nasal carriage is a known risk factor for S. 
aureus infections. However, the precise etiology of carriage is 
largely unexplained. 
Objective  To estimate the impact of environmental and genetic factors in 
determining the S. aureus nasal carrier state. 
Design  Cross-sectional population-based study; April 1 P
st
P 1997 and 
March 31 PstP 2001. 
Setting  The Rotterdam Study and first degree family members of healthy 
volunteers. 
Participants  
  
In all participants two quantitative nasal swab cultures with one-
week intervals were performed. Two carriage patterns were 
distinguished: non-or-intermittent and persistent S. aureus nasal 
carriage. To study the impact of environmental factors 1,001 
household pairs (2,002 persons) out of 4,797 participants in the 
Rotterdam Study were identified. To study genetic factors 82 first
degree relatives and 23 partners of 16 long-term persistent 
carriers and 8 long-term non-carriers were cultured.  
Outcome 
Measures 
 The main outcome measure was the risk of sharing identical S. 
aureus nasal carrier states in household partners and first 
degree family members. 
Results  
  
The proportion of persistent S. aureus nasal carriers was 24% 
(473 out of 2,002) in the elderly cohort and 27% (28 out of 105) in 
the family cohort. The risk of sharing identical S. aureus nasal 
carrier states was 2.39 [95% CI: 1.73-3.31] among 1,001 elderly 
household pairs (n=2,002). Among first degree relatives and 
partners of 16 persistent- and 8 non-carriers of S. aureus, the risk 
of sharing identical carrier states was 4.18 [95% CI 1.02-17.07] 
for members of the same household (n=53) versus 1.81 [95% CI: 
0.58-5.60] for first degree relatives (n=82). Up to 65% of persons 
living in one household shared genetically identical strains.  
Conclusions  Apparently, the repeated (non-) exposure to S. aureus in the 
household environment is a more important determinant of S. 
aureus nasal carriage than the genetic background of first 
degree family members.  
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  Introduction 
 
  Staphylococcus aureus is an important human pathogen and the 
cause of infections ranging from mild to life-threatening. S. 
aureus nasal carriage is the major risk factor for S. aureus (auto-) 
infections in various clinical settings.P1 P Three S. aureus nasal 
carriage patterns can be distinguished: persistent, intermittent 
and non-carriage. P1 P  S. aureus density in P Pthe anterior nares is 
higher in persistent carriers, P2 P which may partly explain their 
increasedP Prisk of S. aureus infections.P3 P Variation among 
colonizing strains is higher for intermittent carriers, P4 P suggesting P 
Pthat the basic determinants of persistent and intermittent 
carriage are P Pdifferent.  
S. aureus nasal carriage has been associated with host factors 
such as ethnicity, gender, age, hormonal status in women, local 
immunity and genetic make-up, as well as concurrent diseases 
such as eczema and diabetes mellitus and environmental factors,
including hospitalization.P1,5 P However, the precise etiology of S. 
aureus nasal carriage is largely unexplained.  
The aim of the present study was to estimate the relative impact 
of ‘environmental’ (defined as living together in the same 
household with a partner, who is not a family member) versus 
‘genetic’ (defined as being a first degree family member of 
either a long-term persistent S. aureus nasal carrier or a long-
term non-carrier) factors in determining the S. aureus nasal 
carrier state.  
 
 
 
  Material & Methods 
 
  This study consisted of two parts. In the first part, two 
quantitative nasal swab cultures with one-week intervals were 
taken in 3,851 (on a total number of 4,797) participants aged 55 
years and over, as part of the second follow-up of the Rotterdam 
Study, a population-based prospective cohort study on chronic 
diseases in the elderly.P6 P The second part consisted of a family 
study in which two quantitative nasal swab cultures with one-
week intervals were taken in partners and first degree relatives 
of 16 long-term persistent carriers and 8 long-term non-carriers 
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(index persons). According to an earlier validated ‘culture rule’, 
two different carrier states were defined: non- or intermittent 
and persistent S. aureus nasal carriage. P2P Genotyping, using 
pulsed field gel electrophoresis, was done on all S. aureus 
isolates of the family cohort and on a random selection of 100 
household pairs of the elderly cohort. Counts and percentages 
were compared by Fisher’s exact test. The study was approved 
by the Medical Ethics Committee of the Erasmus MC, University 
Medical Center Rotterdam. Informed consent was obtained of all 
participants.  
 
 
 
 
  Results 
 
  In the elderly cohort, 1,001 household pairs (2,002 persons) 
were identified, of which 473 persons (24%) were persistent 
carriers (Table 1). In total 1,456 S. aureus strains were isolated in 
983 persons (510 with only 1 culture positive and 473 with both 
cultures positive). S. aureus nasal carrier states were concordant 
between household partners, with a risk of 2.39 [95% CI: 1.73-
3.31] of sharing identical S. aureus nasal carrier states (meaning 
to say that both partners were either persistent or non-or-
intermittent carriers). When only the male-female pairs (983) 
were included, results were identical. In the random set of 100 
household pairs 161 S. aureus strains were isolated in 104 
persons (47 with only 1 culture positive and 57 with both cultures
positive). In 37 household pairs at least one culture was positive 
in both partners. In 2 pairs both had one culture positive, in 15 
pairs one partner had one and the other both cultures positive 
and in the remaining 20 pairs both partners had both cultures 
positive. Genotyping demonstrated that in 24 (65%) of these 37 
household pairs both persons shared genotypically identical S. 
aureus strains. 
In the family cohort, a total of 105 persons (23 partners and 82 
first degree relatives of the 24 index persons) were screened, of 
which 28 persons (27%) were persistent carriers. Fifty-three 
(50%) persons were part of the index persons’ households. In 
total, 75 S. aureus strains were isolated in 46 persons (17 with 
only 1 culture positive and 29 with both cultures positive), 
exclusive of the 16 persistent carrier index strains. S. aureus  
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Tabel 1  S. aureus nasal carrier states of household partners in the 
Rotterdam Study. 
   
 
  
S. aureus nasal carrier state partner 1 
 
  
Non or 
Intermittent 
Persistent Total 
Non or 
Intermittent 
613 117 730 
Persistent 
 
186 85 271 
S. aureus nasal 
carrier state 
partner 2 
Total 
 
799 202 1001 
 
 
 
Tabel 2  S. aureus nasal carrier states of household contacts and first 
degree family members in the family study. 
   
 
  
S. aureus nasal carrier state index person 
 
  
Non or 
Intermittent 
Persistent Total 
Non or 
Intermittent 
14 19 33 
Persistent 
 
3 17 20 
S. aureus nasal 
carrier state of 
household contact 
Total 
 
17 36 53 
     
Non or 
Intermittent 
22 39 61 
Persistent 
 
5 16 21 
S. aureus nasal 
carrier state of  
first degree  
family member Total 
 
27 55 82 
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  nasal carrier states were concordant between persons living 
within the same household with a risk of 4.18 [95% CI 1.02-17.07]
of sharing the same SNC state (Table 2).  No concordance in S. 
aureus nasal carrier states between the index person and first 
degree family members could be demonstrated (risk 1.81 [95% 
CI: 0.58-5.60]; Table 2). Overall, genotypically identical S. 
aureus strains were shared in 9 (18%) out of 46 persons with 1 or 
2 positive nasal swab cultures. Within households identical 
strains were shared in 8 (28%) out of 29 persons versus 1 (5.9%) 
out of 17 non household first degree family members (risk 6.10 
[95% CI: 0.69-53.85]). Within the group of household contacts of 
the persistent carrier index persons, identical strains were 
shared in 8 (36%) out of 22 persons versus 1 (8%) out of 12 non 
household first degree family members (risk 6.29 [95% CI: 0.68-
58.13]). 
 
 
 
  Discussion 
 
  Recently, Peacock et al. found concordant carrier states between
mothers and their children. P7P Furthermore, Bogaert et al. found 
large households (≥ 5 members) to be positively and 
colonization with Streptococcus pneumoniae to be negatively 
associated with persistent S. aureus nasal carriage. P8P The large 
study among an elderly population presented here, 
demonstrates that not only persistent, but also non-or-
intermittent S. aureus nasal carrier states are shared among 
household members. Living together with a persistent carrier 
increases your risk of being a persistent carrier at least twofold, 
while living together with a non-or-intermittent carrier ‘reduces’ 
your chance of being a persistent carrier twofold. Up to 65% of 
persons with positive cultures living within one household 
shared genotypically identical strains. These findings suggest 
that persistent carriers as well as non-carriers can ‘impose’ their 
respective carrier state upon their (intermittent carrier) 
household members. 
From the family study it is clear that a simple Mendelian trait 
does not underlie the different S. aureus nasal carrier states. The 
repeated (non) exposure to S. aureus in the household 
environment is, thus, considered to be a more important 
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determinant of S. aureus nasal carriage than the genetic 
background of family members.  
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  Abstract 
 
  The vitamin D endocrine system has been shown to influence 
immune response and polymorphisms in the vitamin D receptor 
(VDR) gene have been associated with susceptibility to 
infectious diseases. We determined if the Cdx2, FokI and BsmI-
ApaI-TaqI polymorphisms in the VDR gene were associated with 
nasal carriage of Staphylococcal aureus. We analyzed over 2,000 
subjects from the Rotterdam Study. The prevalence of persistent 
S. aureus nasal carriage was 18%, which was, however, not 
different by VDR genotype. Our study is one of the largest in the 
field and suggests that VDR gene variation is not associated with 
S. aureus carriage. 
 
 
 
  Introduction 
 
  S. aureus is an important agent of human disease and the cause 
of a variety of infections ranging from mild to life-threatening. 
Over the last 20 years the incidence of both community-acquired
and hospital-acquired S. aureus infections has increased, while 
antibiotic treatment is increasingly hampered by the spread of S. 
aureus strains resistant to multiple antibiotics including 
methicillin and, more recently, vancomycin. 
The nose (i.e. the anterior nares) has been shown to be the 
primary ecological reservoir of Staphylococcus aureus (S. 
aureus) in humans and S. aureus nasal carriage is a major risk 
factor for S. aureus infections in various clinical settings. P1 P Three 
nasal carriage patterns can be distinguished: persistent, 
intermittent and non carriage. The biology of nasal colonization 
with S. aureus remains incompletely understood, but host factors 
are thought to play a pivotal role. P1P Age, sex, fasting glucose 
levels, diabetes mellitus and smoking were recently 
demonstrated to be independent determinants of S. aureus nasal 
carriage .P2P 
The vitamin D endocrine system has pleiotropic effects on many 
different organ systems including calcium absorption, bone 
biology, cell growth and differentiation, but also the immune 
system. This is exemplified by associations of polymorphisms in 
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the Vitamin D receptor (VDR) gene with a number of diseases 
such as osteoporosis, cancer, diabetes mellitus, but also 
infections.P3 P VDR polymorphisms have been associated with 
susceptibility to tuberculosis,P4,5 P Mycobacterium malmoense 
pulmonary disease,P6 P persistent Hepatitis B infection, P4P leprosyP7 P 
and HIV disease progression.P8 P VDR gene polymorphisms may 
determine the likelihood of persistent infection or colonization 
with intracellular micro-organisms (including S. aureus), since 
Vitamin D metabolites have been shown to play a role in 
macrophage activation and differentiation.P9P Furthermore, recent 
evidence indicates that neutrophils express functional VDR at a 
level similar to that of macrophages, P10 P while neutrophils have 
been demonstrated to play an important role in the innate 
immunity against S. aureus. Cole et al. for example found that 
persistent S. aureus nasal carriage is accompanied by the 
release of epithelial and neutrophil-derived host defense 
peptides into nasal secretions.P11P 
Hence, in search for a single host gene marker for S. aureus 
nasal carriage, we aimed to determine whether certain 
polymorphisms in the Vitamin D receptor gene were associated 
with persistent carriage. 
 
 
 
  Material & Methods 
 
  This study was conducted as part of the Rotterdam Study, a 
prospective, population-based cohort study on the occurrence 
and determinants of disease and disability in elderly persons.P12P 
In 1990, all inhabitants of Ommoord, a suburb of Rotterdam in 
the Netherlands, who were 55 years of age or older and had 
lived in the district for at least one year were invited to 
participate in the study. Of the 10,275 eligible persons, 7,983 
(78%) participated. Participants gave informed consent and 
permission to retrieve information from medical records. At 
baseline, between 1990 and 1993, trained interviewers 
administered an extensive questionnaire covering 
socioeconomics background and medical history, among other 
topics, during a home interview. During subsequent visits to the 
study center, additional interviewing, laboratory assessments, 
and clinical examinations were performed. Information on vital 
status is obtained at regular time intervals from the municipal 
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authorities in Rotterdam. The study was approved by the 
Medical Ethics Committee of the Erasmus MC, University 
Medical Center Rotterdam. Informed consent and permission to 
retrieve information from treating physicians was obtained of all 
participants.  
The second follow-up was performed between April 1 PstP 1997 and 
December 31 PstP 1999 among 4,797 remaining participants. Of 
these, 3,882 persons were able to visit the study center and 
eligible for the present study. In 31 persons an incomplete set of 
nasal swab cultures was obtained, leaving 3,851 persons with 
complete bacteriological results, 2,224 females and 1,627 males. 
Two quantitative nasal swab cultures with one-week intervals 
were performed. Subjects were classified as persistent carriers 
if both cultures were positive with at least 8 colony-forming units 
of S. aureus per culture. Those with both cultures negative were 
classified as non carriers. Intermittent carriers were those with 
intermediate results.P13P  
The intermittent carrier group was excluded from our analyses 
to increase contrast between the groups and to reduce the risk 
of dilution of a possible association due to misclassification. We 
thus gave preference to precision at the cost of power.  
 
The VDR polymorphisms studied were the G to A polymorphism 
in a Cdx2 binding site in the 1e/1a promoter region (results 
available for 3,349 subjects),P14P the N-terminal 3 amino acids 
deletion (also known as the start codon polymorphism; SCP) 
detected as a FokI RFLP (results available for 2,589 subjects)P15P 
and the 3’ polymorphisms detected as BsmI-ApaI-TaqI RFLPs 
(results available for 3,502 subjects). Briefly, the Cdx2 and FokI 
polymorphisms are bi-allelic and, thus, three genotype 
combinations were distinguished, while three common Bsm-
Apa-Taq haplotype-alleles could be distinguished, as described 
before.P16P   
 
Associations between the different genotypes or haplotypes and 
S. aureus nasal carrier status were first analyzed univariately 
using the Chi-square test. Thereafter, multivariate logistic 
regression analysis was employed to evaluate the association of 
the individual gene polymorphisms on carrier status, while 
correcting for age, gender, smoking (coded as never, past, and 
current) and fasting serum glucose levels as potential 
confounders. In the final sample, data on S. aureus nasal carrier 
state and all possible confounders were available for 2,056 
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subjects for the Cdx2 genotype, 1,574 subjects for the FokI 
genotype, and 2,025 subjects for the BsmI-ApaI-TaqI haplotypes 
(1-3). 
 
 
 
  Results 
 
  In the group of 3,851 persons in whom the S. aureus nasal carrier 
state was determined, median age was 71 years (range 61-101), 
58% were women, 34% were current and 50% were past 
smokers and mean fasting glucose was 5.9 mmol/L (range 1.6-
20.5). These baseline characteristics were not different from the 
complete Rotterdam Study cohort or the final sample in which 
the analyses were performed (Table 1).  
The distribution of the Cdx2 and FokI genotypes and the Bsm-
Apa-Taq haplotype genotypes were in compliance with the 
Hardy-Weinberg equilibrium (p>0.05; Table 2). Univariate 
analysis (analysis I) did not show any significant association 
between a polymorphism and S. aureus nasal carrier state (Table
2). After correction for possible confounders by logistic 
regression analyses (analysis II), no association could be 
demonstrated either. There was a slight trend for the Cdx2 A-
allele to be increased in frequency in the persistent carrier 
group but this was not significant. Similarly, the T-allele of the 
FokI RFLP was slightly increased in frequency in the persistent 
carrier group, but again this was not significant. 
 
 
 
 
  Discussion 
 
  Our study demonstrated none of the polymorphisms (Cdx2 or 
FokI genotype and Bsm-Apa-Taq haplotypes) in the Vitamin D 
receptor gene to be significantly associated with S. aureus nasal 
carriage status. We assume that selection bias was of no 
importance in our study, since allele combinations in any 
genotype or haplotype and the distribution of possible 
confounders was similar in the complete cohort and the subsets 
that were analyzed. 
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Other evidence has pointed to the influence of host genetic 
variations on the S. aureus nasal carriage status.P17-19P However, no 
earlier study examined specific gene polymorphisms as genetic 
determinants of S. aureus nasal carriage. From the results 
obtained in this study we conclude that these polymorphisms in 
the VDR gene do not relate to S. aureus nasal carriage. However, 
future studies of the VDR gene examining additional 
polymorphisms, or analysis of polymorphisms in other candidate
genes might reveal genetic host differences determining S. 
aureus nasal carriage status.  
 
 
 
Table 1  Baseline characteristics of the study population. 
   
 
 Rotterdam Study 
second follow-up 
study population 
S. aureus nasal 
carriage status 
determined 
Final sample with 
all variables 
available 
Sample size – no. 4,797 
 
3,851 1,547 
Median age  (range) 73 (61-106) 71  (61-101) 73 (62-96) 
    
Female  – no. (%) 2,875 (60) 2,224 (58) 836 (54) 
Males  – no. (%) 1,922 (40) 1,627 (42) 711 (46) 
    
Smoking    
 Never – no. (%) 1,649 (35) Pa P 1314 (34) PcP 490 (32) 
 Past – no. (%) 2,264 (48) 1921 (50) 809 (52) 
 Current – no. (%) 768 (16) 592 (16) 248 (16) 
    
Fasting serum glucose 
(mmol/l) (sd) 
5.9 (1.35) PbP 5.9 (1.32) Pd P 5.8 (1.25) 
P
a
P116 missings 
P
b
P1002 missings 
P
c
P24 missings 
P
d
P245 missings 
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Table 2  The distribution of individual VDR polymorphisms and haplotypes 
and S. aureus nasal carriage status. 
   
 
VDR 
genotype / 
haplotype 
THWE TP aTP 
P-
value 
N-SNC 
no. (%) 
P-SNC 
no. (%) 
Total 
no. 
Analysis I  
(Crude) 
P Value Pb P 
Analyses II 
(Adjusted) 
P Value PcP 
   Cdx2  0.53 1,678 (81.6) 378 (18.4) 2,056   
GG  1,116 (82.1) 244 (17.9) 1,360 0.61 0.40 
GA  502 (81.1) 117 (18.9) 619   
AA  60 (77.9) 17 (22.1) 77   
  A=18.5% A=20.0%    
       
   FokI 0.46 1,275 (81.0) 299 (19.0) 1,574   
CC  526 (81.7) 118 (18.3) 644 0.84 0.81 
CT  575 (80.4) 140 (19.6) 715   
TT  174 (81.0) 41 (19.1) 215   
  T=36.2% T=37.1%    
       
Bsm-Apa-Taq 0.24      
Haplo 1 (baT)  1,653 (81.6) 372 (18.4) 2,025   
0 copy  454 (80.5) 110 (19.5) 564 0.44 0.90 
1 copy  803 (82.8) 167 (17.2) 970   
2 copies  396 (80.7) 95 (19.3) 491   
  1=48.3% 1=48.0%    
       
Haplo 2 (BAt)  1,653 (81.6) 372 (18.4) 2,025   
0 copy  612 (82.8) 127 (17.2) 739 0.58 0.34 
1 copy  749 (80.9) 177 (19.1) 926   
2 copies  292 (81.8) 68 (18.9) 360   
  2=40.3% 2=42.1%    
       
Haplo 3 (bAT)  1,653 (81.6) 372 (18.4) 2,025   
0 copy  1,320 (81.1) 307 (18.9) 1,627 0.49 0.18 
1 copy  310 (83.6) 61 (16.4) 371   
2 copies  23 (85.2) 4 (14.8) 27   
  3=10.8% 3=9.3%    
P
a 
PHardy Weinburg equilibrium 
P
b 
PUnivariate: Pearson Chi-Square test,  
P
c 
PMultivariate after correction for age, gender, cigarette smoking behavior and serum glucose 
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  Abstract 
 
  No single bacterial or host factor essential for nasal colonization 
with Staphylococcus aureus in humans has been identified yet. P1-5P 
Earlier studies into the presumed genetic background of S. 
aureus nasal carriage in humans have generated conflicting 
results.P6-8P We determined whether four polymorphisms in the 
glucocorticoid receptor gene were associated with persistent 
nasal carriage of S. aureus in nearly 3,000 participants of a 
population-based cohort study. We demonstrate that GG-
homozygotes of the exon 9beta polymorphism have a 68% 
reduced risk of persistent S. aureus nasal carriage (odds ratio 
0.32; 95% confidence interval, 0.13-0.82), while carriers of the 
haplotype containing the 9beta G-allele and the codon 23 Lys-
allele have an 80% increased risk (odds ratio 1.80; 95% 
confidence interval, 1.08-3.00). This study identifies the first 
human genetic variants as determinants of individual S. aureus 
nasal carriage. 
 
 
 
 
  Introduction 
 
  The anterior nares are the primary ecological reservoir of 
Staphylococcus aureus in humans and S. aureus nasal carriage is 
a major risk factor for a variety of infections.P9,10P Three human 
nasal S. aureus carriage patterns can be distinguished: 
persistent-, intermittent- and non-carriage.P11 P S. aureus density in P 
Pthe anterior nares is highest in persistent carriers, P12 P which may 
explain their increasedP Prisk of developing S. aureus infections.P13 P 
Variation among colonizing strains is higher for intermittent 
carriers, P14 P suggestingP Pthat the basic host determinants of 
persistent and intermittent carriage are P Pdifferent. The biology of 
nasal colonization with S. aureus remains incompletely 
understood. Environmental factors, P15-17Pas well as host factors are 
thought to play a pivotal role in determining the S. aureus nasal 
carrier state.P4,5,18,19 P 
The hypothalamic-pituitary-adrenal (HPA) axis is known to 
influence glucose levels by regulating insulin sensitivity, but it 
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also plays a role in susceptibility to infectious disease. P20P 
Glucocorticoids repress a large number of pro-inflammatory 
cytokines and key inflammatory mediators such as TNF, IL-6, IL-
12, and prostaglandin E2, while activating a number of anti-
inflammatory genes (IL-10, IL-4, and TGFbeta) as well.P21-23 P In 
addition, up-regulation of cell adhesion molecules such as 
ICAM-1 occurs P21P, while down-regulation of neutrophil adhesion 
molecules has also been documented. P24 P Thus, glucocorticoids 
exert repressive effects on the innate immune system with 
downstream fallout for adaptive immunity and inflammation. 
Several glucocorticoid receptor (GR) gene polymorphisms have 
been described and found associated with variation in 
glucocorticoid sensitivity, variation in insulin sensitivity, 
changes in body fat distribution and with autoimmune diseases 
such as rheumatoid arthritis.P25-30P 
Polymorphisms in the glucocorticoid receptor gene can 
predispose to a more or less active immune system through 
modulation of the systemic or local pro/anti-inflammatory 
cytokine balance.P21,22,25-30P Alternatively, concurrent changes in 
insulin sensitivity may influence the availability of glucose in 
circulation as well as at the tissue level. Blood or mucosal 
glucose levels may influence the expression or modulation of 
bacterial adherence and colonization, by fostering non-
enzymatic glycation of cellular structures in the nasal 
epithelia P31,32 P or by promoting staphylococcal growth or biofilm 
formation.P33,34P Hyperglycaemia and hyperinsulinaemia have also 
been associated with reduced phagocytic activation of 
neutrophils and macrophages, as well as with impaired killing of 
intracellular micro-organisms (including S. aureus).P35P The ability 
of S. aureus to evade the inflammatory response of the host by 
surviving inside neutrophils has been shown to be a virulence 
factor earlier.P36 P Impaired phagocytic activity is probably also a 
central factor in determining S. aureus nasal carriage, as was 
shown by Pos et al. in patients infected with the human 
immunodeficiency virus (HIV). P37 P Interestingly, in HIV patients 
serum cortisol levels were shown to be elevated at all stages of 
HIV infection, while a linear negative association between CD4 
cell counts and cortisol level was found. P38P Consequently, 
changes in glucocorticoid sensitivity may predispose to or 
protect from microbial colonization or infection on the one hand, 
or to auto-immune disease on the other. 
 
Hence, in search of host genetic markers for S. aureus nasal 
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carriage, we aimed to determine whether functional 
polymorphisms in the glucocorticoid receptor gene are 
associated with persistent S. aureus nasal carriage.  
 
 
 
  Material & Methods 
 
  Study population 
  This study was conducted as part of the Rotterdam Study, a 
prospective, population-based cohort study on the occurrence 
and determinants of disease and disability in elderly persons 
started in Rotterdam, The Netherlands in 1990 among in 7983 
participants.P19,39 P The second follow-up of this study was 
performed between April 1 PstP 1997 and December 31 PstP 1999 
among 4,797 remaining participants. Persons able to visit the 
study center were eligible for the present study. We obtained 
complete bacteriological results in 3,851 persons, 2,224 females 
and 1,627 males. The study was approved by the Medical Ethics 
Committee of the Erasmus MC, University Medical Center 
Rotterdam. Informed consent and permission to retrieve 
information from treating physicians was obtained from all 
participants. Two quantitative S. aureus specific nasal swab 
cultures with one-week intervals were performed. Subjects were 
classified as persistent carriers (n = 678) if both cultures were 
positive. Those with both cultures negative were classified as 
non carriers (n = 2804). The remaining subjects were 
intermittent carriers (n = 369). P12P The intermittent carrier group 
was excluded from our analyses to increase contrast between 
the groups and to reduce the risk of dilution of a possible 
association due to misclassification. 
 
  Genotyping 
  Participants were genotyped for four glucocorticoid receptor 
gene polymorphisms. Figure 1 schematically depicts the 
glucocorticoid receptor gene, the location of the four 
polymorphisms studied in the glucocorticoid receptor gene, 
their specific nucleotide variations and the allele frequencies. 
The glucocorticoid receptor gene polymorphisms studied were 
Bcl-1, an intronic C-to-G nucleotide substitution detected as a 
restriction fragment length polymorphism (RFLP) of 646 
nucleotides downstream from exon 2 which results in fragments 
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of 2.2 kb and 3.9 kb. P27 P We described the Arg23Lys and 
Asn363Ser polymorphisms in relation to a specific human GR 
cDNA sequence (accession number NM_ 000176), in which 
position 198/200 of the protein coding sequence is the first 
nucleotide of the start of the next closest exon to the 
polymorphisms studied (exon 2). The polymorphisms have also 
been described at HTUhttp://www.ncbi.nlm.nih.gov/SNPUTH under 
identification numbers rs 6189 (E22E ), rs 6190 (R23K ), rs.6195 
(N363S. ). The Asn363Ser polymorphism is an asparagine to 
serine polymorphism in codon 363 of exon 2, located in the 
transactivation domain.P25P The Arg23Lys polymorphism is a 
combination of two linked single-nucleotide variations in codons 
22 and 23 leading to an arginine-to-lysine change in codon 23 in 
the transactivation domain.P29P The 9beta polymorphism is an A-
to-G nucleotide substitution located in the 3’ end of exon 9β, 
which encodes for the 3’ UTR of the mRNA of the hGRβ isoform. 
The A to G nucleotide substitution is located in the ‘ATTTA’ motif 
(to GTTTA). This ‘ATTTA’ motif is known to destabilize 
mRNA.P30,40P  
 
For the analysis DNA was isolated from peripheral blood 
leucocytes of subjects using standard techniques. DNA was 
extracted using proteinase K and sodium-dodecyl-sulphate 
digestion at 37P0 PC overnight and purified using phenol-
chloroform or high-salt extractions. The extracted DNA was then 
precipitated using 4 mol/L NaCl and two volumes of cold 
absolute ethanol. DNA was solubilized in double-distilled water 
and stored at -20 P0 PC until used for DNA amplification. PCR 
amplification and genotyping were performed using 5 ng 
genomic DNA for the Taqman allelic discrimination assay. 
Primer and probe sequences were optimized using the SNP 
assay-by-design service of Applied Biosystems. For details see 
HTUhttp://store.appliedbiosystems.com UTH. Reactions were performed 
on the Taqman Prism7900HT (Applied Biosystems, Foster City, 
CA, USA) in 384 wells format.  
To calculate the possibilities of these four polymorphisms 
occurring together on the same allele, we used statistical 
methods for haplotype reconstruction: the Phase Reconstruction 
Method. P41 P All four polymorphisms are mutually exclusive, 
except for the codon 23 Lys-allele, which is always present in 
combination with the 9beta G-allele. Per haplotype allele three 
combinations were distinguished, carrying 0, 1 or 2 copies of the
haplotype allele.  For studying the different genotypes all 15 
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possible haplotype allele combinations were analyzed 
seperately.   
 
 
 
 
 
 
Figure 1  Schematic overview of the glucocorticoid receptor (GR) gene 
polymorphisms and haplotypes. 
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  Statistical analysis 
  To compare baseline characteristics between the complete 
Rotterdam Study cohort, participants with complete 
bacteriologic results (the S. aureus cohort) and participants with 
a complete dataset on S. aureus nasal carrier state, confounding 
variables and all glucocorticoid receptor gene polymorphisms 
(the final cohort), Pearson’s Chi-square test was used for 
dichotomous variables and Mann-Whitney’s test or Kruskal-
Wallis’ test were used for continuous variables where 
appropriate.  
Associations between the GR haplotypes and S. aureus nasal 
carrier status were first analyzed univariately using Pearson’s 
Chi-square test. Multivariate logistic regression analysis was 
then employed to correct for the covariates age, gender, 
smoking (coded as never, past, and current), eczema (coded yes
or no) and fasting serum glucose levels. First analysis for 
dominant, recessive or allele dose effects was performed by 
stratification for allele copy number 0, 1 and 2 for all haplotype 
alleles, while correcting for covariates.  Thereafter, the 15 
possible genotypes were entered into the logistic regression 
model, again correcting for covariates. Results are reported as 
odds ratios with 95 percent confidence intervals. Two-sided P 
values of less than 0.05 were considered to indicate statistical 
significance. 
 
 
 
  Results 
 
  For 2,929 participants (final cohort) a complete dataset on S. 
aureus nasal carrier state, confounding variables (age, gender, 
smoking, fasting glucose level and eczema) and all 
glucocorticoid receptor gene polymorphisms were available. 
Median age was 72 years, 58% were women, 18% were current 
and 48% were past smokers and mean fasting glucose was 5.9 
mmol/L (Table 1). These baseline characteristics were not 
significantly different from those for the complete Rotterdam 
Study cohort or the 3,851 participants with complete 
bacteriologic results (S. aureus cohort). Prevalence of persistent 
S. aureus nasal carriage in the final cohort was 19.2% (563/2929),
which was somewhat higher than in the S. aureus cohort (17.6%; 
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678/3851) due to selection of only non- and persistent carriers in 
the present study. 
 
In non S. aureus carriers, the distribution of genotypes for all 
individual glucocorticoid receptor gene polymorphisms were in 
compliance with the Hardy-Weinberg equilibrium (p>0.05; 
Table 2). Frequencies of the haplotype alleles are presented in 
Figure 1. 
 
First, the associations of the haplotype alleles of the different 
polymorphisms and S. aureus nasal carrier state were analyzed 
separately. Univariate analysis demonstrated the G-allele of the 
exon 9beta polymorphism to be significantly associated with a 
lower prevalence of S. aureus nasal carriage with evidence for a 
recessive effect (Table 2). After correction for age, gender, 
fasting glucose, eczema and smoking habit by logistic 
regression analyses, this association remained essentially 
unchanged (Table 2). GG homozygotes of the exon 9beta 
polymorphism had a 68% lower risk of persistent S. aureus nasal 
carriage compared to the AA homozygotes (odds ratio 0.32; 95%
confidence interval (0.13-0.82).  
The G-allele of the Bcl-1 polymorphism was also associated with 
a lower prevalence of S. aureus nasal carriage. GG homozygotes 
of the Bcl-1 polymorphism had a 20% lower risk of persistent S. 
aureus nasal carriage compared to CC homozygotes. The 
association was, however, not statistically significant (odds ratio 
0.80; 95% confidence interval (0.59-1.08).  
The haplotype containing the G-allele of the exon 9beta 
polymorphism combined with the Lys-allele of the codon 23 
polymorphism was associated with a higher prevalence of S. 
aureus nasal carriage. Heterozygote 23Lys-carriers were shown 
to have a 38% higher risk of persistent S. aureus nasal carriage 
compared to their 23Arg-carrying counterparts. This association 
was just not statistically significant (odds ratio 1.38; 95% 
confidence interval (0.97-1.97).  
No direct relation was found between fasting blood glucose 
levels and any of the polymorphisms investigated. 
 
Hereafter, all potential haplotype allele combinations (i.e. 
genotypes) were analyzed using logistic regression analysis. 
Next to the association of the GG homozygotes of the exon 9beta 
polymorphism, only the combination of the haplotype containing
the G-allele of the exon 9beta polymorphism combined with the  
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Table 1  Baseline characteristics of the study population. 
 
   
 
 
 Rotterdam Study 
second follow-up 
study population 
S. aureus nasal 
carriage status 
determined 
Final sample 
population with 
all variables 
available 
Sample size  
 - n 
 
4,797 
 
3,851 2,929 
Median age   
 (range) 
73 (61-106) 71  (61-101) 72 (61-101) 
    
Gender    
 Women  
 - n (%) 
2,875 (60) 2,224 (58) 1,689 (58) 
 Men 
 - n (%) 
1,922 (40) 1,627 (42) 1,240 (42) 
    
Smoking    
 Never 
 - n (%) 
1,649 (35) 1,314 (34) 1,003 (34) 
 Past 
 - n (%) 
2,264 (48) 1,921 (50) 1,414 (48) 
 Current 
 – n (%) 
768 (16) 592 (16) 512 (18) 
    
Eczema    
 No 
 - n (%) 
3,438 (89) 3,438 (89) 2,648 (90) 
 Yes 
 - n (%) 
364 (11) 364 (11) 281 (10) 
    
Fasting serum glucose 
 (mmol/l) (sd) 
5.9 (1.35) 5.9 (1.32) 5.9 (1.46) 
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Table 2  The distribution of the glucocorticoid receptor gene alleles and  
S. aureus nasal carriage status. 
 
P
a 
PHardy Weinburg equilibrium 
P
b
P non S. aureus nasal carrier 
P
c
P persistent S. aureus nasal carrier 
P
e 
PAdjusted for age, gender, smoking, eczema and fasting serum glucose 
T o ta l s tu d y  g ro u p  b y   
G R  g e n o ty p e  
H W E a  
P -
v a lu e  
N -S N C b  
n  (% ) 
P -S N C c  
n  (% ) 
T o ta l  
n  
M u ltiv a ria te  
a n a ly sis  e  
O R  (9 5 %  C I) 
W ild  ty p e  a lle le  (4 1 .9 % ) 0 .2  2 ,3 6 6  (8 0 .8 ) 5 6 3  (1 9 .2 ) 2 ,9 2 9   
  2  c o p ie s   4 2 3  (7 9 .7 % ) 1 0 8  (2 0 .3 % ) 5 3 1  1  (re fe re n c e ) 
  1  c o p ie s   1 ,1 1 7  (8 0 .1 % ) 2 7 8  (1 9 .9 % ) 1 ,3 9 5  0 .8 5   
(0 .6 8 -1 .0 4 ) 
  0  c o p ie s   8 2 6  (8 2 .4 % ) 1 7 7  (1 7 .6 % ) 1 ,0 0 3  0 .8 5   
(0 .6 5 -1 .1 1 ) 
      
B c l-1  G -a lle le  (3 6 .7 % ) 0 .5  2 ,3 6 6  (8 0 .8 ) 5 6 3  (1 9 .2 ) 2 ,9 2 9   
  0  =  C C   9 4 5  (8 0 .2 )  2 3 3  (1 9 .8 ) 1 ,1 7 8  1  (re fe re n c e ) 
  1  =  C G   1 ,0 9 9 (8 0 .6 )  2 6 5  (1 9 .4 ) 1 ,3 6 4  0 .9 7   
(0 .8 0 -1 .1 8 ) 
  2  =  G G   3 2 2  (8 3 .2 )   6 5  (1 6 .8 )  3 8 7  0 .8 0   
(0 .5 9 -1 .0 8 ) 
      
E x o n  9 b e ta  G -a lle le  (1 4 .5 % ) 0 .9 4  2 ,3 6 6  (8 0 .8 ) 5 6 3  (1 9 .2 ) 2 ,9 2 9   
  0  =  A A   1 ,7 2 5  (8 0 .5 ) 4 1 8  (1 9 .5 ) 2 ,1 4 3  1  (re fe re n c e ) 
  1  =  A G   5 8 1  (8 0 .6 )  1 4 0  (1 9 .4 ) 7 2 1  1 .0 1   
0 .8 1 -1 .2 5 ) 
  2  =  G G   6 0  (9 2 .3 )  5  (7 .7 ) 6 5  0 .3 2   
(0 .1 3 -0 .8 2 ) 
      
C o d o n  3 6 3  S e r-a lle le  (3 .7 % ) 0 .8 1  2 ,3 6 6  (8 0 .8 ) 5 6 3  (1 9 .2 ) 2 ,9 2 9   
  A A   2 ,1 9 7  (8 0 .9 ) 5 2 0  (1 9 .1 ) 2 ,7 1 7  1  (re fe re n c e ) 
  A G   1 6 6  (7 9 .4 )  4 3  (2 0 .6 ) 2 0 9  1 .1 3   
(0 .8 0 -1 .6 1 ) 
  G G   3  (1 0 0 ) 0  (0 )  3   
      
C o d o n  2 3  L y s -a lle le  +  9 b e ta  
G -a lle le  h a p lo ty p e   (3 .4 % ) 
0 .1 6  2 ,3 6 6  (8 0 .8 ) 5 6 3  (1 9 .2 ) 2 ,9 2 9   
  G G   2 ,2 1 8  (8 1 .0 ) 5 1 9  (1 9 .0 ) 2 ,7 3 7  1  (re fe re n c e ) 
  G A   1 4 3  (7 6 .5 )  4 4  (2 3 .5 ) 1 8 7  1 .3 8   
(0 .9 7 -1 .9 7 ) 
  A A   5  (1 0 0 ) 0  (0 )  5   
      
G e n o ty p e  c o m b in a tio n  o f a  
c o d o n  2 3  L y s -a lle le  +  9 b e ta  
G -a lle le  &  a  w ild  ty p e  a lle le    
0 .2 6  2 ,3 6 6  (8 0 .8 )  5 6 3  (1 9 .2 )  2 ,9 2 9  1 .8 0   
(1 .0 8 -3 .0 0 ) 
  n o   2 ,3 1 0  (8 1 .0 % )  5 4 1  (1 9 .0 % )  2 ,8 5 1   
  y e s   5 6  (7 1 .8 % )  2 2  (2 8 .2 % )  7 8   
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  Lys-allele of the codon 23 polymorphism and a wild type 
haplotype allele was significantly associated with S. aureus nasal 
carriage (Table 2). This latter genotype was shown to increase 
the risk of persistent S. aureus nasal carriage by 80% (odds ratio 
1.80; 95% confidence interval, 1.08-3.00). 
 
 
 
 
  Discussion 
 
  Earlier evidence has pointed to the possible influence of host 
genetic variation on the S. aureus nasal carriage status P4,6-8P. 
However, no previous study identified specific gene 
polymorphisms as genetic determinants of S. aureus nasal 
carriage. The current availability of high-tech, high-throughput 
genomics tools in combination with a large prospective 
population-based epidemiologic survey, has provided a unique 
opportunity to study genetic determinants of S. aureus nasal 
carriage. Our study demonstrates that polymorphisms in the 
glucocorticoid receptor gene are significantly associated with S. 
aureus nasal carriage status.  
 
We assume that selection bias was of little importance in our 
study, since allele frequencies and genotypes were similar to 
those observed in other Caucasian study populations P26,28P. Allele 
frequencies and genotypes and the distribution of possible 
confounders were also similar in the total Rotterdam study 
cohort and in the final cohort that was analyzed. 
 
The four glucocorticoid receptor gene polymorphisms have all 
been previously associated with variation in glucocorticoid 
sensitivity P28 P. We found that homozygous presence of the G-
allele of the exon 9beta polymorphism conferred a 68% lower 
risk of persistent S.aureus nasal carriage. The G-allele of the 
exon 9beta polymorphism has previously been found to be 
over-represented in a group of patients with rheumatoid 
arthritis. The mechanism for this is unknown, but stabilization of 
the GRbeta mRNA by the presence of this G-allele – as indeed 
observed in vitro P30,40 P – may play a role. The G-allele destroys an 
mRNA destabilizing ATTTA motif, resulting in a higher stability 
for the GRbeta mRNA. This stabilization may induce relative 
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glucocorticoid insensitivity through accumulation of the GRbeta 
protein which has been reported to have a dominant negative 
influence on GRalpha action P30,40 P. This in turn may lead to a 
slightly more active immune system, predisposing to chronic 
inflammatory disease such as rheumatoid arthritis on one hand, 
while protecting from S.aureus colonization on the other hand. 
The Ser-allele of the Asn363Ser polymorphism has been shown 
to increase glucocorticoid sensitivity and to increase the insulin 
response to dexamethasone P25,26P. It was, however, not associated 
with S. aureus carriage.  
The G-allele of the Bcl-1 polymorphism  was previously found to 
be associated with increased glucocorticoid sensitivity and 
increased abdominal obesity, while at higher age a lower body 
mass index (BMI) accompanied by a tendency towards lower 
lean body mass was documented P27P. It showed a slight but 
statistically non-significant, protective effect with regard to 
S.aureus carrier status.  
The Lys-allele of the Arg23Lys polymorphism has been 
associated with increased resistance to glucocorticoids, higher 
cortisol levels after dexamethasone suppression testing, lower 
fasting insulin concentrations and better insulin sensitivity P2942 P. 
From our haplotype analysis we determined that this allele is 
always present on an allele that also carries the G-variant of the 
exon 9beta polymorphism. Remarkably, we found that 
heterozygous carriers of this haplotype allele were at an 
increased risk of persistent S. aureus carriage, which just failed 
to reach significance (OR 1.38; 95% CI, 0.97-1.97). However, 
persons with the genotypic combination of a wild type allele 
together with this haplotype allele had an 80% higher risk of 
persistent S. aureus carriage versus all other genotypes. It is 
difficult to reconcile these observations: two polymorphisms, 
both associated with reduced glucocorticoid sensitivity have 
opposite effects. First, it should be noted, however, that the 
protective effect of the G-allele of the exon 9beta polymorphism 
was only present in homozygotes, while the genotypic 
combination of a wild type allele together with this haplotype 
allele includes only 9beta heterozygotes. This suggests a 
recessive effect of the 9beta G-allele. Second, all five 23Lys 
homozygotes were non-carriers of S. aureus, which, might be 
due to the fact that they are also 9beta G-allele homozygous. 
Due to their low number, this was not amendable to statistical 
analysis  
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Our data show that genetic variation in the glucocorticoid 
receptor gene influences the risk of persistent S. aureus nasal 
carriage. The 9beta GG-homozygotes may have a more active 
immune system through increased glucocorticoid resistance as 
demonstrated by the association with autoimmune disease, 
notably rheumatoid arthritis P30P. Although no data on insulin 
sensitivity or tissue glucose concentrations are available for the 
population studied, the lack of association between fasting blood
glucose and the exon 9beta polymorphism suggests that a lack 
of glucocorticoid-induced immune suppression is the most likely
explanation for the association observed here. Furthermore, 
where glucocorticoid receptor mediated gene activation mostly 
acts through DNA binding, one of the key regulatory pathways of
the immune system, the strong anti-inflammatory effect of 
glucocorticoids is the result of glucocorticoid receptor mediated 
regulation of pro- / anti-inflammatory genes through differential 
activity of the pro-inflammatory nuclear transcription factor 
kappa B (NF-kappa B) P21,22P. Lys-carriers of the Arg23Lys 
polymorphism show a relative glucocorticoid resistance due to a 
lesser transactivation in combination with normal transinhibition 
of NF-κB P43,44P. We hypothesize that the higher cortisol levels in 
these carriers lead to an increased transinhibition and thus to 
suppression of the immune system. However, too little is 
currently known on the physiological basis of the (combined) 
effects of glucocorticoid receptor gene polymorphisms, and 
future research should lead to better insight in the underlying 
mechanisms. In addition, it has recently been demonstrated that 
glucocorticoids, in conjunction with pro-inflammatory cytokines, 
affect the expression of toll-like receptor 2 (TLR-2), the main 
pattern recognition molecule for gram positive pathogens such 
as S. aureus P45-47 P. Whether the various glucocorticoid receptor 
gene polymorphisms studied here are (partially) defective in 
supporting this biological activity is currently unknown, but, 
again, warrants further investigation. These further 
investigations would form a de novo field of research focusing 
on S. aureus carriage and glucocorticoid/ glucocorticoid 
receptor gene dependent innate immune determinants. 
 
In conclusion, this study identifies the first human genetic factor 
as a (co-)determinant of individual S. aureus nasal carriage. 
Apparently, polymorphisms and combinations thereof in the 
glucocorticoid receptor gene affect the human colonization 
resistance against S. aureus. This knowledge should be taken 
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into account when designing future studies into the fundamentals
of staphylococcal colonization and infection. 
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  Abstract 
 
Context  S. aureus nasal carriage is a risk factor for nosocomial and 
community-acquired infections. No data are available on overall 
health effects in the community. 
Objective  To determine if in the community S. aureus nasal carriage is 
associated with mortality and antibiotic use. 
Design  Prospective population-based cohort study. 
Setting  The Rotterdam Study. 
Participants  3,851 individuals, 61 years of age and older. 
Outcome 
Measures 
 Between April 1
st 1997 and December 31st 1999 S. aureus nasal 
carriage status was determined. Non-or-intermittent and 
persistent carriage were distinguished. Follow-up ended on 
December 1st 2003. The influence of potential prognostic factors 
on mortality was evaluated using Cox proportional hazards 
model. To evaluate the influence of potential prognostic factors 
on antibiotic use we used Poisson regression analysis. 
Results  678 (17.6%) persons were persistent carriers. 2510 (65.2%) 
persons used antibiotics and 516 (13.4%) persons died. Male 
gender (hazard ratio [HR], 1.88; 95% confidence interval [CI], 
1.54-2.30), age (HR per 10 years increase 2.86; 95% CI, 2.52-
3.24), smoking (HR 1.75; 95% CI, 1.33-2.29), fasting glucose 
level (HR per mmol/L increase 1.09; 95% CI, 1.04-1.14), and 
diastolic blood pressure (HR per 10 mm Hg increase 1.01; 95% 
CI, 1.01-1.02) were significantly associated with mortality. 
Persistent S. aureus nasal carriage was not associated with 
increased mortality (HR 1.03; 95% CI, 0.82-1.30).  
Persistent S. aureus nasal carriage was associated antibiotic use 
(incidence rate ratio [IRR], 1.09; 95% CI, 1.03-1.14), as were 
female gender (IRR, 1.29; 95% CI, 1.23-1.34), age (IRR per 10 
years increase, 1.10; 95% CI, 1.07.-1.13), current smoking (IRR, 
1.17; 95% CI, 1.11.-1.24), eczema (IRR, 1.10; 95%CI, 1.03-1.17) 
and history of skin infections (IRR, 1.20; 95% CI, 1.04-1.40). 
Conclusions  Among elderly persons in the community, persistent S. aureus 
nasal carriage was not associated with all-cause mortality.  
Persistent S. aureus nasal carriage was, however, associated with
a slight, though significant increase in antibiotic use. 
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  Introduction 
 
  Staphylococcus aureus is the cause of a variety of infections 
ranging from mild, including skin infections and food poisoning, 
to life-threatening, including pneumonia, sepsis, osteomyelitis, 
and infective endocarditis.1 Over the last 20 years the incidence 
of both community-acquired and hospital-acquired S. aureus 
infections has increased, accounting for about 13 percent of 
nosocomial infections in U.S. hospitals.2-4 In Europe, the EPIC 
study demonstrated that more than 30% of infections in the 
intensive care unit (ICU) were due to S. aureus.5 In Canada, 
severe community-acquired blood stream infections (BSI) 
necessitating ICU admission (incidence 15.7 per 100,000 per 
year) were caused by S. aureus in 20% of all cases.6 Infections 
by S. aureus are the cause of serious attributable morbidity and 
mortality, especially in the elderly.6-10 
The nose (i.e. the anterior nares) has been shown to be the 
primary ecological reservoir of S. aureus in humans.11 Three S. 
aureus nasal carriage patterns can be distinguished: persistent, 
intermittent and non-carriage.12 Persistent S. aureus nasal 
carriage is the major risk factor for the development of S. aureus 
infections, the majority being of endogenous origin.12-14 
Eradication of S. aureus nasal carriage by application of topical 
mupirocine results in a reduction in endogenous infections in 
various populations at risk.15-18 However, the absolute risk of 
developing a nosocomial S. aureus infection among nasal 
carriers is only 2 to 5%.13,14 
In contrast to the numerous studies on consequences of S. aureus 
nasal carriage in the hospital setting, limited data are available 
about the risks of S. aureus carriage in the community.19-21 
Recently, we demonstrated that persistent nasal carriage 
decreases with increasing age.22 This could be due to decreased
survival of nasal carriers, as the elderly are at highest risk of 
serious S. aureus infections.6,10  
To examine this hypothesis we performed a prospective 
population-based study on the relation between S. aureus nasal 
carriage, mortality and antibiotic use in a cohort of elderly 
persons.  
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  Material & Methods 
 
  Study sample 
The Rotterdam Study 
population 
 The present study was conducted as part of the Rotterdam Study, 
a prospective, population-based cohort study on the occurrence 
and determinants of disease and disability in elderly persons.23 
In 1990, all inhabitants of Ommoord, a suburb of Rotterdam in 
The Netherlands, who were 55 years of age or older and had 
lived in the district for at least one year were invited to 
participate in the study. Of the 10,275 eligible persons, 7983 
(78%) participated. Participants gave informed consent and 
permission to retrieve information from medical records. At 
baseline, between 1990 and 1993, trained interviewers 
administered extensive questionnaires during a home interview. 
During subsequent visits to the study center, additional 
interviewing, laboratory assessments, and clinical examinations 
were performed.  
The second follow-up was performed between April 1st 1997 and 
December 31st 1999 among 4,797 remaining participants. Using 
two quantitative nasal swab cultures with one-week interval, the 
S. aureus nasal carrier state was determined in 3,851 (80%) 
persons: 2,224 females and 1,627 males. All 3,851 were followed 
from the moment of culturing (between April 1st 1997 and 
December 31st 1999) until they died, or reached the end of the 
study at December 1st 2003. The Medical Ethics Committee of 
the Erasmus MC, Rotterdam, The Netherlands, approved the 
study. 
 
  Exposure Definition 
Defining the S. aureus 
nasal carrier state 
 S. aureus nasal carriage was defined according to an earlier 
validated culture rule.24 In brief, this culture rule used qualitative
data (i.e. nasal swab cultures being positive or not) combined 
with quantitative data (i.e. number of colony forming units 
(CFUs) in cultures). Persons were classified as persistent 
carriers when both nasal swab cultures were positive with an 
earlier defined number of S. aureus CFUs.24 All other persons 
were classified as non-or-intermittent carriers. The S. aureus 
nasal carrier state is thought to be a characteristic of the 
individual and for the present study we assumed it to be stable 
over time.25 
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Microbiological 
procedures 
 Nasal swabs were cultured as described earlier.25 In brief, 
samples were obtained using sterile cotton-wool swabs 
(Transwab, Medical Wire & Equipment Co. Ltd., Corsham, 
United Kingdom). Both the left and right anterior nares were 
sampled and swabs were immediately placed in Stuart’s 
transport medium and kept at 4 0C until further processing 
(within 24 hours). Swabs were cultured quantitatively on 
selective media: phenol-red mannitol salt agar (PHMA) and 
phenol red mannitol salt broth (PHMB). Identification of S. aureus 
was based upon colony morphology on the PHMA medium. 
Suspected colonies were cultured overnight on Columbia blood 
agar plates (Becton-Dickinson B.V., Etten-Leur, The 
Netherlands). A catalase test (positive) and a latex agglutination 
test (Staphaurex PlusR, Murex, Dartford, UK), positive in case of 
S. aureus, were then performed. 
 
  Outcome Definition 
  The outcomes of interest included all-cause mortality and overall
antibiotic use as a parameter of morbidity. Information on vital 
status was obtained at regular time intervals from the municipal 
authorities in Rotterdam. Antibiotic use was recorded as the 
number of filled antibiotic prescriptions during follow-up (count 
data). In the research area, there are 7 fully computerized 
pharmacies that are linked into a single network. During the 
study, all participants obtained their medication in 1 of these 7 
pharmacies. Data on all dispensed drugs between 1 January 
1991 and October 1st 2003 were available in computerized 
format on a day-to-day basis. The data include the date of 
prescribing, the total amount of drug units per prescription, the 
prescribed daily number of units, product name, and the 
Anatomical Therapeutic Chemical (ATC) code.26,27 
 
  Co-factors 
  The following baseline patient characteristics were individually 
assessed as potential confounders: age, gender, current 
smoking, diabetes mellitus, fasting serum glucose level and skin 
diseases (eczema, boils or other infections). Diabetes mellitus 
was defined as the use of glucose-lowering medication or a 
fasting serum glucose level of equal to or greater than 7.0 
mmol/L (126 mg/dl).28 Impaired fasting glucose was defined as a
fasting serum glucose level equal to or higher than 6.1 mmol/L 
(110mg/dl) but lower than 7.0 mmol/L (126 mg/dl).  
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  Statistical Analysis 
  Kaplan-Meier curves and the log-rank test were used to evaluate 
the difference in survival between the carrier states. We used a 
Cox proportional hazards model to assess the effect of S. aureus 
nasal carriage on mortality.29 Antibiotic use was evaluated as the 
number of antibiotic prescriptions using Poisson regression. In 
these analyses follow-up ended either at time of death, or end of 
the study period. The non-or- intermittent S. aureus nasal carrier 
state was the reference category in all regression models. 
Gender, age, smoking habit, a history of eczema and fasting 
blood glucose level were included in all regression models to 
correct for potential confounding, since these were recently 
shown to be independent determinants of S. aureus nasal 
carriage. Other variables were additionally included to assess 
their prognostic contribution. Some of these variables had 
missing data, which never exceeded 2.5% of participants. To 
enable inclusion of these individuals in analyses, we created a 
missing value indicator when applicable. Results are reported as
hazard ratios with 95 percent confidence intervals. Two-sided P 
values of less than 0.05 were considered to indicate statistical 
significance. 
 
 
 
 
  Results 
 
  Table 1 shows baseline characteristics for persistent S. aureus 
nasal carriers and non-or-intermittent carriers. The majority of 
persons enrolled in the study was living independently, together
with a partner.  More than 80% did not currently smoke, while 
34% had never smoked. The prevalence of diabetes mellitus 
was 12% and 43% of the persons had experienced one or more 
skin diseases prior to the study. 
 
Mortality  Total duration of follow-up included 18,359 person-years. Five-
hundred and sixteen participants died during follow-up (13.4%): 
98 (14.5%) in the persistent carrier group and 418 (13.2%) in the 
non-or-intermittent carrier group. The Kaplan-Meier calculated 
mean survival in the persistent carrier group was 6.08 years 
versus 6.11 years in the non-or-intermittent carrier group (P = 
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0.48; log-rank test). Through Cox proportional hazards analyses 
only male gender, age, current smoking, fasting glucose level, 
and diastolic blood pressure were identified as significantly 
contributing to mortality in this elderly population (Table 2). 
Persistent S. aureus nasal carriage was not associated with 
mortality (HR 1.03; 95% CI, 0.82-1.30, from a Cox model 
containing all above variables). 
A secondary analysis was performed within gender and smoking
habit subgroups. However, also in these analyses persistent S. 
aureus nasal carriage was not associated with mortality. 
 
Antibiotic use  Of a total of 3,851 participants in this study, 2,510 (65%) were 
prescribed at least one course of antibiotics.  Follow-up for 
antibiotic use analysis ended at death or end of the medication 
registration period (October 1st 2003). The antibiotic use follow-
up included 17,717 person-years. Poisson regression analysis 
demonstrated persistent S. aureus nasal carriage, female 
gender, age, a history of skin infections or eczema and current 
smoking to be significantly associated with antibiotic use in this 
elderly population (Table 2).  
As with the mortality analysis, a secondary analysis was 
performed within gender and smoking habit subgroups. No 
gender differences were found. However, within smoking habit 
subgroups persistent S. aureus nasal carriage was only 
significantly associated with increased antibiotic use in the past-
or-never smokers group (IRR, 1.11; 95%, 1.05-1.17) and not 
anymore in the current smokers group (IRR, 0.99; 95% CI, 0.88-
1.13). 
 
 
 
 
  Discussion 
 
  In our large prospective population-based study among elderly 
persons we found no relation between persistent S. aureus nasal 
carriage and all-cause mortality. However, persistent S. aureus 
nasal carriage was associated with a slight, but significant 
increase in antibiotic use. When analyzing subgroups, the effect 
of persistent S. aureus nasal carriage was only substantiated in 
the past-or-never smokers. No effect of persistent carriage on 
antibiotic use was seen in current smokers. 
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  Earlier retrospective cohort or case-control studies have 
demonstrated increasing age, male gender, alcoholism, lung 
disease, cancer, diabetes mellitus and end stage renal failure 
and dialysis to be risk factors for community-acquired S. aureus 
infections necessitating hospital admission.6,30-32 These factors 
have also been identified earlier as determinants of S. aureus 
nasal carriage in case-control or cross-sectional studies.12 As 
reported before, we found male gender, age, smoking, higher 
fasting glucose levels and higher diastolic blood pressure to be 
independent predictors of mortality. Earlier we demonstrated 
that male gender and higher fasting glucose levels were 
positively, and increasing age and current smoking negatively 
associated with persistent S. aureus nasal carriage22 indicating 
that these factors should indeed be considered as confounders 
in the present analyses.  
Next to persistent S. aureus nasal carriage, female gender, 
increasing age, smoking and skin infections were shown to be 
independent predictors of (any) antibiotic use. This finding was 
anticipated since women are known to have a higher risk of 
urinary tract infections,33-35 smoking is associated with higher 
risk of upper and lower respiratory tract infections36-38 and 
persons with a history of skin infections are likely to have a 
higher rate of skin infections.  
In the present cohort, males are significantly more often current 
smokers (21.6% versus 14.5%), and report boils (58.6% versus 
41.4%) and other skin infections (8.2% versus 6.2%) significantly
more often than women. These are all factors associated with 
antibiotic use as well. The findings from the subgroup analyses 
suggests that the impact of persistent S. aureus nasal carriage on 
antibiotic use is higher in past-or-never smokers than in current 
smokers.  
 
The major limitation of our study is that we studied all-cause 
mortality and overall antibiotic use and not infection-related 
mortality or specific anti-staphylococcal antibiotic prescriptions. 
It remains possible that persistent S. aureus nasal carriage is 
associated with mortality from S. aureus infections. However, 
since persistent carriage did not significantly attribute to the all-
cause mortality, the absolute assignable risk for S. aureus nasal 
carriage-related mortality due to infection will, if any, be low. 
Also, the vast majority of antibiotics prescribed in the 
community are for urinary tract and respiratory tract infections, 
RISKS/ Chapter 8/ Effect of Staphylococcus aureus Nasal Carriage on Mortality & Antibiotic Use in the Community. IV - 11
 
2004 © J.L. Nouwen \ December 8th 2004 \ Thesis: Determinants, Risks & Dynamics of Staphylococcus aureus Nasal Carriage 
and not for the major community-acquired S. aureus infections, 
mostly skin infections. Therefore, in the community, the relative 
contribution of S. aureus infections may be too small to 
demonstrate an large effect on overall antibiotic consumption, 
although a slight effect was demonstrated. 
 
From this large population-based prospective cohort study we 
conclude that in the community setting, the healthy elderly 
persistent S. aureus nasal carrier does not die earlier, but is  
prescribed antibiotics more often than his or her non-or-
intermittent carrier counterpart. 
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  Abstract 
 
Context  S. aureus nasal carriage has been demonstrated to be a major 
risk factor for S. aureus infections in patients on continuous 
peritoneal dialysis (CPD). 
Objective  To study the impact of the different staphylococcal carriage 
patterns on the incidence of infections among CPD patients. 
Design  Retro- and prospective cohort study. 
Setting  Tertiary care university hospital. 
Participants  Patients were screened for Staphylococcus aureus carriage and 
categorized as persistent, intermittent or non S. aureus nasal 
carriers. Patients were subsequently recultured every 12 weeks 
for S. aureus and coagulase negative staphylococcal (CoNS) 
carriage and followed-up for CPD related infections and 
antibiotic resistance.  
Outcome 
Measures 
 Incidence of CPD-related infections, antibiotic usage and 
antibiotic resistance. 
Results  Fifty-two patients were included: 20 peristent, 10 intermittent 
and 22 non S. aureus carriers. Only persistent S. aureus carriage 
was significantly associated with an increased risk for all CPD 
related infections (incidence rate ratio (IRR) 3.52 [95% CI: 2.56-
4.85]), exit site infections (IRR 5.59 [95% CI: 3.50-8.92]) and 
peritonitis (IRR 2.19 [95% CI: 1.39-3.45]), as well as increased 
antibiotic use (IRR 3.43 [95% CI: 2.50-4.72]), including 
vancomycin (IRR 2.15 [95%: 2.13-2.16]). No vancomycin resistant
S. aureus strains were detected. However, 8 (2%) out of 407 
CoNS strains isolated were vancomycin intermediately 
susceptible. In all 5 patients (4 persistent and 1 intermittent 
carriers) concerned this was significantly related to a higher 
antibiotic (including vancomycin) usage (IRR 2.65 [95% CI: 1.82-
3.84]).  
Conclusions  Persistent - but not intermittent - S. aureus nasal carriage is thé 
major determinant of CPD related infections and associated with 
a significantly higher consumption of antibiotics, including 
vancomycin. The highly diverse population of CoNS appears to 
be the prime reservoir of staphylococcal vancomycin resistance. 
Accurate determination of the S. aureus nasal carriage state of 
CPD patients is essential to better target intervention strategies 
to prevent CPD related infections.  
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  Introduction 
 
  Continuous peritoneal dialysis (CPD) is a commonly used 
technique in patients with chronic renal failure. CPD-catheter 
related infections (including peritonitis, exit-site and tunnel 
infections) are frequently encountered complications and result 
in significant morbidity, mortality and costs. The majority of 
these CPD related infections are caused by Staphylococcus 
aureus and coagulase-negative staphylococci (CoNS).  
S. aureus nasalP Pcarriage is a major risk factor for the 
developmentP Pof both community-acquired and nosocomial 
infections, including CPD related infections.P1-5 P The anterior 
nares are the primary reservoir of S. aureus in humans.P6-8P The 
prevalence of S. aureus nasal carriage has been estimated to be 
50% in CPD patients, P9,10 P while cross-sectional P Psurveys of healthy 
adult populations have reported carriage rates between 20 and 
55%.P11-13P From longitudinal studies it is known that S. aureus 
nasal carriage patterns differ between individuals, andP Pthat 10 to 
35% of individuals carry S. aureus persistently (hence called 
persistent S. aureus nasal carriers), 20P Pto 75% carry S. aureus 
intermittently (intermittent carriers), and 5 to 50% never carry S. 
aureus in their nose (non-carriers). P14-18P However, data on the true
status of S. aureus carriage based on longitudinal studies in 
patients on CPD are lacking. 
 
Since S. aureus nasal carriage has been demonstrated to be a 
major risk factor for S. aureus infections in CPD patients, P4,19-25P 
several intervention studies have adopted different strategies 
including vaccinationP26,27P and eradication of S. aureus using 
antimicrobial prophylaxis .P10,28-32P These latter studies 
consistently demonstrated a significant reduction in the 
incidence of exit site infections, but not a consistent reduction in 
the incidence of CPD related peritonitis. Mupirocin is the 
antibiotic agent commonly used in these intervention studies. 
However, due to its popularity, resistance to mupirocin is on the 
rise, compromising its usefulness as an intervention tool in the 
prevention of S. aureus infections.P33P Also, the cost-effectiveness 
of applying mupirocin in the CPD setting has been questioned. P34 P 
As a consequence new intervention strategies need to be 
developed. 
One of these strategies would be the targeting of prophylactic 
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antibiotics to high-risk patient groups only, instead of the whole 
(CPD) population. In the case of S. aureus nasal carriage there 
still is no consensus on how to define the S. aureus carrier 
states.P35 P Precise determination of the S. aureus nasal carriage 
state is relevant, since earlier studies have shown the mean 
number of colony forming units (CFU) of S. aureus isolated fromP 
Pthe anterior nares to be higher in persistent carriers than in 
intermittent carriers, P36,37P resulting in more extensive dispersal ofP 
Pthe staphylococci in the environmentP38P and in an increasedP Prisk 
of S. aureus infections.P39-41P 
Even less is known about the long term molecular epidemiology 
of CoNS in CPD patients, with respect to CPD related infections 
caused by CoNS. P42-44P Furthermore, the long term use of 
glycopeptides as first line antibiotics in CPD related infections 
has been related to the development of glycopeptide resistance 
in staphylococci (mainly CoNS). Since in our medical center 
vancomycin treatment is part of the empiric antibiotic treatment 
of CPD related peritonitis, it could be questioned if short term 
vancomycin treatment is also a risk factor for the development of 
glycopeptide resistance in staphylococci. 
The main objectives of the present study, therefore, were to 
provide more insight in the long-term molecular epidemiology 
of S. aureus and coagulase negative staphylococci (CoNS) 
carriage in CPD patients and to determine the value of 
differentiating between persistent carriage, intermittent 
carriage and non-carriage in predicting the subsequent risk of 
CPD related infections. In addition, we determined the impact of 
empiric use of vancomycin in CPD related peritonitis on the risk 
of vancomycin resistance in S. aureus and CoNS. 
 
 
 
  Material & Methods 
 
  Patients 
  The Erasmus University Medical Center Rotterdam (Erasmus 
MC) is a 1,250 bed tertiary care university hospital with 
approximately 60 adult patients in its CPD program. Table 1 sum 
marizes the definitions used in the present study for the different 
CPD related infections. The empiric antimicrobial therapy for 
CPD related peritonitis consisted of ceftazidime (loading dose of 
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500mg/L intraperitoneally, followed by 125 mg/L CPD dialysate 
qid) plus vancomycin (2 grams intraperitoneally once every 5-7 
days). Antimicrobial therapy was adjusted according to culture 
results and given for at least two weeks. Exit and tunnel 
infections were treated according to (routine) culture results. 
From January 1998 onwards all current and new patients on CPD 
were screened for S. aureus carriage with 6 consecutive nasal 
swab cultures (vestibulum nasi) taken at one week intervals. S. 
aureus screening cultures of the CPD catheter exit site were 
performed together with the first and last nasal swab culture. 
Based on these culture results patients were divided into three 
categories (non carriers, intermittent carriers and persistent 
carriers) according to the definitions in table 2.   
After this initial screening period, nasal swab cultures, cultures 
of CPD catheter exit site and cultures of contralateral (i.e. 
opposite to the catheter exit site) abdominal skin were taken 
every 12 weeks during follow-up visits to identify colonization 
with S. aureus, CoNS species and/or other microorganisms. 
Cultures from other sites (CPD dialysis fluid, wounds, blood, 
etc.) were performed on indication only. Patients were followed-
up for an overall period of four years until December 31 PstP 2001 or
until the date of ending CPD treatment, whichever date came 
earlier. 
From January 1PstP 1998 until December 31 PstP 2001, data on 
antibiotic use and (CPD related) infections were collected 
prospectively. Data on the molecular epidemiology of CoNS and 
vancomycin resistance of the staphylococci isolated were 
collected prospectively between January 1 PstP 1998 and December 
31PstP 2000. Data on antibiotic use and (CPD related) infections 
before January 1998 were collected retrospectively by chart 
review.  
Written informed consent was obtained from all patients 
included. This study was approved by our institutional Medical 
Ethics Review Committee (METC 165.585/1997/164). 
 
  Microbiological procedures 
Phenotyping  Cultures from abdominal skin, catheter exit site, nose 
(vestibulum nasi), blood and CPD dialysis fluid were performed 
according to standard procedures. P45P Blood and CPD dialysis 
fluid were cultured using the BACTEC 9240 system (Becton-
Dickinson Diagnostic Instrument Systems, Sparks, Md., USA). In 
the case of CPD catheter removal, the tip was cultured in 
thioglycolate broth (Brewer modified). MicroScan WalkAway-96 
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Table 1  Definitions of CPD related infections.  
 
Peritonitis Peritonitis was diagnosed if at least two of the 
following three criteria were met:  
≡ turbid peritoneal effluent with more then 100 
leukocytes/mm, of which more then 50% were 
neutrophilic granulocytes;  
≡ abdominal pain or tenderness;  
≡ micro-organisms cultured from the peritoneal 
effluent. 
Peritonitis was considered relapsing when it was 
caused by the same micro-organism as in the 
preceding episode, within four weeks after 
discontinuing antimicrobial therapy. 
Exit-site infection Exit site infection (including tunnel- and cuff 
infection) was defined as the presence of redness, 
pain, swelling and/or induration of the catheter exit 
site and/or of the overlying tissues, with or without 
purulent discharge or abscess formation, together 
with a positive exit site culture. 
Bacterial colonization Bacterial colonization was defined as micro-
organisms present on the skin or mucosal surfaces 
without local signs or symptoms of infection. 
 
Table 2  Definitions of the different S. aureus carrier states.  
 
Non-carriers Non carriers had zero out of 6 nasal screening 
cultures positive for S. aureus. 
Persistent carriers Persistent carriers had either 6 out of 6 nasal 
screening cultures positive for S. aureus, or 4 or 5 
out of six nasal screening cultures positive for S. 
aureus and at least one of the exit site cultures 
positive for S. aureus at screening. Genotyping 
showed all these S. aureus isolates to be identical. 
Intermittent carriers Intermittent carriers had either less than 4 out of six 
nasal screening cultures positive for S. aureus, or 4 
or 5 out of six nasal screening cultures positive for S. 
aureus but no positive exit site culture or 
genotypically non-identical S. aureus strains. 
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  (Dade International Inc., West Sacramento, CA, USA) and Vitek 
equipment (bioMérieux Vitek, Hazelwood, Mo, USA) were used 
for the identification of microorganisms.  
Swabs from nose, abdominal skin and catheter exit site were 
also cultured quantitatively on phenol-red mannitol salt agar 
(PHMA) and in phenol red mannitol salt broth (PHMB) for S. 
aureus according to a standard operating procedure as 
described earlier. P35,37P Culture results were recorded as 0 (no S. 
aureus), 1 (S. aureus only from PHMB), 2 (2-9 CFU), 3 (10-99 
CFU), 4 (100-999 CFU), or 5 (≥ 1000 CFU) (CFU= colony forming 
units). Identification of S. aureus was based upon colony 
morphology on the PHMA. Suspected colonies were cultured 
overnight on Columbia blood agar plates (Becton-Dickinson 
B.V., Etten-Leur, The Netherlands). A catalase test and a latex 
agglutination test (Staphaurex Plus PRP, Murex, Dartford, UK) were 
then performed on all staphylococcal isolates. The ID32Staph 
test (bioMérieux, Lyon, France) was used for further speciation 
of the CoNS. All staphylococcal isolates were stored at -70 0C in 
glycerol containing liquid media. 
Susceptibility testing  MicroScan WalkAway-96 and Vitek equipment were also used 
for susceptibility testing. Based on the NCCLS breakpoints, 
strains were categorized as resistant (R), intermediately 
sensitive (I), or sensitive (S) to the antibiotic used.P45-47 P Further 
MIC determinations were done using E-test (AB Biodisk, Solna, 
Sweden). Methicillin susceptibility of staphylococci was tested 
using the disc diffusion method. Testing for vancomycin 
intermediate sensitivity (VISA or VISE) or vancomycin resistance 
(VRSA or VRSE) was done according to the method described by
Hiramatsu.P48P  
 
Genotyping  
(analysis of genetic 
relatedness) 
 Pulsed-field gel electrophoresis (PFGE) was performed based 
on protocols as previously described. P49P Bacteria were 
embedded in a agarose plugs and treated with lysostaphin 
(Sigma Aldrich, Germany), proteinase K (Merck, Germany) and 
the restriction enzyme SmaI (Boehringer Mannheim, Mannheim, 
Germany) prior to electrophoresis. The electrophoresis 
program consisted of two blocks (10 hrs 5-15 seconds switch 
time followed by 10 hrs 15-45 seconds switch time) and was 
performed at 14 P0 PC and 6 V/cm. Gels were photographed after 
ethidium bromide staining and banding patterns were 
interpreted according to Tenover et al. P50P 
 
Statistical procedures  Percentages were compared by the Chi-square test (Fisher’s 
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exact test in case of 2x2 tables). To compare the number of CPD-
related infections and number of antibiotic courses (including 
vancomycin) used during follow-up between the different S. 
aureus carrier states, Poisson regression analysis was employed. 
The influence of potential prognostic factors on the incidence of 
CPD related infections and antibiotic usage was evaluated using 
Poisson regression as well. Kaplan-Meier curves and the log-
rank test were used to evaluate differences in survival between 
the carrier states. We used a Cox proportional hazards model to 
assess the effect of S. aureus nasal carriage on mortality. P51P In 
these analyses follow-up ended either at death, date of renal 
transplantation or switch to intermittent hemodialysis, or end of 
the study period. The non-or- intermittent S. aureus nasal carrier 
state was the reference category in all multiple regression 
models. Sex and age were included in all multiple regression 
models to correct for potential confounding. 
All statistical tests were two tailed and performed at the 0.05 
significance level. SAS statistical software (The SAS system for 
Windows, release 8.0; SAS Institute inc., Cary, NY, USA) was 
used for Poisson regression analyses. All other statistical tests 
were done using SPSS statistical software (SPSS for Windows, 
version 12.0.1; SPSS inc., Chigago, IL, USA).  
 
 
 
 
  Results 
 
Demographics  Fifty-two patients were included in the study. Demographic data 
and prior history before start of the current CPD episode are 
summarized in table 3.  Nearly twice as many males as 
compared to females participated (33 vs. 19). 
 
S. aureus nasal 
carriage patterns 
 The distribution of the different S. aureus nasal carriage groups, 
based on six weekly nasal swab cultures, is shown in table 4.  
There were 22 non-, 10 intermittent and 20 persistent carriers. 
No difference in distribution between males and females was 
found. Of the intermittent carriers, 9 had only one nasal 
screening culture positive and one had 3 cultures positive but 
with two genotypically different strains and with negative exit 
site cultures. Of the 20 persistent carriers 13 had 6 out of 6 nasal 
screening cultures positive. All of these 13 persons had positive  
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Table 3  Characteristics of the CPD population at inclusion. 
 
   
 
Participants (n) Males 33 
 Females 19 
   
Age (median-range) Males 50.0 (22.6-76.9) 
 Females 47.4 (19.0-70.4) 
   
Cause of end stage renal disease (n) Vascular disease 11 
 Diabetes Mellitus 9 
 Glomerulonephritis 12 
 Urinary tract infections 10 
 TTP*/HUS P†P 2 
 Other 8 
   
Previous kidney transplantation(s) 
(n) 
No 38 
 1 8 
 2 4 
 3 2 
   
Previous chronic intermittent 
hemodialysis (n) 
No 36 
 Yes 16 
   
Number of CPD catheters (n) 1PstP 42 
 2Pnd P 8 
 3PrdP 1 
 4Pth P 1 
   
Diabetes Mellitus (n) No 37 
 Insulin dependent 10 
 Non-insulin dependent 5 
   
Immunosuppressive medication (n) No 47 
 Corticosteroids 3 
 Other 2 
* TTP = thrombotic thrombocytopenic purpura; P†PHUS = hemolytic uraemic syndrome 
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  exit site cultures on at least one occasion and all strains isolated 
at screening were genotypically identical. The other 7 persistent 
carriers had 4-5 positive nasal screening cultures. In all of these 
patients, also, exit site cultures were positive on at least one 
occasion and all strains isolated at screening were genotypically 
identical.  
Neither the cause of end stage renal disease, a history of renal 
transplantation, a history of intermittent hemodialysis, the 
presence of diabetes mellitus, nor the use of corticosteroids or 
other immunosuppressive drugs were significantly associated 
with S. aureus nasal carriage. 
Follow-up  Total duration of follow-up was 2,260 months, with a median of 
33.6 months (mean 43.5; range 1.6-204). There was no difference 
in follow-up between the three S. aureus nasal carriage groups 
(table 5). Eighteen patients were still on CPD at the end of the 
study. In 34 patients CPD therapy was stopped during the study 
(16 non-, 5 intermittent and 13 persistent carriers; P=ns). 
Fifteen patients received a kidney transplantation (5 non-, 3 
intermittent and 7 persistent carriers; P=ns). In 6 patients 
persisting or relapsing CPD peritonitis necessitated removal of 
the CPD catheter (3 non- and 3 persistent carriers; P=ns): 3 were 
caused by Candida albicans, 1 caused by C. albicans in 
combination with Escherichia coli and 2 caused by a perforation 
of the colon.  
Thirteen patients died during follow-up (8 non-, 2 intermittent 
and 3 persistent carriers; P=ns). Three patients died of CPD 
related infections (1 caused by C. glabrata in combination with 
Enterobacter cloacae, 1 caused by S. aureus and 1 by a 
perforation of the colon), 2 died of non-CPD related infections (1 
of fasciitis necroticans and 1 of pneumonia) and 8 died of non-
infectious causes (atherosclerosis related cardiac and 
neurological events). No CPD catheter had to be removed 
because of (recurrent) exit-site or tunnel infections. Persistent S. 
aureus nasal carriage was not associated with mortality (hazard 
ratio1.276 [95% confidence interval (CI): 0.658-2.475]). 
 
CPD related infections  CPD related infections occurred in all three carriage groups and 
are summarized in table 5. As compared to non- and intermittent 
carriers, persistent carriers patients had significantly higher 
incidences of all-cause CPD related infections (overall 0.13 
/month [P<0.001], exit site infections 0.09/month [P<0.001], 
peritonitis 0.05/month [P=0.019]) and S. aureus CPD related 
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infections (overall 0.08 /month [P<0.001], exit site infections 
0.07/month [P<0.001], peritonitis 0.01/month [P=0.026]; Table 
5). Intermittent carriers behaved like non-carriers as their 
incidence rates for CPD related infections were similar (Table 
5). 
To calculate incidence rate ratio’s, the non- and intermittent 
carrier groups were merged and compared with the persistent 
carrier group.  Age, sex, cause of end stage renal disease, 
history of intermittent hemodialysis and use of corticosteroids or 
other immunosuppressive drugs were not associated with any 
category of CPD related infections in Poisson regressions 
analysis. Only persistent S. aureus nasal carriage and the 
presence of diabetes mellitus were found to be significantly 
associated with CPD related infections. Persistent carriers had a 
more than 3-fold higher risk of all-cause CPD related infections 
(incidence rate ratio (IRR) 3.52 [95% CI: 2.56-4.85]) and a more 
than 9-fold higher risk of S. aureus CPD infections (IRR 9.54 [95% 
CI: 5.25-17.33]) compared to non-or-intermittent carriers. The 
IRR for exit site infections, S. aureus exit site infections, all 
peritonitis, S. aureus peritonitis and CoNS peritonitis were 5.59 
[95% CI: 3.50-8.92], 10.75 [95% CI: 5.45-21.19], 2.19 [95% CI: 
1.39-3.45], 6.54 [95% CI: 1.83-23.31] and 3.37 [95% CI: 1.45-
7.83], respectively (Table 5). 
Patients with diabetes mellitus were at a 2-fold higher risk of all-
cause CPD related infections (IRR 1.99 [95% CI: 1.44-2.75]), S. 
aureus CPD infections (IRR 2.02 [95% CI: 1.28-3.18]), all-cause 
exit site infections (IRR 2.33 [95% CI: 1.53-3.55]) and S. aureus 
exit site infections (IRR 2.03 [95% CI: 1.23-3.34]). However, no 
significant association between diabetes mellitus and peritonitis 
was found.  
 
Antibiotic usage  Antibiotic usage also differed significantly between the 
persistent carrier group and the combined non-or-intermittent 
carrier group: the number of antibiotic courses per month for all 
infections was 0.13 [95% CI: 0.11-0.16] in the persistent carrier 
group versus 0.04 [95% CI: 0.03-0.07] in the non-or-intermittent 
carrier group (IRR 3.43 [95% CI: 2.50-4.72]; P<0.001). Also, 
vancomycin consumption was higher in persistent carriers 
compared to non-or-intermittent carriers: 203 milligrams of 
vancomycin per month [95% CI: 202-204] in persistent carriers 
versus 103 milligrams [95% CI: 102-104] in non-or-intermittent 
carriers (IRR 2.15 [95%: 2.13-2.16]; P<0.001). Diabetes mellitus 
was significantly associated with higher antibiotic (including  
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Table 4  S. aureus carriage patterns of CPD patients on screening.  
 
   
 
  non intermittent persistent Total 
 
nasal carriage (n) 
 
     
male 13 (39%) 6 (18%) 14 (42%) 33 (100%) 
 
female  9 (47%) 4 (21%) 6 (32%) 19 (100%) 
 
Total 
 
22 (42%) 10 (19%) 20 (39%) 52 (100%) 
 
 
 
  vancomycin) consumption as well. Diabetics used nearly twice 
as much antibiotics (IRR 1.95 [95% CI: 1.41-2.54], while 
vancomycin use was increased with 36% (IRR 1.36 [95% CI: 
1.35-1.37] compared to patients without diabetes mellitus. 
 
Molecular epidemiology 
of staphylococcal 
isolates 
 In this study a total of 407 different S. aureus isolates were 
cultured, consisting of 44 genotypically (PFGE) distinct strains. 
During follow-up 16 of the 20 persistent carriers remained 
persistently colonized with the same resident S. aureus strain as 
found during the initial screening phase. In four persistent 
carriers there was a change in colonizing S. aureus strain during 
follow-up. These changes were all related to antecedent anti-
staphylococcal antibiotic treatment for S. aureus exit-site 
infection or peritonitis. In 2 of these patients exit site and nasal S. 
aureus isolates were different by PFGE. Except for one case of S. 
aureus peritonitis, all 78 S. aureus infections in the persistent 
carriers were of endogenous origin, i.e. with the same genotype 
strain as had been found on screening. Four genotypically 
identical S. aureus strains were isolated from 2 patients each, 
while all other strains were distinct genotypes. 
Only one intermittent carrier patient developed S. aureus 
infections: two exit site infections with genotypically non-
identical strains. Six non-carriers suffered from S. aureus 
infections (9 exit site infections and 3 peritonitis episodes) 
during follow-up. Two of them turned into a persistent carrier, 
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becoming colonized at the CPD catheter exit-site as well as in 
their nose with an identical S. aureus strain in each case, causing 
their S. aureus infections. Two non-carriers became 
intermittently colonized at the exit-site, but their nasal swab 
cultures remained negative. The two remaining non-carriers 
with S. aureus infections had nasal swab and exit-site cultures 
that were always negative for S. aureus. 
 
All 52 patients had one or more cultures positive for coagulase-
negative staphylococci (CoNS). A total of 407 different CoNS 
isolates were cultured, consisting of 189 genotypically (PFGE) 
distinct strains. Per patient a median of 5 genotypically distinct 
CoNS were isolated from the nose, exit-site and/or abdominal 
skin. Results varied widely per culture and per culture site. 
Moreover, CoNS strains involved in CPD peritonitis were 
different from those found in the screening and follow-up 
cultures within patients. Thus, no CoNS carriage ‘pattern’ could 
be detected in individual patients. The source of CoNS strains 
causing infections was not the patients’ microflora on the 
abdominal skin or vestibulum nasi. 
 
Antibiotic resistance  All 407 S. aureus strains isolated were methicillin sensitive S. 
aureus (MSSA), no methicillin resistant S. aureus (MRSA) was 
cultured in this period in this patient group. 
A total of 135 S. aureus isolates were tested for vancomycin 
(intermediate) resistance. These included all 92 isolates 
associated with CPD related infections and the 43 genotypically 
distinct ‘colonizing’ strains. None of these S. aureus isolates were 
vancomycin intermediately susceptible or resistant.  
In contrast to the S. aureus strains, methicillin resistance was 
demonstrated in 280 (69%) and intermediate vancomycin 
susceptibility (MIC 8 µg/L) was detected in 8 (2%) out of all 407 
CoNS strains tested. The 8 vancomycin intermediately 
susceptible CoNS strains were all genotypically distinct S. 
epidermidis strains and were isolated from 5 different patients. 
In one person 3 distinct strains were isolated on different time 
points, in one person 2 distinct strains were isolated on different 
time points and in 3 persons each one distinct strain was isolated 
only once. None of these 8 vancomycin intermediately 
susceptible CoNS strains were implicated in (CPD related) 
infection. Four of the 5 patients from which a vancomycin 
intermediately susceptible CoNS strain was isolated were 
persistent carriers, one patient was an intermittent carrier 
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(P=0.066 when comparing persistent carriage with non-
carriage/intermittent carriage).  
Antibiotic usage was significantly higher in patients with a 
vancomycin intermediately susceptible CoNS strain than in 
patients without: 0.19 (95% CI: 0.14.-0.27) versus 0.07 (95% CI: 
0.04-0.15) antibiotic courses per month for all causes (IRR 2.65 
[95% CI: 1.82-3.84]; P<0.001). Also, the presence of a 
vancomycin intermediately susceptible CoNS strain was 
significantly associated with increased vancomycin 
consumption: 390 (95% CI: 388-393) versus 123 (95% CI: 121-
125) milligrams of vancomycin per month (IRR 3.17 [95%: 3.15-
3.20]; P<0.001). When adjusting for age, sex, diabetes mellitus 
and S. aureus nasal carrier state, carrying a vancomycin 
intermediately susceptible CoNS strain was still significantly 
associated with antibiotic usage (IRR 2.07 [95% CI: 1.37-3.12]) 
and vancomycin consumption (IRR 2.53 [95% CI:2.51-2.55]). 
 
 
 
 
  Discussion 
 
  In the study presented here 52 patients on CPD were followed-
up closely for a total of 2,260 months. More than 2,000 cultures 
were performed, resulting in the isolation of 407 S. aureus and 
407 CoNS strains. All 814 staphylococcal isolates were 
genotyped using PFGE and all CoNS plus 135 S. aureus strains 
were tested for vancomycin resistance according to Hiramatsu. P48P 
This is the first large scale study to combine the careful 
assessment of S. aureus and CoNS carriage patterns and 
dynamics with their clinical impact on CPD related morbidity 
and mortality.  
 
S. aureus nasal carriage has been found to be a major risk factor 
for infections in CPD patients before, mainly associated with exit 
infections but not CPD peritonitis and the incidence rates found 
in this study are comparable with these earlier studies.P4,19-25P Not 
surprisingly, intervention studies consistently demonstrated a 
significant reduction in the incidence of exit site infections, but 
not a consistent reduction in the incidence of CPD related 
peritonitis.P10,28-32 P These studies have led to the widespread use 
of antimicrobial prophylaxis, mainly with mupirocin, in CPD 
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patients to prevent S. aureus infections, often irrespective of the 
individual carrier state.  
However, in these studies only one or two nasal swab or exit site 
cultures were used to determine the S. aureus carrier state 
(carrier versus non-carrier) and genotyping techniques were not
routinely applied. Given the lack of accepted definitions for the 
different S. aureus P35P and given the fact that precise 
determination of the S. aureus nasal carriage state seems 
relevant, P36-41P we earlier derived and validated a culture rule to 
adequately determine the true carrier state with the least 
effort. P37 P In healthy individuals it is possible to predict the carrier 
state with only two nasal swab cultures. Since CPD patients are 
treated with antibiotics regularly, we anticipated that two 
cultures would not be enough, and we extended our screening 
to six nasal swab cultures together with genotyping all strains 
isolated. Here we demonstrate that differentiation between the 
non-carrier, intermittent carrier and persistent carrier state in 
CPD patients is feasible and of clinical importance. Persistent 
carriage, but not intermittent carriage, is thé major determinant 
of CPD related infections, including CPD peritonitis of all 
microbial causes and CPD peritonitis by CoNS. Persistent 
carriage is also associated with significantly higher antibiotic 
consumption, including vancomycin. Targeting interventions to 
prevent CPD related infections is thus possible, thereby 
eliminating unnecessary prophylactic and therapeutic antibiotic 
use and resistance development.P33P Intermittent carriers behave 
like non-carriers as their risk for CPD related infections is 
equally low (0.04 infections per patientmonths at risk). In our 
opinion, therefore, neither intermittent nor non-carriers should 
be offered antibiotic prophylaxis for the prevention of S. aureus 
CPD related infections. In contrast, prophylaxis should be 
reserved for patients shown to be persistent carriers, since only 
they have a high rate of CPD related infections (0.13 per 
patientmonths at risk). 
Two out of 22 non-carriers became persistent carriers, while 2 
others converted to the intermittent carrier state during follow-
up. Thus, in a proportion of CPD patients, colonization with S. 
aureus is a dynamic process. Consequently, screening for S. 
aureus carriage should not be limited to the start of CPD 
treatment, but regular (e.g. once a year) determination of the 
current carrier state should be performed and action taken 
accordingly.  
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Eighty percent of persistent carriers were persistently colonized 
with their own resident S. aureus strain during follow-up, which 
is in concordance with earlier studies. P35,52P Anti-staphylococcal 
antibiotic treatment for S. aureus exit-site infection or peritonitis 
induced a change in S. aureus genotype. As reported earlier, 
nearly all S. aureus infections in persistent carriers were of 
endogenous origin. P3,53 P In total 44 distinct S. aureus strains were 
identified. In contrast to other S. aureus infections such as 
impetigo, no clonal spread of strains was observed. P54 P No 
significant cross-contamination between patients occurred, 
since only 4 genotypically identical S. aureus strains were 
isolated from 2 patients each, while all other strains were patient 
unique. Whether S. aureus strains causing CPD related infections 
harbour specific virulence factors necessary for successful 
colonization and infection, as was reported in other clinical 
settings, P54-56 P is currently not known, but will need to be the 
subject of future research. 
 
The molecular epidemiology of CoNS proved to be extremely 
complex and dynamic. CoNS were cultured in all 52 patients, but
the great variety and variability of strains within individual 
patients and the lack of concordance between colonizing and 
infecting strains, made it impossible to establish a CoNS 
carriage ‘pattern’. In contrast to other settings, no clonal spread 
was observed. P57 P Thus, the exact source of CoNS strains causing 
CPD related infections could not be determined.  
 
No vancomycin resistance was detected in our S. aureus isolates, 
despite the fact that vancomycin intraperitoneally is part of the 
empiric treatment of CPD peritonitis together with 
intraperitoneal ceftazidime. However, antibiotic treatment is 
adjusted according to culture results within 72 hours. Since the 
prevalence of methicillin resistant S. aureus (MRSA) is lower than 
0.1% in our hospital (including our CPD population), 
vancomycin is nearly always changed to flucloxacilline in the 
case of  S. aureus peritonitis. Only peritonitis by CoNS has to be 
treated with vancomycin intraperitoneally since about 70% of 
the CoNS strains are methicillin resistant. Exit- and tunnel 
infections by S. aureus are treated with flucloxacilline or 
clindamycine orally, since there is no need for vancomycin 
therapy.  
However, among the 407 genotypically highly diverse (189 
different genotypes) CoNS strains collected, 8 (2%) 
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demonstrated intermediate susceptibility to vancomycin. On a 
strain level, this rate is comparable to the rate found in a survey 
of hospital wide CoNS blood culture isolates in 1991 and 1997.P58 P 
But, more importantly, this implies that on a patient level 5 out of 
52 (or 9.6%) were colonized at least once with a vancomycin 
intermediately susceptible CoNS strain between January 1PstP 1998 
and December 31 PstP 2000. In all 5 patients (4 persistent carriers 
and 1 intermittent carrier) concerned this was significantly 
related to a higher antibiotic (including vancomycin) usage as 
compared to the other 47 CPD patients (P<0.001). This 
implicates that even in a setting with relative low vancomycin 
consumption and low prevalence of MRSA, the CoNS population 
serves as a potential reservoir of vancomycin resistance. 
 
In summary, we conclude that persistent, and not intermittent, 
nasal carriage of S. aureus is thé major determinant of CPD 
related (S. aureus) infections and that persistent carriage of S. 
aureus associated with a higher consumption of antibiotics, 
including vancomycin. Accurate determination of the S. aureus 
nasal carriage state makes it possible to better target future 
prophylactic strategies. Not only to prevent CPD related 
infections, but also to reduce antibiotic consumption and the 
further emergence of (vancomycin) resistance staphylococci.  
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  Abstract 
 
Context  S. aureus nasal carriage has been demonstrated to be a major 
risk factor for S. aureus infections in patients on continuous 
peritoneal dialysis (CPD). 
Objective  To study the epidemiology and risks of S. aureus carriage in CPD
patients. 
Design  Retrospective cohort study. 
Setting  Tertiary care referral hospital. 
Participants  From January 1995 until June 1999, cultures were taken routinely 
from CPD exit site and vestibulum nasi. All S. aureus isolates 
from these cultures as well as from cultures taken during 
infectious complications were genotyped (pulsed-field gel 
electrophoresis). Vancomycin resistance was tested in vitro. 
Data on CPD related infections, antibiotic use and clinical course 
were collected retrospectively. 
Outcome 
Measures 
 Incidences of CPD-related infections and antibiotic usage 
associated with the various S. aureus carriage patterns. 
Results  Seventy-five patients (on a total of 98) with at least one culture 
positive for S. aureus in this period were included. Fifty-three 
patients had more than 2 cultures positive for S. aureus: 43 had 
genotypically identical S. aureus strains in over 80% of cultures 
and were classified as persistent carriers; 10 were classified as 
chronic carriers since their cultures were mostly positive for S. 
aureus, but all isolates were genotypically different. Twenty-two 
patients were intermittent carriers. Persistent carriage was 
associated with a 2.91 [95% confidence interval (CI): 2.17-3.90] 
higher risk for all CPD related infections and 6.06 [95% CI: 5.99-
6.14] higher vancomycin consumption compared to intermittent 
and chronic carriers. Chronic carriers and intermittent carriers 
had similar risks for all CPD related infections analyzed. No 
vancomycin resistance was detected. 
Conclusions  Forty-four percent of CPD patients were persistent carriers of S. 
aureus, and at a 3-fold higher risk for CPD related infections 
compared to intermittent and chronic carriers. Precise 
determination of the S.aureus carrier state of CPD patients is 
possible and needed to adequately target prevention strategies. 
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  Introduction 
 
  Continuous peritoneal dialysis (CPD) is commonly used in 
patients with end stage renal failure. CPD-catheter related 
infections, including peritonitis, exit-site and tunnel infections 
are, however, major and frequent complications and the cause of
significant morbidity and mortality. Most of these infections are 
caused by the ubiquitously present staphylococci. P1 P. It is thought 
that these bacteria are part of the patients own endogenous 
bacterial flora, although most of the evidence is circumstantial. 
Earlier cross-sectional studies, have found S. aureus nasal carrier
rates to be about 50% in CPD patients. The same studies 
demonstrated S. aureus nasal carriage to be a major risk factor 
for the development of S. aureus infections.P2-4 P The risk for exit-
site infections for example is 3-6 times higher in carriers than in 
non-carriers.  Typing of causative strains has revealed that 
frequently the strain isolated from the infection site and the 
strain that colonizes the nose are identical.P3,5 P Therefore, 
prophylactic interventions aiming at the elimination of nasal 
carriage may be effective.  
In order to effectively intervene in the infectious process, 
additional insight in the long term epidemiology of 
staphylococcal carriage in the specific CPD patient group is 
required. In addition, the more fundamental aspects of nasal 
carriage of S. aureus in CPD patients and the effect of frequent 
use of glycopeptides as first line antibiotics against CPD 
infections needs further analysis as well. Prolonged use of these 
antibiotics has been associated with the development of 
glycopeptide resistance in staphylococci. P6,7 P 
Since S. aureus carriage has already been established as a major 
risk factor for the development of CPD related infections 
compared to non-carriers,P4 P we studied the long-term 
epidemiology of S. aureus carriage within carriers only. Thus, we
aimed to identify subgroups of S. aureus carriers in CPD patients 
and their associated risks for CPD related (S. aureus) infections. 
Furthermore, we wanted to investigate if glycopeptide 
resistance developed in S. aureus strains from CPD patients in a 
single tertiary care institution, where glycopeptides were not 
used as the first line antibiotics for CPD related (staphylococcal) 
infections.  
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  Material & Methods 
 
  Patients 
  The Jeroen Bosch Hospital is a 600 bed tertiary care teaching 
hospital with about 50 adult patients on CPD. CPD patients were 
followed-up every 6 to 8 weeks. Between January 1995 and 
December 1998, cultures of the nose (vestibulum nasi) and CPD 
catheter exit site were performed routinely during follow-up 
visits. Cultures from other sites (CPD dialysis fluid, wounds, 
blood, etc.) were done on indication only. Based on these 
culture results patients were subsequently divided in four 
categories (non-carriers, intermittent carriers, chronic carriers 
and persistent carriers), according to the definitions stated in 
table 1.   
The intermittent, chronic and persistent carriers were further 
analyzed and data on CPD related infections, antibiotic use and 
clinical course were collected retrospectively by chart review. 
CPD related infections were defined according international 
standards P8P. The empiric antimicrobial therapy for CPD related 
peritonitis consisted of cephalotin plus tobramycin 
intraperitoneally. Antimicrobial therapy was adjusted according 
to culture results and given for at least two weeks. Exit and 
tunnel infections were treated according to (routine) culture 
results.  
This study was approved by our institutional medical ethics 
review committee (METC 165.585/1997/164). 
 
  Microbiological procedures 
Phenotyping  Cultures from skin, exit site, nose (vestibulum nasi), blood and 
CPD dialysis fluid were performed according to standard 
procedures. P9 P For blood and CPD dialysis fluid culturing, the 
BACTEC 9240 system (Becton-Dickinson Diagnostic Instrument 
Systems, Sparks, Md., USA) was used. After removal of the CPD 
catheter the tip was cultured in thioglycolate bouillon (Brewer 
modified medium). MicroScan WalkAway-96 (Dade International 
Inc., West Sacramento, CA, USA) and Vitek equipment 
(bioMérieux Vitek, Hazelwood, Mo, USA) were used for the 
identification of microorganisms. Staphylococcal isolates were 
identified using the catalase test, followed by a latex 
agglutination test (Staphaurex Plus®, GenProbe, Massachusetts, 
USA). The ID32Staph test (bioMérieux) was used for further  
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Table 1  Definitions of the different S. aureus carrier states. 
 
Non-carriers Non-carriers had zero cultures positive for S. aureus. 
 
 
Intermittent carriers  
 
Intermittent carriers had at least one but less than 
80% of cultures positive for S. aureus. 
 
 
Chronic carriers 
 
Chronic carriers had more than 80% of cultures 
positive for S. aureus with genotypically different 
serial S. aureus isolates. 
 
 
Persistent carriers 
 
Persistent carriers had more than 80% of cultures 
positive for S. aureus with genotypically identical S. 
aureus isolates. 
 
 
 
 
  speciation of coagulase negative staphylococci (CoNS). All 
staphylococcal isolates were stored at -70 0C in glycerol 
containing liquid media. 
Susceptibility testing  MicroScan WalkAway-96 (Dade International Inc.) and Vitek 
equipment (bioMérieux) were also used for susceptibility 
testing. Strains were categorized as resistant (R), intermediately 
resistant (I), or sensitive (S) to the antibiotic used based on the 
NCCLS breakpoints.P10P Further MIC determinations were done 
using E-test (AB Biodisk, Skolna, Sweden). Methicillin 
susceptibility of staphylococci was tested using the disc diffusion
method. All staphylococcal isolates in this study were 
subsequently tested for vancomycin intermediate sensitivity 
(VISA or VISE) or vancomycin resistance (VRSA or VRSE) 
according to the method as described by Hiramatsu. P11,12 P This 
required that 10P8 P bacteria were inoculated on Vancomycin 
Screen agar plates (Becton Dickinson, USA). These media 
contain 6 µg/mL of vancomycin. The plates were visually 
inspected for bacterial growth after 24 and 48 hrs of incubation. 
In the case that colonies grew on the agar, the MIC was 
determined by agardilution and the individual colonies showing 
a MIC of ≥ 8 µg/mL were inoculated onto a fresh bloodagar plate 
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an reinoculated every day for nine consecutive days. After this 
passaging procedure the MICs were determined again. 
Heterogeneous resistance was defined when the isolate 
maintained its resistance level after passaging.  
Bacterial genotyping  Pulsed-field gel electrophoresis (PFGE) was subsequently 
performed based on protocols as previously described. P13-15P 
Bacteria were embedded in agarose plugs and treated with 
lysostaphin (Sigma-Aldrich, Münich, Germany), proteinase K 
(Merck, Darmstadt, Germany) and the restriction enzyme SmaI 
(Boehringer Mannheim, Mannheim, Germany) prior to 
electrophoresis. The electrophoresis program consisted of two 
blocks (10 hrs 5-15 seconds switch time followed by 10 hrs 15-45 
seconds switch time) and was performed at 14P0 PC and 6 V/cm. 
Gels were photographed after ethidium bromide staining and 
banding patterns were interpreted according to Tenover et al.P16P 
 
  Statistical procedures 
  Percentages were compared by the Chi-square test (Fisher’s 
exact test in case of 2x2 tables). To compare the number of CPD-
related infections and number of antibiotic courses (including 
vancomycin) used during follow-up between the different S. 
aureus carrier states, Poisson regression analysis was employed. 
The influence of potential prognostic factors on the incidence of 
CPD related infections and antibiotic usage was evaluated using 
Poisson regression as well. Sex and age were included in all 
multiple regression models to correct for potential confounding. 
All statistical tests were two tailed and performed at the 0.05 
significance level. SAS statistical software (The SAS system for 
Windows, release 8.0; SAS Institute inc., Cary, NY, USA) was 
used for Poisson regression analyses. All other statistical tests 
were done using SPSS statistical software (SPSS for Windows, 
version 12.0.1; SPSS inc., Chigago, IL, USA). 
 
 
 
  Results 
 
Epidemiology of  
S. aureus carriage 
 A total of 98 patients were treated with CPD at the Bosch 
Medicenter in this 5-year period, 60 males and 38 females. In 23 
(23%) patients none of the cultures performed were positive for 
S. aureus. These patients were classified as non-carriers and not 
followed-up any further. Seventy-five (76%) patients had at least 
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Table 2  Characteristics of the CPD study population.P$ 
 
   
 
Participants (n) Males 46 
 Females 29 
   
Age (median-range) Males 49 (18-75) 
 Females 53 (36-74) 
   
Cause of end stage renal disease (n) Vascular disease 22 
 Diabetes Mellitus 18 
 Glomerulonephritis 16 
 Urinary tract infections 15 
 TTP*/HUS P†P 2 
 Other 2 
   
Duration of end stage renal disease 
prior to start of study  
(months; median-range) 
 3 (0-120) 
   
Duration of CPD prior to start of 
study  
(months; median-range) 
 1 (0-119) 
   
Number of CPD catheters (n) 1PstP 60 
 2Pnd P 14 
 4Pth P 1 
   
Diabetes mellitus (n) No 49 
 Insulin dependent 20 
 Non-insulin dependent 6 
   
Prior kidney transplantation (n) No 70 
 1 4 
 4 1 
P
$
P Intermittent, chronic and persistent carriers only 
* TTP = thrombotic thrombocytopenic purpura;  
P
†
P HUS = hemolytic uraemic syndrome 
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  one culture positive for S. aureus and were included in this 
study. Total duration of follow-up in these 75 patients was 2,402 
months, with a median of 27.2 months (mean 32.0; range 6.7-60). 
Table 2 summarizes the main characteristics of this study 
population. 
Twenty-two patients (22%) carried S. aureus in their nose and/or 
exit site only now and then, exchanging culture-positive with 
culture-negative periods (Table 3). These patients were 
classified as intermittent carriers. 
Fifty-three (54%) patients had 3 or more cultures positive for S. 
aureus on 2 or more outpatient visits. Forty-three of these 
patients had genotypically identical strains in all cultures during 
their follow-up, while in ten of them sometimes a second S. 
aureus strain could be isolated in one or more cultures. These 43 
(44%) patients were classified as persistent carriers. Overall 
carriage rates among males and females were not significantly 
different (Table 3). 
One of the 53 patients switched S. aureus strains on two 
occasions during his 4 year follow-up, both times related to 
antibiotic treatment for CPD related infections. However, in this 
patient, nasal and exit site cultures yielded concordant results, 
showing genotypically identical strains at all points in time. The 
remaining 9 (out of 53) patients were chronically colonized with 
S. aureus, but all S. aureus strains were genotypically different 
when their serial culture isolates were compared. Together, the 
latter 10 (10%) patients were classified as chronic carriers.  
All S. aureus isolates were unique to each of the patients as 
defined by the PFGE analysis, suggesting that cross-colonization 
and –infection were not a problem in this CPD population during 
the monitoring period. 
CPD related infections  CPD related infections occurred in all three carrier groups 
analyzed and are summarized in table 4. Compared to chronic 
and intermittent carriage, persistent S. aureus carriage was 
associated with significantly higher incidences of CPD related 
infections from all causes (0.17/month, p<0.0001), S. aureus CPD 
related infections (0.13/month, p<0.0001), exit site infections 
from all causes (0.10/month, p<0.0001), S. aureus exit site 
infections (0.09/month, p<0.0001), CPD peritonitis from all 
causes (0.07/month, p=0.0011) and S. aureus CPD peritonitis 
(0.04/month, p=0.0023). Chronic carriers and intermittent 
carriers had similar risks for all CPD related infections analyzed. 
The relative risk for all CPD related infections for persistent 
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carriers as compared to the combined intermittent-or-chronic 
carrier group was 2.91 [95% confidence interval (CI): 2.17-3.90]. 
Likewise, the relative risk for S. aureus CPD related infections for
persistent carriers as compared to the combined intermittent-or-
chronic carrier group was 3.42 [95% CI: 2.40-4.88]. 
 
Glycopeptide use  
& resistance 
 The overall use of vancomycin during this study was 196 grams. 
More vancomycin was consumed in the persistent carrier group 
(166 grams) than in the chronic (10 grams) or intermittent 
groups (20 grams). When adjusted for the duration of follow-up, 
the use of vancomycin still was 6-fold higher in the persistent 
carrier group (145 milligrams/month) than in the chronic (23 
milligrams/month) and intermittent carrier groups (24 
milligrams/month), which was highly statistically significant 
(p<0.0001).  
Neither high-level nor intermediate glycopeptide resistance was
detected in a collection of 446 S. aureus strains isolated from the 
group of 98 CPD patients. In 34 strains a small number of 
colonies were found on the Vancomycin Screen agar plate, but 
after subsequent subculturing the existence of vancomycin 
resistant phenotypes could not be confirmed. 
 
 
 
 
Table 3  S. aureus carriage patterns of CPD patients. 
 
   
 
 non intermittent chronic persistent total 
nasal 
carriage (n) 
     
 
male 
14 (23%) 13 (22%) 5 (8%) 28 (47%)  60 (100%) 
 
female 
9 (24%) 9 (24%) 5 (13%) 15 (39%)  38 (100%) 
 
Total 
23 (23%) 22 (22%) 10 (10%) 43 (44%) 98 (100%) 
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  Discussion 
 
  Forty-four percent of all CPD patients were persistently 
colonized with a single unique S. aureus strain, indicating that 
long term persistent S. aureus carriage is common in this group 
of patients. This prevalence of persistent carriage in itself is not 
clearly different from the rates observed in both healthy 
individuals and other patient cohorts, P3,17 P but persistent carriage 
was clearly associated with a 3-fold increased risk for CPD 
related infections.  
Ten percent of patients were chronically colonized with S. 
aureus, but by genotypically different strains at subsequent 
occasions and 20% were only intermittently colonized by S. 
aureus. Whether the chronic carrier group should also be 
defined as persistent carriers is a matter of definition and 
debate.P18P Although apparently these patients carry S. aureus for 
prolonged periods of time, their risk of invasive S. aureus 
infections was similar to that of the intermittent carrier group. As 
such, chronic carriers should in our opinion be viewed as ‘high 
level’ intermittent carriers and be separated from persistent 
carriers.  
We did not present comparative data from the non-carrier group 
in this CPD population. However, as we demonstrated before, 
among CPD patients intermittent carriers behave like non-
carriers, as they are not at an increased risk for CPD related 
infections.P17 P Now we also demonstrate that it is only the 
genuinely persistent S. aureus carrier who is at an increased risk 
of CPD related infections. Thus, accurate determination of the 
true S. aureus carrier state would enable us to improve the 
prevention of S. aureus infections in CPD patients and thus limit 
antibiotic (including vancomycin) usage. Prevention of S. aureus 
infections can be achieved by procedures such as antimicrobial 
prophylaxis including mupirocin application,P19-21P 
vaccination, P22,23 P or even bacterial interference. P24P In a recent pilot 
study we demonstrated that interference with S. aureus 502A in 
persistent carrier CPD patients resulted in successful 
replacement of the wild type S. aureus strain from the nose in all 
and eventually from the CPD catheter exit site in most patients 
by the interfering strain. P25P Earlier, interference with S. aureus 
502A has been shown to be successful in the prevention of S. 
aureus infections in neonates and patients with recurrent 
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furunculosis. P24P   
Although the mechanisms of resistance differ from those 
encountered in vancomycin-resistant enterococci, P11,12,26,27 P the 
risk that a strain of S. aureus could ultimately acquire the genetic 
elements for high level resistance is considered significant P28 P and 
indeed the first vancomycin resistant MRSA strains have already 
been identified. P29 P Little is as yet known about the precise 
mechanisms by which staphylococci acquire low level 
resistance against vancomycin and other glycopeptides. Most 
probably, several factors cooperate in this event, cell wall 
thickness and the presence of cell wall biosynthesis enzymes 
with reduced affinity for glycopeptides are important features.P30P 
No glycopeptide resistance was demonstrated in S. aureus in a 
center where glycopeptides are not routinely used in the 
empiric treatment of CPD related infections. This suggests that 
the epidemiology of glycopeptide resistance in S. aureus is 
different from that in enterococci. Where in enterococci 
glycopeptide usage in the environment (hospitals and 
veterinary industry) is related to glycopeptide resistance 
development,P27P in staphylococci resistant strains seem to 
emerge after frequent and long term exposure of glycopeptides 
in the individual patiënt.P6,12,31 P Recent studies by our group 
revealed that in a university hospital where vancomycin was 
used in the first-line empiric treatment of CPD related infections, 
exposure to large quantities of vancomycin was a risk factor to 
become colonized with low level vancomycin resistant 
coagulase-negative staphylococci. P17 P In that study also no 
resistance, either low of high level, to glycopeptide was 
demonstrated in S. aureus. Our current finding suggests that the 
routine use of glycopeptide therapy in a group of patients that is 
quite susceptible to staphylococcal infection should be avoided, 
since, in a setting were glycopeptides are not routinely used, 
patients do not seem to be at an increased risk of acquiring 
glycopeptide resistant staphylococcal strains.  
 
In conclusion, 44% of CPD patients were persistent carriers of S. 
aureus, and at a 3-fold higher risk for CPD related infections as 
compared to intermittent and chronic carriers. Precise 
determination of the S.aureus carrier state including bacterial 
genotyping is possible, makes sense and is needed to 
adequately target prevention strategies. No vancomycin 
resistance in S. aureus was encountered in this setting of low 
level glycopeptide use. However, continued screening for the 
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emergence of glycopeptide resistant isolates of S. aureus 
remains a prudent strategy. 
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  Abstract 
 
Context  The incidence of Staphylococcus aureus infections has steadily 
increased, coinciding with the widespread dissemination of S. 
aureus strains resistant to multiple antibiotics.  These 
developments again necessitate the search for new strategies to 
combat S. aureus infections. 
Objective  To study the dynamics of inoculation with S. aureus 502A (SA-
502A) in volunteers (group I, n=8), chronic peritoneal dialysis 
(CPD) patients (group II, n=4) and furunculosis patients or 
methicillin-resistant S. aureus (MRSA) carriers (group III, n=3). 
Design  Prospective cohort study (pilot). 
Setting  Tertiary care university hospital. 
Participants  Participants were pretreated with mupirocin (group II and III 
only) and systemic antibiotics (group III). They were 
subsequently inoculated with 10 P8 P bacteria only once (group I), 
or for 3 consecutive days and every 2 weeks thereafter (groups 
II and III). Cultures were performed weekly in group I and every 
4 weeks in groups II and III. 
Outcome 
Measures 
 Eradication of wild type S. aureus. 
Results  In group I SA-502A could be co-cultured with the resident strain 
in all for one week. At week 6 all persons had lost SA-502A, 
while retaining their resident strain. In group II, all persons 
became colonized in the nose with SA-502A. After 11 months SA-
502A had replaced the resident strain at the exit site in 2 
persons, was co-cultured with the resident strain in one, while in 
one person only the resident strain remained present. In group 
III, the person with furunculosis became successfully colonized 
by SA-502A in the nose and skin. Ultimately, she lost SA-502A 
and remained without furunculosis. In the persistent MRSA nasal 
carrier, it was successfully replaced by SA-502A. In the throat 
carrier of MRSA, inoculation with SA-502A failed. No side effects 
were noted.  
Conclusions  Inoculation with SA-502A in persistent carriers can replace wild 
type S. aureus strains in a several patient categories provided 
that their resident strain is eradicated first.  
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  Introduction 
 
  Staphylococcus aureus is an important agent of human disease 
and the cause of a variety of infections.P1 P The nose (i.e. the 
anterior nares) has been shown to be the primary ecological 
reservoir of S. aureus in humansP2 P and S. aureus nasal carriage is 
a major risk factor for S. aureus infections,P3,4 P the majority being 
of endogenous origin. P5P Host factors,P4,6 P as well as environmental 
factors contribute to the S. aureus nasal carrier state.P7-9P Recent 
studies have suggested that S. aureus nasal carriage is a process 
of permissive colonization, resulting from failing local 
inflammatory responses.P10,11P  
Bacterial interference has been hypothesized to be a major 
determinant of the S. aureus carrier state.P12-15P The concept of 
bacterial interference has been successfully taken into clinical 
testing, employing artificial nasal inoculation with S. aureus 502A 
(SA-502A) or Corynebacterium species.P16-21P However, the 
practice of  artificial nasal inoculation with SA-502A was 
abandoned after alleged complications, P22-24P and the advent of 
newer anti-staphylococcal antibiotics.  
Since then, the incidence of S. aureus infections has steadily 
increased, P25 P  coinciding with the widespread dissemination of S. 
aureus strains resistant to multiple antibiotics including 
methicillin and, more recently, vancomycin. P26P  These 
developments again necessitate the search for new strategies to 
combat S. aureus infections. The logical starting point would be 
the prevention of endogenous S. aureus infections by eradication
of (nasal) carriage of wild type S. aureus strains in individual 
persons at increased risk of infection. In the study presented 
here we investigated the risks and dynamics of artificial 
colonization with SA-502A in three groups of adults with 
persistent S. aureus carriage This effort was undertaken to 
establish the optimal strategy for bacterial interference as a tool 
in the eradication of S. aureus carriage and the prevention of S. 
aureus infections.  
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  Material & Methods 
 
  Selection of Volunteers 
  Three different groups of adults with persistent S. aureus 
carriage were studied: healthy volunteers (group I, n=8), 
chronic peritoneal dialysis (CPD) patients (group II, n=4) and 
otherwise healthy persons suffering from either recurrent 
furunculosis or persistent carriage with methicillin-resistant S. 
aureus (MRSA) (group III, n=3). Written informed consent was 
obtained from all participating persons and the study protocol 
was approved by the Medical Ethics Review Committee of the 
Erasmus MC, Rotterdam, The Netherlands (METC: 
156.137/1996/186 and 165.585/1997/164). 
 
Group I  In 1988 a cohort of healthy volunteers (staff members of the 
departments of Medical Microbiology & Infectious Diseases and 
Virology of the Erasmus MC) was formed to investigate bacterial 
and human factors associated with S. aureus nasal carriage.P27 P The
composition of this volunteer cohort was flexible, in that 
outgoing personnel were considered lost to follow-up and 
replaced by incoming personnel. All participants were screened
initially with 12 consecutive quantitative nasal swab cultures 
taken with one-week intervals. After this initial establishment of 
S. aureus nasal carriage status, volunteers were re-screened 
regularly with 4 quantitative nasal swab cultures with one-week 
intervals. Long term persistent carriers (i.e. in follow-up for at 
least 2 years and with at least 16 nasal swab cultures positive 
with a genotypically identical S. aureus strain) were invited to 
participate. 
 
Group II  Approximately 60 adult patients are taken care for in the chronic 
peritoneal dialysis (CPD) program of the Erasmus MC, a 1,250 
bed tertiary care university hospital. From January 1998 onwards
all current and new patients on CPD were screened for S. aureus 
carriage with 6 consecutive nasal swab cultures (vestibulum 
nasi) taken with one week intervals. S. aureus screening cultures 
of the CPD catheter exit site were performed together with the 
first and last nasal swab culture. CPD patients with all 6 initial 
nasal swab and both CPD exit site cultures positive with a 
genotypically identical S. aureus strain were invited to 
participate.  
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Group III  This group consisted of one patient and two health care workers 
visiting the Infectious Diseases outpatient clinic of the Erasmus 
MC. One patient was seen for recurrent furunculosis for which 
she had been treated elsewhere for 5 years. Treatment had 
consisted of drainage of skin abscesses, multiple courses of 
antibiotics, local and nasal mupirocin treatment and multiple 
hygienic measures (chloorhexidine and povidon-iodine 
washings, thorough house cleaning, washing of underwear and 
bed sheets at high temperatures). However, eradication of S. 
aureus nasal carriage had failed and the furunculosis problem 
persisted. When she was seen at our outpatient clinic, 6 nasal 
swab and 6 skin cultures with one-week intervals were 
performed. All cultures were positive with a genotypically 
identical S. aureus strain, and she was thus confirmed to be a 
persistent S. aureus carrier. The two other participants in this 
group were both healthy health care workers documented to be 
persistently carrying MRSA (one person was a persistent nasal 
carrier, the other a persistent throat carrier). In The Netherlands 
personnel carrying MRSA are not allowed to work in hospitals as 
long as they remain MRSA positive. MRSA carrying hospital 
personnel is referred for MRSA eradication therapy. The two 
participants described here, were persistent carriers of MRSA, 
despite multiple eradication attempts using nasal ointments 
(mupirocin, fusidic acid) in combination with systemic antibiotic 
combination therapy and hygienic measures. Also, all household
or intimate contacts were screened for MRSA carriage and 
treated accordingly if positive. All eradication efforts had failed 
in these persons and all agreed to participate in the present 
study. 
 
Exclusion criteria  Participants were excluded if they suffered from diabetes 
mellitus, non-staphylococcal skin diseases, chronic obstructive 
pulmonary disease, and cardiac valve abnormalities or were 
taking immunosuppressive agents.  
 
 
  Inoculation and Follow-up 
  From all participants blood was drawn by venepuncture at 
inoculation for the determination of erythrocyte sedimentation 
rate (ESR), C-reactive protein (CRP), leukocyte count, leukocyte 
differentiation and anti-staphylococcal antibodies (ASTA) titer. 
These tests were repeated in case of (suspected) side effects 
and at the end of the study. In all participants inoculation was 
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performed using cotton-wool swabs drenched in PHMB 
containing 10 P9 PCFUs/mL of SA-502A. Per nostril, one swab was 
firmly applied against the inner side of both anterior nares and 
turned around 4 times. In this way, strains were inoculated in a 
total amount of 10P8 P-10P9 P CFUs.  
Pre-inoculation treatment, inoculation frequency and follow-up 
differed per study group: 
 
Group I  In order to assess colonization resistance, no pre-inoculation 
antimicrobial treatment was used in this group. Participants 
were inoculated only once. After inoculation nasal swab cultures 
were taken weekly for 6 consecutive weeks. At week 6 post-
inoculation the study was ended. 
 
Group II  Before inoculation participants were pretreated with mupirocin 
nasal ointment two times daily for 5 days in both nostrils. One 
week later they were inoculated on 3 consecutive days. 
Inoculation was repeated every 2 weeks until the end of the 
study. Nasal swab cultures and cultures of CPD catheter exit site 
were taken every 6 weeks during follow-up visits. Cultures from 
other sites (CPD dialysis fluid, wounds, blood, etc.) were 
performed on indication only. Patients were followed-up from 
January 1PstP 1998 until December 31 PstP 2001 or until the date of 
ending CPD treatment, whichever date came first. 
 
Group III  Before inoculation participants were pretreated with mupirocin 
nasal ointment two times daily for 5 days (two participants) or 
fusidic acid nasal ointment two times daily for 7 days (one 
participant carried a mupirocin resistant, fusidic acid sensitive 
MRSA strain in his throat), systemic antibiotic therapy for 14 days
(co-trimoxazol 960 mg bid + rifampin 600 mg oid, ciprofloxacin 
750 mg bid + rifampin 600 mg oid and clindamycine 600 mg 
tablets tid + rifampin 600 mg oid), combined with hygienic 
measures during 2 weeks. These measures included 
chlorhexidine scrub body washings daily, chlorhexidine hair 
washings twice weekly, chlorhexidine lozenges 2.5 mg tablets 
every 2 hours during daytime, chlorhexidine solution 10 ml 
(=20mg) bid, daily washing of underwear and bed sheets at high
temperatures and thorough professional housecleaning. One 
week after finishing this treatment, participants were inoculated 
on 3 consecutive days. Inoculation was repeated every 2 weeks 
for 3 months. Cultures of the vestibulum nasi, throat and perineal 
skin were taken every 2 weeks. The study was ended 12 weeks 
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after the last inoculation. 
 
  Microbiological procedures 
Phenotyping  Nasal swab cultures were performed as described earlier. P27P 
Swabs were cultured quantitatively on selective media: phenol-
red mannitol salt agar (PHMA) and phenol red mannitol salt 
broth (PHMB). The number of CFUs was recorded quantitatively. 
Initial identification of S. aureus was based upon colony 
morphology on the PHMA. All morphologically different 
colonies were recultured overnight on Columbia blood agar 
plates (Becton-Dickinson B.V., Etten-Leur, The Netherlands) and 
a catalase- and latex-agglutination test (Staphaurex PlusPRP, 
Murex, Dartford, UK) were performed. Per culture taken at each 
point in time for each of the participants, all morphologically 
different S. aureus isolates, were stored at -70 P0 PC in glycerol 
containing liquid media. 
Cultures from skin, CPD catheter exit site, blood and CPD 
dialysis fluid were performed according to standard 
procedures. P28P Blood and CPD dialysis fluid were cultured using 
the BACTEC 9240 system (Becton-Dickinson Diagnostic 
Instrument Systems, Sparks, Md., USA). In the case of CPD 
catheter removal, the tip was cultured in thioglycolate broth 
(Brewer modified). Vitek equipment (bioMérieux Vitek, 
Hazelwood, Mo, USA) was used for the identification of 
microorganisms.  
 
Genotyping  To obtain bacterial DNA for strain typing purposes, S. aureus 
isolates were grown overnight at 37 P0 PC on Brucella blood agar. 
Between 2 and 5 colonies were suspended in 150 µL of 25 
mmol/L Tris-HCl pH 8.0, 10 mmol/L EDTA, and 50 mmol/L 
glucose (TEG buffer). To prepare spheroplasts, 75 µL of a 
lysostaphin solution (100 µg/ml in water) was added. After 
incubation at 37 P0 PC for 1 hour, DNA was isolated. P29P DNA (10 ng 
per ml of 10 mmol/L Tris-HCl pH 8.0 and 1 mmol/L EDTA) was 
stored at -20 P 0 PC. Restriction fragment length polymorphisms 
(RFLP) of the coagulase and protein A genes were determined 
for identification purposes for SA-502A and all resident S. aureus 
strains before inoculation. P30 P Furthermore, all S. aureus strains 
isolated two and twelve weeks after inoculation and/or from the 
last positive culture were genotyped using RFLP of the coagulase
and protein A genes. Pulsed-field gel electrophoresis (PFGE) 
was performed to confirm the results obtained by RFLP, as 
described earlier. P31P 
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  Results 
 
Group I  The inoculation of SA-502A was initially successful in all 
participants. SA-502A could be demonstrated in all 8 persons 
until at least two weeks after inoculation, albeit together with the 
individuals’ resident S. aureus strain. Thereafter, participants 
gradually lost the SA-502A strain. At week four, SA-502A was 
recovered in 2 persons only and at week six all persons had lost 
SA-502A, while still retaining their resident strain (Table 1).  
 
Group II  SA-502A was retained in the nares of all four persons after 
repeated inoculations. In contrast, cultures from their CPD exit 
site continued to grow their resident strain for many months after
start of the study. After a mean of 11 months of follow-up SA-
502A had replaced the resident strain at the exit site in two 
persons (after 6 months in person 4015 and after 18 months in 
person 4030),  or could be co-cultured with the resident strain in 
one person (after 9 months in person 1026). In the remaining 
person (1031) the resident strain remained present as the single 
S. aureus strain on the exit site (Table 2). 
Mean follow-up was 18 months and a total number of 12 CDP 
related infections occurred (mean incidence 0.22 per person 
months at risk [95% CI: 0.08-0.35]). Eight infections were caused 
by S. aureus (four exit site infections and four peritonitis), two by 
Serratia marcescens (one exit site infection and one peritonitis) 
and two by coagulase-negative staphylococci (both peritonitis). 
All of the S. aureus infections encountered were caused by the 
resident S. aureus strain as cultured from these persons nose and 
exit site prior to inoculation. Of note, SA-502A was not involved 
in any CDP related infection.  
 
Group III  The person with recurrent furunculosis became successfully 
colonized by SA-502A in her nose, as well as on her skin, 
replacing her resident strain. After stopping the inoculation after 
3 months, she rapidly lost SA-502A from her nose and skin. 
Thereafter, she remained a non-carrier and did not experience a 
recurrence of furunculosis. In one persistent nasal carrier of 
MRSA, the MRSA strain was successfully replaced by SA-502A 
after three months of inoculation. In the other person, a throat 
carrier of MRSA, inoculation with SA-502A failed to eradicate 
MRSA carriage from this niche (Table 3).  
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  No clinical side-effects such as skin lesions, abscesses or other 
infections were noted in all 15 persons. Laboratory parameters 
at inoculation and at the end of the study were all within normal 
limits. 
 
 
 
Table 1  Artificial inoculation with S. aureus 502A in healthy persistent S. 
aureus nasal carriers. 
ID Age 
(yrs) 
Sex S. aureus 
nasal isolate 
before 
inoculation 
S. aureus 
nasal 
isolate – 
week 2 
S. aureus 
nasal 
isolate – 
week 4 
S. aureus 
nasal 
isolate - 
week 6 
1 48 female R1 P¶P 
R1 + 
502AP§ P 
R1 + 
502A 
R1 
2 47 male R2 
R2 + 
502A 
R2 + 
502A 
R2 
3 29 male R3 
R3 + 
502A 
R3 R3 
4 33 male R4 R4 R4 R4 
5 34 male R5 
R5 + 
502A 
R5 R5 
6 25 male R6 
R6 + 
502A 
R6 R6 
7 28 female R7 
R7 + 
502A 
R7 R7 
8 34 female R8 
R8 + 
502A 
R8 R8 
P
¶ 
PR1 to R8 refer to the original resident S. aureus strains of the volunteers 1-8 before artificial 
inoculation with S. aureus 502A 
P
§ 
P502A is S. aureus 502A 
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  Discussion 
 
  Bacterial interference therapy using nasal inoculation with SA-
502A in persistent S. aureus carriers is safe and successful in 
replacing wild type resident S. aureus strains in a variety of 
patient categories. The principle of bacterial interference and its 
clinical application in the control of outbreaks of S. aureus 
infections dates back to the early 1960s, and was explored at that
time by Shinefield and colleagues.P32-36P They elegantly 
demonstrated that when an ecological niche is already occupied 
by certain bacteria, other bacteria do not seem to have the 
means to replace this resident bacterial population.P12-15P We also 
found that in order to successfully ‘interfere’ with the resident 
flora, this resident flora must be reduced or eliminated. P13P Failure 
to eradicate the resident flora will lead to failure of the 
interference therapy, as we clearly noticed in  our group I. The 
same volunteers were on a later occasion also inoculated with a 
S. xylosis strain producing RNAIII inhibiting protein (RIP, by 
courtesy of Dr. N. Balaban, Tufts University School of Veterinary 
Medicine Department of Biomedical Sciences, Infectious 
Diseases, North Grafton, Massachusetts, USA P37P) without pre-
inoculation antimicrobial treatment. Again, interference therapy 
failed, and the S. xylosis strain could not be retrieved from any of 
the eight volunteers two weeks after inoculation (data not 
shown). The analysis of the carriage status of the CPD patients 
(group II) and the throat MRSA carrier (group III), revealed that 
eliminating and replacing the wild type strain in the nose does 
not necessarily imply that colonization of other body sites by the 
wild type strain is simultaneously eliminated or replaced. 
Probably, the CPD catheter exit site and throat act as separate 
niches that need to be specifically addressed when attempting 
to replace resident wild type S. aureus.P38 P The data from the CPD 
group also suggest, however, that there is continuous 
interference by SA-502A from the nose to the skin and CPD exit 
site, which over time may lead to replacement of the original 
resident strain on the exit site in a significant proportion of 
persons. To test if in CPD patients replacement of the wild type 
resident S. aureus strain in the nose and at the CPD exit site by 
SA-502A will lead to a reduction of (S. aureus) CPD related 
infections, further studies are needed. From this preliminary 
study, we conclude that nasal application of SA-502A in CPD 
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patients persistently colonized with wild type S. aureus is safe in 
the short-, as well as the longer-term and can successfully 
replace the resident S. aureus strain. 
As mentioned already, inoculation with SA-502A has been 
successfully used earlier in nurseries during out-breaks of S. 
aureus infections in the 1960s and for treatment of patients with 
recurrent furunculosis, P16-20P. However, the early practice of  
artificial inoculation with SA-502A was abandoned after alleged 
complications,P22-24P and the advent of newer anti-staphylococcal 
antibiotics in the early 1970s. At that time, the authors reporting 
these side effects explicitly stated that, despite the potential 
(serious) side-effects of artificial inoculation with SA-502A, the 
‘benefits far outweigh the hazards’, claiming that it is an effective 
tool to prevent serious or recurring S. aureus problems from wild
type strains.P23,24P From our present study we conclude that 
artificial inoculation with SA-502A is safe when applied to 
individuals known to be long-term persistent carriers of S. 
aureus. In a previous study, we demonstrated that when long-
term persistent S. aureus carriers were inoculated with a mixture 
of S. aureus strains, none suffered from side-effects from the 
inoculation. P6 P In that study also individuals known to be free of 
wild type S. aureus were inoculated, and two out of eight of those 
long-term non-carriers suffered from minor self-limiting skin 
lesions after artificial inoculation.P6 P Thus, we claim that 
determining the exact S. aureus carrier state is an essential part 
of performing artificial inoculation and that bacterial 
interference by artificial inoculation with SA-502A should be 
restricted to individuals known to be long-term persistent S. 
aureus carriers.  
 
In conclusion, artificial inoculation with SA-502A in persistent S. 
aureus carriers is safe and can be used to successfully to replace 
wild type resident S. aureus strains in a variety of patient 
categories provided that the resident strain is eradicated first. 
This strategy holds promise for the prevention of S. aureus 
infections and may help limit the spread of wild type, potentially 
more virulent and hard-to-treat S. aureus strains including MRSA.
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  Determinants 
 
  S. aureus nasal carriage has been identified as the key to 
preventing S. aureus infections. As stated earlier, to fully exploit 
this key we will first have to unlock the fundamental mechanisms 
underlying it. Much research so far has focused on bacterial 
factors in trying to explain carriage. Often in vitro data could not 
be corroborated in vivo, not to mention real life. So far, no single 
common genetic or phenotypic characteristics segregating 
successful from less- or non-successful colonizing S. aureus 
strains have been identified.P1-5 P However, lipoteichoic acid and 
clumping factor B (ClfB) P6 P have been implicated as essential 
bacterial factors for S. aureus nasal colonization recently.P7 P 
Furthermore, most studies on host factors associated with 
carriage have been performed in the hospital setting. We, 
therefore, decided to study the host as the main determinant of 
S. aureus nasal carriage in the community setting. 
 
Since the underlying mechanisms determining persistent and 
intermittent carriageP Pdiffer,P8-15P adequate differentiation between 
persistent and intermittent carriage is relevant for 
epidemiological studies. In the Rotterdam Study an efficient and 
reliable way to assess S. aureus nasalP Pcarriage was obligatory. It 
would be impossible to perform 10-12 weekly nasal swab 
cultures in all participants. Thus, we developed a ‘culture rule’ to
discriminate reliably between persistent-carriage and non-or-
intermittent carriage, with a minimum of nasal swab cultures 
(chapter 2). Combining qualitative results with quantitative data 
is, in our opinion, conceptionally the best choice. Incorporating 
quantitative data makes it possible to refine associations 
between potential determinants and S. aureus nasal carriage, 
since not only carriers are compared with non-carriers, but also 
carriers with low CFUs can be compared with carriers with high 
CFUs in their anterior nares. Incorporating quantitative data will 
also make it possible to refine associations between carriage 
state and morbidity and mortality. However, in large-scale 
epidemiologic studies, simplicity will often prevail, because of 
logistic reasons and resources. It is therefore reassuring that in 
the validation cohort the simple qualitative culture results 
performed as good as the more complicated ‘culture rule’. Two 
nasal swab cultures taken at a one-week interval were shown to 
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provide sufficient information to indeed adequately predict the 
S. aureus nasal carriage state. Using only one nasal swab culture 
to predict the carriage state, as is often done, cannot be 
recommended on the basis of our data since it will lead to 
misclassification of the carriage state. On the other hand, the 
addition of a 3 Prd P or 4 Pth P quantitative nasal swab culture only 
minimally improved test performance. Importantly, no persons 
with the first 2 cultures positive were found to be non-carriers. 
One negative ‘screening’ culture virtually excludes persistent 
carriage. Predicting the non-carrier state from 2 nasal swab 
cultures is more difficult since at least 7 nasal swab cultures 
would be needed to distinguish intermittent from non-carriers. 
Apart from its role in the Rotterdam study, we hope that the 
presented ‘culture rule’ will prove to be a helpful tool in 
identifying determinants of S. aureus nasal carriage and 
infections, as well as in identifying high-risk patient populations 
and the implementation of new methods in the prevention of S. 
aureus infections. 
 
From the other studies presented in the first section (chapters 3-
7) of this thesis we conclude that indeed the human host that is a, 
if not thé major factor in determining the individual carrier state. 
After artificial inoculation (chapter 3) with a mixture of S. aureus 
strains, median nasal survival of S. aureus was significantly 
longer in persistent carriers than in non-carriers. Half of non-
carriers became non-carriers again within 2 weeks after 
inoculation. Only one non-carrier became a persistent carrier, 
coinciding with minor self-limiting skin lesions. These data 
suggest that host characteristics significantly co-determine the S. 
aureus carrier state and that optimal fit between host and 
bacteria seems to be important.  
We found a striking difference in the amount of S. aureus in the 
nose of persistent carriers between young healthy volunteers 
and healthy elderly participants (chapter 2). No prior data are 
available regarding age and the number of CFUs in the noses of 
persistent carriers. From the Rotterdam study (3851 persons) the 
high numbers of CFUs (median geometric mean 2.8) in elderly 
persistent carriers are confirmed, but the underlying 
mechanisms of this finding remain to be elucidated. 
Furthermore, the main findings in this population-based study 
(chapter 4) are the positive association of fasting blood glucose 
levels with persistent S. aureus nasal carriage, and the negative 
association or ‘protective’ effect of current smoking on the rate 
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and density of S. aureus nasal carriage. We confirm that age, sex 
and a history of skin disease are independent determinants of S. 
aureus nasal carriage. As for diabetes mellitus and blood 
glucose levels, in earlier studies only insulin dependent 
diabetics were found to have a higher prevalence of persistent 
carriage.P16,17P We now found that, apart from the diabetic state 
and its treatment, fasting blood glucose levels, even within the 
normal range, are associated with persistent carriage. The 
pathophysiological basis of this association remains to be 
discovered, but we hypothesize that phagocytic activity of 
neutrophils and macrophages, as well as the amount of killing of 
intracellular micro-organisms (including S. aureus) are pivotal.P18 P 
Another major finding is the negative association of smoking and
persistent carriage. In a population-based cohort of children and 
adolescents it was recently also shown that cigarette smoking 
lowers the prevalence of S. aureus nasopharyngeal carriage. P19 P 
Past smokers have the same prevalence of persistent carriage as 
those who have never smoked. Therefore, the “protection 
against carriage” conferred by smoking seems rapidly 
inducible and transient in nature. The fact that within the cohort 
of persistent carriers, current smoking was associated with a 
significantly lower density of S. aureus CFUs in the nares also 
points toward a direct effect of (cigarette) smoke on carriage. 
Cigarette smoking is known to induce airway inflammation. P20,21P 
Cole et al. reported that nasal secretions obtained from S. aureus 
carriers contained higher levels of inflammatory proteins 
including defensins, but lacked antimicrobial activity in vitro, 
while nasal fluid from non-carriers was bactericidal.P3 P From these 
and our data, we hypothesize that S. aureus colonization of the 
anterior nares is less likely to occur in smoking persons because 
of a toxic effect of smoke on S. aureus combined with smoke 
induced airway mucosa infiltration of inflammatory cells. 
Environmental factors were also shown to play an important role 
in determining the S. aureus nasal carrier state (chapter 5). The 
risk of sharing identical carrier states was 2 to 4-fold increased 
for members of the same household, while first degree relatives 
did not ‘share’ identical carrier states. Apparently, the repeated 
(non-) exposure to S. aureus in the household environment is a 
more important determinant of S. aureus nasal carriage than the 
genetic background of first degree family members.  
The vitamin D endocrine system (chapter 6) has been shown to 
influence immune response and polymorphisms in the vitamin D 
receptor (VDR) gene have been associated with susceptibility to 
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infectious diseases. VDR polymorphisms have been associated 
with susceptibility to infections.P22-26 P VDR gene polymorphisms 
may determine the likelihood of persistent infection or 
colonization with intracellular micro-organisms (including S. 
aureus), since Vitamin D metabolites have been shown to play a 
role in macrophage activation and differentiation.P27P However the 
prevalence of persistent S. aureus nasal carriage was not 
different by VDR genotype, suggesting that VDR gene variation 
is not associated with S. aureus carriage.  
We also determined whether functional polymorphisms in the 
glucocorticoid receptor (GR) gene (chapter 7) were associated 
with persistent nasal carriage of S. aureus. We demonstrated that 
genetic variantion in the GR gene are associated with S. aureus 
nasal carriage: GG-homozygotes of the exon 9beta 
polymorphism had a 67% reduced risk of persistent S. aureus 
nasal carriage (odds ratio 0.33; 95% confidence interval, 0.15-
0.74), while heterozygous carriers of the haplotype containing 
the 9beta G-allele and the codon 23 Lys-allele had a 80% 
increased risk (odds ratio 1.80; 95% confidence interval, 1.08-
3.00). Our data show that glucocorticoid regulation influences 
the risk of persistent S. aureus nasal carriage, either through 
modulation of the pro/anti inflammatory cytokine balance or 
through changes in insulin sensitivity. The 9beta GG-
homozygotes may have a more active immune system through 
increased glucocorticoid resistance as demonstrated by the 
association with autoimmune disease, notably rheumatoid 
arthritis.P28 P In addition, as a result of relative glucocorticoid 
resistance 9beta GG homozygotes could have an increased 
insulin sensitivity leading to lower insulin and/or overall glucose 
levels. However, too little is currently known on the 
physiological effect of GR mutation combination and future 
research should resolve this apparent controversy. In addition, it
has recently been demonstrated that glucocorticoids, in 
conjunction with pro-inflammatory cytokines, affect the 
expression of toll-like receptor 2 (TLR-2), the main pattern 
recognition molecule acting on gram positive pathogens such as 
S. aureus.P29-31P Whether the various GR gene polymorphisms 
studied here are (partially) defective in supporting this 
biological activity is currently unknown, but again warrants 
further investigation. We thus report the first genetic factor as a 
determinant of individual S. aureus nasal carriage.  
Combined these data suggest that glucose metabolism, insulin 
sensitivity and glucocorticoid sensitivity interact in eliminating 
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or tolerating S. aureus in its niche, the anterior nares. Whether 
other ‘infection’ genes (e.g. IL-4, IL-10, TNF-alpha, TGFbeta) are 
involved is currently unknown, but the subject of future 
research. Also further research is needed into the contribution of
the innate immunity, since defensins and also Toll-like receptors 
(e.g. TLR-2) are thought to play an important role. P2,29,30,32P 
 
 
 
 
  Risks 
 
  Most of the studies on the risks associated with S. aureus nasal 
carriage have been performed in the hospital setting and limited
data are available on the health effects of S. aureus nasal 
carriage in the community setting. Moreover, studies in 
populations at risk, such as patients on continuous peritoneal 
dialysis (CPD), have been hampered by lack of adequate 
definition of the different S. aureus nasal carrier states, thereby 
impeding the adequate targeting of prophylactic measures. 
Accurate determination of the true S. aureus carrier state would, 
theoretically, enable us to improve the prevention of S. aureus 
infections in CPD patients. 
 
In a community setting of elderly persons (chapter 8), persistent 
S. aureus nasal carriage was not associated with all-cause 
mortality. However, persistent S. aureus nasal carriage was 
associated with a slight though significant increase in antibiotic 
use. This association was even more pronounced in the 
subgroup of non-smokers. The major limitation of this study was 
that we studied all-cause mortality and overall antibiotic use and 
not infection-related mortality or specific anti-staphylococcal 
antibiotic prescriptions. It remains possible that persistent S. 
aureus nasal carriage is associated with mortality from S. aureus 
infections. However, since persistent carriage did not 
significantly attribute to the all-cause mortality, the absolute 
assignable risk for S. aureus nasal carriage-related mortality due 
to infection will, if any, be low. Also, the vast majority of 
antibiotics prescribed in the community are for urinary tract and 
respiratory tract infections, and not for the major community-
acquired S. aureus infections, mostly skin infections. Therefore, 
in the community, the relative contribution of S. aureus infections 
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may be small, explaining the only slight increase in overall 
antibiotic consumption. 
 
In both studies in CPD patients (chapters 9 & 10) we clearly 
demonstrated that persistent, but not intermittent, S. aureus nasal
carriage is thé major determinant of CPD related infections and 
associated with a significantly higher consumption of antibiotics, 
including vancomycin. Nearly half of all CPD patients were 
persistently colonized with a single unique S. aureus strain, 
indicating that long term persistent S. aureus carriage is common
in this group of patients. This prevalence of persistent carriage 
in itself was not different from the rates observed in both healthy 
individuals and other patient cohorts, P33 P but persistent carriage 
was associated with a more than 3-fold increased risk for CPD 
related infections.  
In the second CPD study (chapter 10) 10% of patients were 
chronically colonized with S. aureus, but by genotypically 
different strains at subsequent occasions and 20% were only 
intermittently colonized by S. aureus. Whether the chronic 
carrier group should also be defined as persistent carriers is a 
matter of definition and debate. P34P Although apparently these 
patients carry S. aureus for prolonged periods of time, their risk 
of invasive S. aureus infections was similar to the intermittent 
carrier group. As such, chronic carriers should in our opinion be 
viewed as ‘high level’ intermittent carriers and be separated 
from persistent carriers.  
The highly divers population of CoNS appears to be the prime 
reservoir of staphylococcal vancomycin resistance, although no 
vancomycin resistance in S. aureus was encountered. However, 
continued screening for the emergence of glycopeptide 
resistant isolates of S. aureus remains a prudent strategy. 
From our CPD studies we conclude that only persistent carriers 
of S. aureus have a significantly increased risk for CPD related 
infections as compared to non-carriers. Intermittent and chronic 
S. aureus carriage is not associated with increased infection risk. 
Moreover, in a recent large multicenter study it was clearly 
demonstrated that routine culture for S. aureus nasal carriage at 
admission and subsequent mupirocin application does not 
provide effective prophylaxis against nosocomial S. aureus 
infections in non-surgical patients. P35P Precise determination of the 
S.aureus carrier state is possible, makes sense and is needed to 
adequately target prevention strategies to high risk patient 
groups. 
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  Dynamics 
 
  S. aureus remains an important pathogen in human disease. P36 P 
The incidence of both community-acquired and hospital-
acquired S. aureus infections is still increasing and, despite 
antibiotic therapy, the cause of serious morbidity and high 
mortality.P37,38P That S. aureus is capable of developing resistance 
to all available antibiotics has been clearly demonstrated again 
with the dramatic advent of community-acquired MRSA  and 
vancomycin-resistant S aureus (VRSA) strains.P39-42P In the era of S. 
aureus ‘multi-resistance’ prudent use of antibiotics in prevention 
and therapy is highly needed. Also, alternative strategies, 
including interference therapy, P43-45 P vaccination,P46-48P phage-
therapy and non-antibiotic therapies such as honey, to combat S. 
aureus are necessary. 
 
We studied the dynamics of inoculation with Staphylococcus 
aureus 502A in volunteers, CPD patients, furunculosis patients or 
methicillin-resistant S. aureus carriers. inoculation with SA-502A 
has been successfully used earlier in nurseries during out-
breaks of S. aureus infections in the 1960s and for treatment 
of patients with recurrent furunculosis. P49-53P.However, the early 
practice of artificial inoculation with SA-502A was abandoned 
after alleged complications,P54-56P and the advent of newer anti-
staphylococcal antibiotics in the early 1970s. At that time, the 
authors reporting these side effects explicitly stated that, despite
the potential (serious) side-effects of artificial inoculation with 
SA-502A, the ‘benefits far outweigh the hazards’, claiming that it 
is an effective tool to prevent serious or recurring S. aureus 
problems from wild type strains.P55,56 P From our present study we 
conclude that artificial inoculation with SA-502A is safe when 
applied to individuals known to be long-term persistent carriers 
of S. aureus. In a previous study, we demonstrated that when 
long-term persistent S. aureus carriers were inoculated with a 
mixture of S. aureus strains, none suffered from side-effects from 
the inoculation. P57 P In that study also individuals known to be free 
of wild type S. aureus were inoculated, and two out of eight of 
those long-term non-carriers suffered from minor self-limiting 
skin lesions after artificial inoculation.P57 P Thus, we claim that 
determining the exact S. aureus carrier state is an essential part 
of performing artificial inoculation and that bacterial 
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interference by artificial inoculation with SA-502A should be 
restricted to individuals known to be long-term persistent S. 
aureus carriers.  
In conclusion, artificial inoculation with SA-502A in persistent S. 
aureus carriers is safe and can be used to successfully to replace 
wild type resident S. aureus strains in a variety of patient 
categories provided that the resident strain is eradicated first. 
This strategy holds promise for the prevention of S. aureus 
infections and may help limit the spread of wild type, potentially 
more virulent and hard-to-treat S. aureus strains including MRSA.
 
 
 
 
  Conclusions & Future Developments 
 
  Worldwide, MRSA rates have increased dramatically during the 
last decades. The threat of development of resistance to 
vancomycin, the only antimicrobial agent effective against 
MRSA, and the emergence of community-acquired MRSA (CA-
MRSA) is alarming. The worldwide use of vancomycin has 
increased dramatically over the past years.  
Optimization of preventive strategies is needed to control 
staphylococci. Therefore, new strategies have to be 
developed. The ability to control staphylococcal infections in the 
future will depend on the development of new 
therapeutic agents and the optimization of infection control 
measures.  
In this thesis we have demonstrated that the human host is the 
prime determinant of the S. aureus nasal carrier state. ‘To 
tolerate or to eliminate?’ that’s the question! S. aureus nasal 
carriage is definitively a multifactorially defined status, with 
bacterial and environmental factors involved as well. More in 
depth research will be necessary to elucidate the host-pathogen 
interaction. The results from the studies presented in this thesis 
set the stage for future research to be directed towards host 
genetic factors and in vivo host-bacterial interaction studies. The 
completion of both the human genome project and the S. aureus 
genome project opens new possibilities to pinpoint individuals 
at risk, as well as ‘risky’ bacteria, and could thus ‘personalize’ 
our preventive options. 
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For now, mupirocin is the most effective drug available to 
achieve eradication of carriage. However, resistance to 
mupirocin is increasing, and it must be asked for how long this 
agent will be effective. One strategy that has been used 
successfully in the past is bacterial interference. This alternative 
approach to controlling staphylococcal infections could offer 
new opportunities if strains with minimal virulence and maximal 
competition for the binding sites in the nose could be 
developed.  
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  Determinanten 
 
  Neusdragerschap van S. aureus wordt wel beschouwd als de 
sleutel tot het voorkomen van S. aureus infecties. Om deze 
sleutel optimaal te kunnen benutten is meer onderzoek nodig 
naar de fundamentele mechanismen van dragerschap. Veel 
onderzoek heeft zich voornamelijk gericht op bacteriële 
factoren. Keer op keer konden in vitro bevindingen niet in vivo 
worden bevestigd. Daardoor zijn er tot op heden geen 
bacteriële factoren essentieel voor S. aureus dragerschap 
geïdentificeerd. P1-5P Recent werden lipoteichoïne zuur (LTA) en 
clumping factor B (ClfB) als essentiële factoren voor kolonisatie 
beschreven. P6,7 P Echter, ook van deze factoren moet in het ‘echte’ 
leven nog blijken of zij inderdaad zo essentieel zijn. 
Tevens is het merendeel van de studies naar gastheerfactoren 
geassocieerd met S. aureus dragerschap verricht in het 
ziekenhuis of de polikliniek. Derhalve besloten wij om de 
gastheer als primaire determinant van S. aureus 
neusdragerschap te bestuderen in de open bevolking. 
 
Het adequaat kunnen onderscheiden van de verschillende 
dragerschapcategorieën (nooit, intermitterend en persisterend 
dragerschap) is essentieel voor het kunnen doen van 
epidemiologisch onderzoek. P8-15P Om binnen ERGO de associatie 
tussen S. aureus neusdragerschap en gastheerfactoren te kunnen
bestuderen, moest er als eerste een methode ontwikkeld 
worden om op een zo efficiënt en betrouwbaar mogelijke 
manier de S. aureus nesudragerschapstatus vast te kunnen 
stellen. Het zou namelijk onmogelijk geweest zijn om bij iedere 
van de bijna 4000 ERGO deelnemers gedurende 10-12 weken 
een neuskweek af te nemen. Door kwalitatieve gegevens (= 
aantal positieve neuskweken) te combineren met kwantitatieve 
gegevens (= aantal bacterie kolonies in een neuskweek) kon 
een ‘kweekregel’ worden ontworpen, waarbij middels 2 
neuskweken met één week tussenpoos met een 94% 
betrouwbaarheid de dragerschapstatus van de ERGO 
deelnemers adequaat kon worden vastgesteld (hoofdstuk 3). Het
toevoegen van een 3 Pe P of 4Pe P kweek had geen significante 
verbetering tot gevolg. Wel bleek dat het gebruik van slechts 
één neuskweek, zoals vaak in klinische studies wordt gedaan, 
ter vaststelling van de dragerschapstatus onvoldoende was. Wel 
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sluit één negatieve kweek persisterend dragerschap vrijwel uit. 
Naast het gebruik in ERGO, zou deze ‘kweekregel’ ook in 
andere omstandigheden kunnen worden gebruikt in studies 
naar determinanten van S. aureus dragerschap en infecties en de
implementatie van nieuwe strategieën in de preventie van 
infecties. 
 
Uit de gegevens van de studies beschreven in de hoofdstukken 
3-7 concluderen wij dat de gastheer inderdaad een belangrijke, 
zo niet dé belangrijkste, determinant is van S. aureus 
neusdragerschap. Na artificiële inoculatie met een mengsel van 
S. aureus stammen (hoofdstuk 4), bleek de overleving van S. 
aureus in de neus significant langer te zijn bij persisterend 
dragers dan bij niet-dragers. Bij de helft van de niet-dragers 
waren binnen 2 weken de geïnoculeerde stammen alweer 
verdwenen uit de neus. Slechts één voorheen niet-drager werd 
na inoculatie een persisterend drager, gepaard gaande met 
milde huidlesies. Deze gegevens suggereren dat 
gastheerfactoren een belangrijke rol spelen in het bepalen van 
het type dragerschap. Tevens lijken gast en gastheer elkaar ‘uit 
te zoeken’ in de zin dat persisterend dragers vaak langdurig 
drager zijn van hun eigen S. aureus stam. 
Opvallend is het, tot nu toe niet eerder beschreven en ook nog 
onverklaarde, verschil in de hoeveelheid S. aureus bacteriën in 
persisterend dragers tussen jongeren en ouderen. Oudere 
persisterend dragers hebben 10-maal zoveel bacteriën in de 
neus dan jongeren (hoofdstuk 2). 
De belangrijkste bevindingen uit ERGO zijn de positieve 
associatie tussen nuchtere glucose waarde en persisterend S. 
aureus neusdragerschap en het beschermende effect van roken. 
Verder wordt bevestigd dat geslacht (mannen vaker drager dan 
vrouwen), leeftijd (des te ouder des te minder dragers) en 
huidaandoeningen (met name eczeem) geassocieerd zijn met S. 
aureus dragerschap. In eerdere studies werd alleen een 
associatie gevonden tussen insuline-afhankelijke diabetes 
mellitus en S. aureus dragerschap.P16,17P Echter uit onze ERGO 
studie blijkt dat de nuchtere glucose waarde, zelfs in het 
normale gebied, is geassocieerd met S. aureus dragerschap. Het 
pathofysiologische mechanisme hierachter is (nog) niet bekend, 
maar waarschijnlijk spelen neutrofiele granulocyten en 
macrofagen en hun intracellulaire dodend vermogen hierbij een 
belangrijke rol. P18 P 
Dat roken de kans op dragerschap verminderd komt overeen 
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met de resultaten van een recente studie onder kinderen. P19P  Het 
feit dat personen die gestopt zijn met roken een vergelijkbare 
kans op persisterend dragerschap hebben als nooit rokers, doet 
vermoeden dat het ‘beschermende’ effect snel induceerbaar en 
reversibel is. Binnen de groep van persisterend dragers hadden 
rokers ook lagere aantallen bacteriën in de neus, wat ook wijst 
in de richting van een direct (toxisch) effect van (sigaretten) 
rook. Eerdere studies hebben laten zien dat roken gepaard gaat 
met een toename van ontstekingsverschijnselen in de 
luchtwegen P20,21 P. Cole et al. vonden dat neussecreet van 
persisterend S. aureus dragers hogere concentraties 
onstekingsmediatoren bevatten (o.a. defensines), maar in 
antibacteriële tekort schoten, in vergelijking met niet-dragers. P3 P 
Onze hypothese is dan ook dat roken een beschermend effect 
tegen persisterend S. aureus neusdragerschap heeft door 
enerzijds een direct toxisch effect van de rook op de bacterie en 
anderzijds door een toegenomen ontstekingsactiviteit in de 
neus. 
 
Omgevingsfactoren blijken ook een belangrijke rol te spelen in 
S. aureus neusdragerschap. Personen behorend tot eenzelfde 
huishouden hadden een 2-4 maal verhoogde kans op dezelfde 
dragerschapstatus als hun partners. Oftewel: persisterend 
dragers wonen met persisterend dragers en niet-dragers wonen 
bij niet-dragers (hoofdstuk 6). Dit in tegenstelling tot 1 Pe P-graads 
familieleden, waarbij geen concordantie in dragerschapstatus 
kon worden gevonden. Blijkbaar speelt het bij herhaling 
worden blootgesteld aan S. aureus (of juist niet) binnen het 
huishouden een belangrijkere rol in het bepalen van de 
individuele S. aureus dragerschapstatus dan de genetische 
achtergrond van 1Pe P-graads familieleden. 
 
Van het vitamine D endocriene systeem (hoofdstuk 6) is 
aangetoond dat het de immuunrespons beïnvloedt. 
Polymorfismen in het vitamine D receptor (VDR) gen zijn 
geassocieerd met een verhoogde gevoeligheid voor infecties. P22-
26
P VDR gen polymorfismen lijken vooral een rol de spelen in de 
afweer tegen intracellulaire micro-organismen (waaronder S. 
aureus), daar vitamine D metabolieten een rol spelen in 
macrofaag activatie en differentiatie.P27 P Echter, wij konden geen 
associatie aantonen tussen VDR gen polymorfismen en de kans 
op persisterend S. aureus neusdragerschap. 
Naast het VDR gen, hebben we, ook binnen ERGO, gekeken of 
GENERAL DISCUSSION/ Chapter 13/Algehele Discussie, Samenvatting & Toekomstperspectief. VI - 19
 
2004 © J.L. Nouwen \ December 8th 2004 \ Thesis: Determinants, Risks & Dynamics of Staphylococcus aureus Nasal Carriage 
functionele polymorfismen in het glucocorticoïd receptor (GR) 
gen geassocieerd waren met S. aureus neusdragerschap 
(hoofdstuk 7). We konden aantonen dat het G-allel in het exon 
9beta polymorfisme en het haplotype bestaande uit de 
combinatie van het G-allel in het exon 9beta polymorfisme 
samen met een Lys-allele in codon 23, significant geassocieerd 
waren met persisterend S. aureus neusdragerschap: GG-
homozygoten in het exon 9beta polymorfisme hadden 67% 
lagere kans op persisterend dragerschap, terwijl heterozygote 
dragers van het G-allel in het exon 9beta polymorfisme samen 
met een Lys-allele in codon 23 een 80% hogere kans op 
persisterend dragerschap hadden. Deze gegevens zijn 
compatibel met de hypothese dat glucocorticoïd regulatie het 
risico op S. aureus dragerschap beïnvloed door middel van 
verandering in de lokale pro/anti-inflammatoire cytokine 
balans, dan wel via veranderingen in insuline gevoeligheid. De 
9beta GG-homozygoten lijken een actiever immuunsysteem te 
hebben, getuige ook de associatie met reumatoïde artritis. P28P 
Verder hebben 9beta GG-homozygoten een relatieve 
glucocorticoïden resistentie, gepaard gaande met een hogere 
insuline gevoeligheid, leidend tot lagere insuline en/of glucose 
spiegels. Tevens werd van glucocorticoïden recent aangetoond 
dat deze, in samenspraak met pro-inflammatoire cytokinen, de 
expressie van Toll-like receptor 2 (TLR-2), het belangrijkste 
‘pattern recognition molecuul’ voor gram-positieve micro-
organismen zoals S. aureus, beïnvloeden.P29-31P Of dat de 
verschillende, door ons onderzochte, GR gen polymorfismen 
daadwerkelijk een rol spelen in de regulatie/expressie van TLR-
2 is op dit moment onbekend. Kortom, met de twee genoemde 
GR gen polymorfismen rapporteren wij de eerste genetische 
determinanten van S. aureus neusdragerschap.  
 
Gecombineerd, suggereren bovengenoemde gegevens, dat 
glucose metabolisme, insuline gevoeligheid en glucocorticoïd 
gevoeligheid interacteren in het elimineren dan wel tolereren 
van S. aureus in zijn niche, de neus. Of en in welke mate andere 
‘infectie’ genen (bijvoorbeeld IL-4, IL-10, TNF-alpha, TGFbeta) 
en de aangeboren immuniteit (defensines, Toll-like receptoren 
etc.) hieraan bijdragen is het onderwerp van toekomstige 
studies.P2,29,30,32 P  
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  Risico’s 
 
  De meeste studies betreffende de risico’s van S. aureus 
dragerschap zijn verricht in de ziekenhuis setting en slechts 
weinig data zijn beschikbaar over de gezondheidseffecten van 
dragerschap in de open bevolking. Hiernaast wordt de 
interpretatie van veel studies naar de effecten van dragerschap 
bij risico patiënten, zoals CAPD (continue ambulante peritoneaal 
dialyse) patiënten, bemoeilijkt door inadequate definities van S. 
aureus dragerschap. Accurate vaststelling van de reële S. aureus 
dragerschapstatus is noodzakelijk voor de studie van zowel 
determinanten van dragerschap als het ontwikkelen van 
preventieve maatregelen tegen S. aureus infecties in risico 
patiënten.  
 
Persisterend S. aureus dragerschap was in de open bevolking 
van ERGO niet geassocieerd met mortaliteit (hoofdstuk 8). 
Echter persisterend dragerschap was wel geassocieerd met een 
lichte, maar significante toename in antibiotica gebruik. De 
toename in antibiotica gebruik was het meest uitgesproken in de
subgroep van niet-rokers. Het is niet uitgesloten dat er een 
associatie bestaat tussen persisterend S. aureus dragerschap en 
(S. aureus) infectiegerelateerde mortaliteit. Echter, gezien het 
ontbreken van een effect op de overall mortaliteit, zal het 
eventuele effect op infectiegerelateerde mortaliteit gering zijn. 
De indicaties voor het merendeel van de voorgeschreven 
antibiotica in de bevolking zijn urineweg- en luchtweginfecties, 
en niet zozeer community-acquired S. aureus infecties, meestal 
huidinfecties. Daarom zal de relatieve bijdrage van S. aureus 
infecties aan het totaal antibiotica gebruik klein zijn. 
 
In beide studies in CAPD patiënten (hoofdstukken 9 en 10), 
bleek dat alleen de echte persisterend S. aureus drager (en niet 
de intermitterend drager!) een 3-voudig verhoogd risico op 
CAPD gerelateerde infecties heeft vergeleken met niet-dragers. 
Persisterend dragerschap was tevens geassocieerd met een 
hoger antibiotica gebruik, inclusief vancomycine. Ongeveer de 
helft van de CAPD patiënten is over een langere periode 
persisterend gekoloniseerd met één en dezelfde S. aureus stam. 
Patiënten die intermitterend drager van S. aureus zijn en 
patiënten die weliswaar chronisch gekoloniseerd zijn met S. 
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aureus maar met steeds (genotypisch) andere stammen, lopen 
géén verhoogd risico op CAPD gerelateerde infecties. De 
infectie-incidentie in deze twee laatste categorieën dragers is 
gelijk aan die van niet-dragers. De door ons zogenoemde 
chronische dragers zijn dus eigenlijk ‘high-level’ intermitterend 
dragers.P33,34P Wij stellen dan ook voor om bij het vaststellen van 
het type dragerschap gebruik te maken van genotyperings 
methoden zoals PFGE (pulsed-field gel electropheresis) ter 
differentiering van persisterend en andere S. aureus dragers, 
zeker omdat dat klinische consequenties heeft. 
In een centrum waar vancomycine deel uit maakt van de 
eerstelijns empirische behandeling van CAPD-peritonitis 
(hoofdstuk 9) bleek 10% van de patiënten op enig moment 
gedurende de studie gekoloniseerd met voor vancomycine 
verminderd gevoelige coagulase-negatieve stafylokokken. 
Blijkbaar is de zeer diverse populatie coagulase-negatieve 
stafylokokken het primaire reservoir van vancomycine 
verminderd gevoelige stafylokokken. In een centrum waar 
vancomycine geen deel uit maakt van de eerstelijns empirische 
behandeling van CAPD-peritonitis, werden geen voor 
vancomycine verminderd gevoelige coagulase-negatieve 
stafylokokken gevonden. Er werd geen vancomycine resistentie 
gevonden in S. aureus. 
In een recente multicenter studie werd geen effect aangetoond 
van het met één neuskweek screenen op S. aureus dragerschap 
en applicatie van mupirocine in niet-chirurgische patiënten op 
het voorkomen van nosocomiale S. aureus infecties.P35P Voor het 
ontwikkelen van effectieve preventie strategieën is precieze 
vaststelling van het type dragerschap mogelijk, zinvol en 
noodzakelijk, zodat deze strategieën kunnen worden gericht op 
die patiëntengroep die er het meest baat van heeft. 
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  Dynamica 
 
  In het tijdperk van de multiresistente S. aureus is het afgewogen 
gebruik van antibiotica in de behandeling, maar ook de 
preventie van S. aureus infecties noodzakelijk. P36,37,38,39-42P Ook het 
nader uitwerken van alternatieve strategieën, zoals interferentie 
therapie,P43-45P vaccinatie,P46-48P faag therapie en niet antibiotische 
behandelingen (honing, lysostaphine) is hoogst gewenst. 
 
Daarom bestudeerden wij de dynamica van artificiële inoculatie 
met Staphylococcus aureus 502A (SA-502A), een verzwakte S. 
aureus stam, als interferentie therapie voor de eradicatie van 
wild type S. aureus in vrijwilligers, patiënten met recidiverende 
furunculose en methicilline-resistente S. aureus (MRSA) 
(hoofdstuk 11). SA-502A is in de jaren 60 en begin jaren zeventig
met succes gebruikt ter preventie en behandeling van S.aureus 
infecties bij pasgeborenen en patiënten met recidiverende 
furunculose. P49-53 P Echter, door de ontwikkeling van nieuwe 
antibiotica en het optreden van een aantal complicaties, werd 
interferentie therapie met SA-502A verlaten. P54-56,55,56P Onze studie 
laat zien dat, indien toegepast bij goed gedefinieerde 
persisterend S. aureus dragers, artificiële inoculatie met SA-
502A veilig en effectief is. Interferentie met SA-502A kan 
succesvol gebruikt worden ter vervanging van de residente wild
type S. aureus mits de residente stam eerst kan worden 
geëradiceerd.   
 
 
 
 
  Conclusies & Toekomstperspectief 
 
  Wereldwijd is de incidentie van MRSA de afgelopen decades 
dramatisch toegenomen. De dreiging van vancomycine 
resistente S. aureus stammen en de opkomst van community-
acquired MRSA (CA-MRSA) zijn alarmerend. 
Preventie van S. aureus infecties en de ontwikkeling van 
resistentie is alleen mogelijk als de huidige preventieve 
strategieën worden geoptimaliseerd en nieuwe kunnen worden 
ontwikkeld. Precieze vaststelling van het type S. aureus 
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dragerschap is daarvoor essentieel. De waarde van 
sneldiagnostiek met nieuwe ontwikkelingen als real-time PCR 
en DNA-chip analyse hierbij, zal moeten worden vergeleken 
met conventionele kweek- en genotyperingsmethoden. 
 
In dit proefschrift hebben we kunnen aantonen dat de gastheer 
een zeer belangrijke, zo niet de belangrijkste determinant van 
S. aureus neusdragerschap is. ‘Tolereren of elimineren?’ is de 
vraag! S. aureus neusdragerschap is multifactorieel bepaald, 
waarbij ook bacteriële en omgevingsfactoren betrokken zijn. 
Natuurlijk is meer onderzoek noodzakelijk om de gast-gastheer 
interactie verder te ontrafelen, maar de resultaten beschreven in
dit proefschrift zijn richtinggevend voor nader onderzoek naar 
onderliggende genetische factoren bij de gast en in vivo gast-
gastheer interacties. Zodat we uiteindelijk risico-patiënten en 
risico-bacteriën kunnen aanwijzen en zodoende onze preventie 
opties kunnen individualiseren. 
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  Dankwoord 
 
  Zoals zo vaak al opgemerkt: het doen van (promotie) onderzoek 
is zelden iets wat je alleen doet (behalve dan als je weer ’s 
avonds laat aan het stoeien bent met de computer en diens 
fratsen). Het resultaat van alle inspanningen, dit boekje, is het 
product van een team van medewerkers in alle opzichten. 
 
In hun dankwoord eindigen de meeste promovendi met 
diegenen die ze het meeste nabij staan. Ik wilde het dit keer 
anders doen. 
Lieve, lieve Angélique, eindelijk is het dan toch gelukt. Het 
boekje is af! Wat zou ik zonder jou moeten? (Ik kan je antwoord 
wel zo’n beetje inschatten!) Je hebt altijd gedreigd ‘te gaan 
scheiden’ als ik zou promotieonderzoek zou gaan doen. 
Gelukkig voor mij was er blijkbaar iets om dat toch maar niet te 
doen. Dank voor je eindeloze geduld, voor je ‘opbouwende’ 
kritiek en vooral voor het mij met beide benen op de grond 
zetten als dat weer eens nodig was. 
Lieve fantastische meiden, lieve Anouk en Lonneke. Ondanks 
jullie oneindige geloof in jullie papa, sloop er ook bij jullie wel 
eens twijfel in: ‘wanneer papa nou eens een keer klaar was met 
dat boekje en niet meer altijd achter die computer hoefde te 
werken’. Willen ze nog dokter worden allebei ook! Zo groot 
alweer allebei, ik ben ongelooflijk trots op jullie. 
 
Helaas mochten mijn ouders dit niet meer meemaken. Zij waren 
altijd zo geïnteresseerd en hebben mij altijd zeer gestimuleerd, 
zowel qua school/studie/specialisatie als op andere vlakken. Ik 
geloof dat ze heel erg trots geweest zouden zijn. 
 
Dit proefschrift is tot stand gekomen onder de bezielende 
leiding van drie promotoren, te weten professor Henri 
Verbrugh, professor Bert Hofman en professor Alex van Belkum. 
Beste Henri, dankzij jou interesses en ideeën heeft dit 
proefschrift zijn uiteindelijke vorm gekregen. Dank voor het 
vertrouwen, het geduld, de ruimte, de mogelijkheden, je 
enthousiasme en je inspiratie. Ik hoop nog vele jaren met je 
samen te kunnen werken, zowel op het gebied van de 
patiëntenzorg, het onderwijs en natuurlijk het onderzoek. 
Beste Bert, dank voor je zeer eigen en enthousiaste begeleiding 
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van mijn onderzoeken. Dankzij de door jou geboden 
mogelijkheden en inspirerende colleges, mag ik me nu ook een 
beetje epidemioloog noemen. En ja, onderwijs is ook leuk, niet 
zo leuk als onderzoek misschien, maar toch. Je bent er in ieder 
geval net zoveel tijd mee kwijt. Ik hoop in de toekomst nog vaak 
met je te mogen discussiëren over onderwerpen voor 
epidemiologisch onderzoek binnen de infectieziekten. 
Beste Alex, tja wat moet ik nu nog verzinnen. Zonder Alex geen 
onderzoek, dus ook geen stafylokokken onderzoek. Alex, 
bedankt voor alles, maar vooral bedankt voor je oneindige 
geduld (’t is dat je zo’n aardige vent bent’). Het is je gave om 
zaken heel snel in hun perspectief te zien, om nieuwe 
ontwikkelingen te integreren in lopend onderzoek. De 
vensterbank is bijna leeg! En die kist met sigaren komt ook nog 
wel. 
 
De leden van de promotiecommissie, professor Marc Bonten, 
professor Ronald de Groot en professor Huib Pols wil ik bedank 
voor het zitting willen nemen in mijn commissie en voor het 
beoordelen van het manuscript. 
Beste Marc, Rotterdam is toch veeeeel leuker dan Utrecht, toch? 
Ik hoop je in de toekomst nog regelmatig (op congressen) tegen 
te komen. 
Beste Ronald, jij was één van degenen die heel hard moesten 
lachen toen ik tijdens een vergadering over het ontwikkelen van 
het thema Infectie- & Immuunziekten zei dat ik dat jaar (2002) 
ook nog wilde promoveren. Je hebt gelijk gekregen, 
Desondanks, dank voor je collegiale steun bij zowel het 
onderwijs als onderzoek. 
Beste Huib, dank voor je interesse in de infectieziekten. We 
zullen elkaar nog regelmatig tegen komen als het de Sectie 
Infectieziekten betreft. 
 
Weinigen zullen weten dat mijn eigenlijke ‘roots’ voor het 
stafylokokken onderzoek in 1984 in Kameroen liggen. Onder de 
bezielende begeleiding van professor Hans Valkenburg, deed 
ik toen gedurende het derde-jaars keuzepraktikum samen met 
Leo Verstraten onderzoek naar de verwekkers (en hun 
antibiotica resistentie) van Tropische Pyomyositis, alsmede 
onderzoek naar de prevalentie van de verschillende Filaria 
soorten ter plekke (Manyemen). Hans Sluiters, parasitoloog 
deed de directe begeleiding van het Filaria onderzoek. Beste 
Hans, dank voor alle begeleiding toen als student en dank voor 
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alle hulp als collega bij patiëntenzorg en onderwijs nu. John 
Degener (toen nog geen professor) was aangewezen door 
professor Michel om ons iets te leren over stafylokokken en dan 
met name S. aureus voor het Tropische Pyomyositis onderzoek. 
Beste John, ik weet niet of je bovenstaande hebt gerealiseerd 
toen je ja zei tegen het verzoek om zitting te nemen in de grote 
commissie bij mijn promotie. De echte begeleiding van het 
microbiologische werk destijds in 1983-1984 werd gedaan door 
Hélène Boelens (in 1983 zelfs nog in de D-vleugel), zoals zij ook 
voor het huidige onderzoek het eigenlijke echte werk heeft 
gedaan. Beste Hélène, dank voor je hulp toen, nog meer dank 
voor het doen van meer dan 10.000 neuskweken in het kader 
van mijn promotieonderzoek. Roken heeft z’n voordelen! Dank 
voor toen en nu ook aan Julia, Jolanda en Ad (naast natuurlijk al 
die andere (oud) analisten). 
 
Dank aan iedereen van het stafylokokken ‘team’, Greet, Alewijn 
(voor alle methodologische, epidemiologische en statistische 
adviezen), Wil, Willem (ook voor het in de stadsbus rondrijden 
in Kopenhagen op zoek naar 3 posters), Heiman en Damian 
(Nature Medicine of JAMA?). Beste Susan, heel erg bedankt voor 
het o zo betrouwbaar verrichten van al het CAPD gerelateerde 
lab zaken. Nicole en Jolanda, dank voor de vancomycine 
verminderde stafylokokken. Marly, dank voor de radioactieve 
stafylokokken. 
 
Alle overige medewerkers aan dit proefschrift bedankt voor alle 
inzet en steun, Marien, Erica, Peter, André, Mark (waar 
Kameroen al niet goed voor is) en Erna. Tevens alle 
medewerkers van de CAPD polikliniek dank voor jullie 
ondersteuning. 
 
Dank aan alle (oud) collega’s, Inge, Hubert, Machteld, Ineke, 
Roel, Mireille, Irma, Nico, Peter, Kees, Johan, Jan, Marjolein, 
Mark, Peter en nog een keer Jan. Dank ook aan alle 
medewerkers van balie 2 van de polikliniek Infectieziekten. Aan 
Iman, Rita, Laura, Sietz, Debby, Marja en Tessa. 
 
Beste Siem, dank voor het mij bieden van de mogelijkheid om 
het aandachtsgebied Infectieziekten te doen op onze afdeling. Ik
leer nog steeds van je. Helaas scheidden onze 
onderzoekswegen door omstandigheden. Maar binnenkort 
praten we weer samen over gisten- en schimmels! 
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Beste Tjaco en Dorien, onze wegen scheiden binnenkort. Over 
het voorportaal hoeven we ons niet meer druk te maken. Wel zal 
ik alle dubbele cappuccino’s missen. Dank voor jullie 
gezelligheid op de kamer. Als ik het niet uithoud kom ik gewoon 
bij jullie zitten. 
 
Beste Michiel, oud kamergenoot, dank voor je altijd opgewekte 
humeur, voor de stimulerende consulten besprekingen, maar 
vooral voor al het gezellige geleuter. We zoeken nog een 
hoogleraar! 
 
En wat zouden we allemaal zijn zonder onze secretaresses. Dank 
voor alle steun, hulp en nog heel veel meer aan de beste van 
allemaal, Paula. Dank aan Marion, Conne, Hinke en sinds kort 
Greet en Marja. 
En dan bijna als laatste, dank aan Nicole en Sander, mijn 
paranymfen. Wie van de drie is allang geleden, maar dankzij 
jullie ja-woord is het cirkeltje eindelijk rond. 
 
Lieve Angélique, Anouk en Lonneke, nu is het tijd voor jullie. 
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  Curriculum Vitae 
 
  Jan Leendert Nouwen werd geboren op 22 juli 1963 te Hendrik-
Ido-Ambacht. Na het behalen van het VWO diploma aan de 
Openbare Scholengemeenschap Walburg te Zwijndrecht, 
begon hij 1981 begonnen met de studie geneeskunde aan de 
Faculteit der Geneeskunde & Gezondheidswetenschappen van 
de Erasmus Universiteit te Rotterdam (het huidige Erasmus MC - 
Faculteit). Gedurende de periode 1983-1987 was hij vier jaar 
bestuurslid van de Medische Faculteitsvereniging Rotterdam 
(MFVR) en viel hij in 1985 als secretaris als een blok voor de 
toenmalige voorzitster Angélique Zondag, nu nog steeds zijn 
levenspartner. In januari 1989 legde hij het artsexamen af. In de 
periode april 1989 tot juli 1990 was hij werkzaam als AGNIO 
Interne Geneeskunde in het toenmalige Bergwegziekenhuis (het 
huidige IJsselland ziekenhuis) bij Dr. G.J.H. den Ottolander. In 
juli 1990 startte hij met de opleiding tot internist in het 
toenmalige Refaja ziekenhuis te Dordrecht (het huidig Albert 
Schweitzer ziekenhuis) (opleider Dr. B.P. Hazenberg). Van juli 
1992 tot januari 1995 vervolgde hij zijn opleiding in het Sint 
Franciscus Gasthuis te Rotterdam (opleider Dr. H.S.L.M. Tjen), 
en van januari 1995 tot juli 1996 in het Academisch Ziekenhuis 
Dijkzigt (het huidige Erasmus MC – Centrumlocatie) (opleider 
Prof. Dr. M.A.D.H. Schalekamp). Op 16 juli 1996 volgde 
inschrijving als internist in het specialisten register. In 
september 1995 begon hij op de afdeling Medische 
Microbiologie & Infectieziekten (hoofd Prof. Dr. H.A. Verbrugh) 
met de opleiding voor het aandachtsgebied Infectieziekten 
(opleider Dr. S. de Marie). In mei 1997 volgde registratie als 
internist-infectioloog. Tijdens deze opleiding begon hij met zijn 
wetenschappelijk onderzoek, aanvankelijk met als focus 
(catheter-gerelateerde) infecties bij de 
immuungecompromitteerde patiënt (Dr. S. de Marie), later met 
als focus het huidige promotie onderwerp ‘Determinanten, 
Risico’s en Dynamica van Staphylococcus aureus 
neusdragerschap’ (Prof. Dr. H.A. Verbrugh, Prof. Dr. A. Hofman 
en ‘last but not least’ Prof. Dr. Dr. A. van Belkum). In het kader 
van dit onderzoek volgde hij tussen augustus 1998 en augustus 
2000 de Master of Science opleiding ‘Clinical Epidemiology’. 
Sinds april 2001 is hij onderwijscoördinator van de afdeling 
Medische Microbiologie & Infectieziekten en sinds december 
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2001 themacoördinator van het tweede jaars thema Infectie- & 
Immuunziekten binnen het curriculum Erasmusarts 2007 aan de 
Faculteit der Geneeskunde & Gezondheidswetenschappen. In 
deze hoedanigheid is hij ook lid van Centraal Coördinatoren 
Overleg (CCO). In juni 2004 werd hem door de medisch 
studenten de MORE onderwijsprijs toegekend en werd hij 
gekozen tot docent van het jaar. Hij is getrouwd met Angélique 
Zondag. Samen hebben zij twee dochters, Anouk (1995) en 
Lonneke (1997). 
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